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‘IF you can keep your head when all about you  
Are losing theirs and blaming it on you, 
If you can trust yourself when all men doubt you, 
But make allowance for their doubting too; 
If you can wait and not be tired by waiting, 
Or being lied about, don't deal in lies, 
Or being hated, don't give way to hating, 
And yet don't look too good, nor talk too wise: 
If you can dream - and not make dreams your master; 
If you can think - and not make thoughts your aim; 
If you can meet with Triumph and Disaster 
And treat those two impostors just the same; 
If you can bear to hear the truth you've spoken 
Twisted by knaves to make a trap for fools, 
Or watch the things you gave your life to, broken, 
And stoop and build 'em up with worn-out tools: 
If you can make one heap of all your winnings  
And risk it on one turn of pitch-and-toss, 
And lose, and start again at your beginnings 
And never breathe a word about your loss; 
If you can force your heart and nerve and sinew 
To serve your turn long after they are gone, 
And so hold on when there is nothing in you 
Except the Will which says to them: 'Hold on!' 
If you can talk with crowds and keep your virtue, 
' Or walk with Kings - nor lose the common touch, 
if neither foes nor loving friends can hurt you, 
If all men count with you, but none too much; 
If you can fill the unforgiving minute 
With sixty seconds' worth of distance run, 
Yours is the Earth and everything that's in it, 
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Inflammation plays a key role in the underlying pathogenesis of obesity and its 
associated health risks, with increased markers of inflammation evident in both liver 
and adipose tissue. In parallel, there is dysregulation of glucocorticoid metabolism in 
obesity, with increased adipose levels of the glucocorticoid-regenerating enzyme 
11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and increased hepatic levels 
of 5α-reductase type 1 (5αR1), which catalyses the reduction of glucocorticoids. 
Both the mechanisms and consequences of this glucocorticoid metabolism 
dysregulation remain unclear, however, there is evidence that it may be related to 
inflammation. In vitro studies have demonstrated that pro-inflammatory markers 
upregulate 11βHSD1 expression in adipocytes, potentially explaining increased 
expression of this enzyme in obesity. Previous work has also demonstrated that the 
glucocorticoid metabolites produced by 5αR1 lack the metabolic effects of the parent 
glucocorticoid, but retain its anti-inflammatory properties, indicating that increased 
expression of hepatic 5αR1 may serve to dampen down inflammation in the liver. 
The hypotheses addressed in this thesis are that in obesity, inflammation regulates 
adipose glucocorticoid metabolism through 11βHSD1, and that hepatic 
glucocorticoid metabolism regulates the inflammatory state of the liver through 
5R1.  
 
The role of inflammation in the regulation of 11βHSD1 was assessed in vivo in mice 
treated with the anti-inflammatory compound sodium salicylate (salicylate). In diet-
induced obese mice, salicylate downregulated 11βHSD1 expression and activity 
selectively in visceral adipose tissue, alongside improved glucose tolerance, reduced 
plasma non-esterified fatty acids, and changes in adipose lipid metabolism. 
11βHSD1-deficient mice fed a high-fat diet were resistant to the insulin sensitising 
effects of salicylate treatment. These results indicate a novel role for 11HSD1 





The mechanisms underpinning the anti-inflammatory properties of 5-reduced 
glucocorticoids were explored in vitro and in vivo. In lipopolysaccharide-stimulated 
murine macrophages, both 5α-reduced glucocorticoid metabolites tested, namely 5α-
dihydrocorticosterone (5αDHB) and 5α-tetrahydrocorticosterone (5αTHB), 
suppressed tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6) release, although 
to a lesser extent than corticosterone (B). Similar to B, both 5αDHB and 5α THB 
suppressed phosphorylation of intra-cellular inflammatory signalling mitogen-
activated protein kinases (MAPK) proteins c-Jun N-terminal kinase (JNK) and p38, 
as well as increasing protein expression of MAPK phosphatase-1 (MKP-1).  
Treatment of phorbol ester-stimulated HEK293 kidney cells with these 5α-
metabolites revealed that 5αDHB suppressed nuclear factor κB (NFκB) and activator 
protein-1 (AP-1) activation to a similar extent to that of B, whilst 5αTHB increased 
activation of these pro-inflammatory transcription factors, indicating cell-specific 
effects of 5αTHB.  
 
In conclusion, reduced intra-adipose glucocorticoid regeneration by 11βHSD1 
mediates the insulin sensitising effects of salicylate, suggesting that altered 
glucocorticoid metabolism may reflect altered intra-adipose inflammation in obesity. 
Furthermore, these data support the concept that this enzyme provides a therapeutic 
target in obesity-related metabolic disorders. 5α-reduced metabolites of 
glucocorticoids have similar anti-inflammatory properties to the parent 
glucocorticoid, indicating that the elevated hepatic levels of 5α-reductase in obesity 
may be a protective mechanism to limit the adverse metabolic effects of 
glucocorticoids upon the liver, but maintain the beneficial anti-inflammatory 
properties. These 5α-reduced glucocorticoid metabolites may provide a potential 






List of Figures 
 
Figure 1.1 Proposed model of insulin signalling. 10 
   
Figure 1.2 Glucocorticoid cyclopentanoperhydrophenanthrene 
structure. 
15 
   
Figure 1.3 Biosynthesis of glucocorticoids. 16 
   
Figure 1.4 Structure of glucocorticoid receptor. 18 
   
Figure 1.5 Nuclear actions of glucocorticoid receptor. 21 
   
Figure 1.6 Glucocorticoid metabolism.  32 
   
Figure 1.7  
 
Figure 1.8 
Reductase activity of 11βHSD1. 
 




   
Figure 3.1 Salicylate improved glucose tolerance in DIO mice. 80 
   
Figure 3.2 Salicylate altered NEFA levels in DIO mice.  82 
   
Figure 3.3 Salicylate did not alter triglyceride levels.  83 
   
Figure 3.4 Salicylate reduced β-hydroxybutyrate (β-HB) levels in DIO 
mice.  
84 
   
Figure 3.5 Salicylate reduced 11βHSD1 transcript levels in omental 
adipose.  
86 
   
Figure 3.6 Salicylate reduced mesenteric adipose 11βHSD1 activity.  87 
   
Figure 3.7 Salicylate altered omental adipose transcript levels.  89 
   
Figure 3.8 Salicylate alters mesenteric adipose transcript levels. 90 
   
Figure 3.9 Salicylate alters subcutaneous (S.C.) adipose transcript 
levels.  
91 
   
   
   
   
xiv 
 
   
Figure 4.1 Salicylate improved glucose tolerance in WT-DIO mice, 
but had no effect in HSD1KO-DIO.  
110 
   
Figure 4.2 Salicylate reduced non-esterified fatty acids (NEFAs) 
levels in WT-DIO mice, but had no effect in HSD1KO-
DIO mice.  
111 
   
Figure 4.3 Salicylate did not influence triglyceride concentrations in 
WT-DIO or HSD1KO-DIO mice.  
113 
   
Figure 4.4 Salicylate reduced 11βHSD1 transcript levels in WT-DIO 
mice.  
114 
   
Figure 4.5 Salicylate reduced 11βHSD1 activity in mesenteric adipose 
of WT-DIO mice.  
114 
   
Figure 4.6 Salicylate effects on omental adipose transcript levels WT-
DIO mice are not replicated in HSD1KO-DIO mice.  
116 
   
Figure 4.7 Salicylate effects on mesenteric adipose transcript levels 
WT-DIO mice are not replicated in HSD1KO-DIO mice.   
117 
   
Figure 4.8 Salicylate effects on subcutaneous adipose transcript levels 
WT-DIO mice are not replicated in HSD1KO-DIO mice. 
118 
   
Figure 5.1 Dose-dependent increase in cytokine release in LPS-
stimulated RAW264.7 macrophages. 
136 
   
Figure 5.2 Glucocorticoids suppress cytokine release from LPS-
stimulated macrophages. 
137 
   
Figure 5.3 Effects of steroids in LPS-stimulated RAW264.7 
macrophages are blocked by GR antagonism. 
138 
   
Figure 5.4 5α-Reduced metabolites suppress JNK and p38 
phosphorylation.  
140 
   
Figure 5.5 Both 5α-reduced metabolites induce MKP-1 expression, 
but 5αDHB induces IκBα expression.  
141 
   
Figure 5.6 Differential effects of steroids on NFκB-mediated 
luciferase activity in transfected HEK293 cells stimulated 
with TPA.  
143 
   
Figure 5.7 Differential effects of steroids on AP-1-mediated luciferase 




   
Figure 5.8 Expression of A-ring reductases in RAW264.7 and 
HEK293 cells.  
145 
   
Figure 5.9 Overview of inflammatory signalling pathways. 149 
   
Figure 5.10 Intra-cellular glucocorticoid targets in inflammation.  151 
   
Figure 5.11 Conformational changes induced in helix 11 of the GR by 
different ligands. 
159 
   
Figure 6.1 Flow cytometric analysis of leukocytes.  171 
   
Figure 6.2 Plasma corticosterone increased in response to 
corticosterone injection. 
174 
   
Figure 6.3 Peritoneal infiltration in response to corticosterone. 174 
   
Figure 6.4 5α-Reduced metabolites reduce cell infiltration in 
peritoneum. 
176 
   
Figure 6.5 Suppression of peritoneal neutrophil and inflammatory 
monocyte infiltration. 
177 
   
Figure 6.6 Peritoneal cytokine and chemokine levels. 179 
   
Figure 7.1 Proposed interactions between inflammation and 
glucocorticoid metabolism in obesity. 
199 
   




List of Tables 
 
Table 2.1 Plasmid DNA composition for transfection. 50 
   
Table 2.2 Details of primers for PCR amplification. 57 
   
Table 2.3 Details of primers for real-time PCR for use with Roche 
Universal Probe Library. 
59 
   
Table 3.1 Housekeeping genes used for each tissue for real-time PCR. 75 
   
Table 4.1 Housekeeping genes used for real-time PCR.  106 
   
Table 4.2 Salicylate-induced changes in body and tissue weights of 
diet-induced obese wild type mice (WT-DIO) were not 
observed in diet-induced obese 11βHSD1 knockout mice 
(HSD1KO-DIO).  
109 
   
Table 5.1 Summary of in vitro effects of corticosterone and its 5α-
reduced metabolites.  
147 
   












5αTHB 5α-tetrahydro corticosterone 
5βR 5β-reductase 
ACTH Adrenocorticotropic hormone 
AdiQ Adiponectin 
AF Activation function 
Agt Angiotensinogen 
AKR Aldo-keto reductase 
AP Activator protein 
ATGL Adipose triglyceride lipase 
B Corticosterone 
β-HB β-hydroxybutyrate 
bp Base pair 
xviii 
 
BSA Bovine serum albumin  
cDNA Complementary DNA  
CMV Cytomegalovirus 
Cp Crossing point  
CRH Corticotrophin-releasing hormone 
DEPC Diethylpyrocarbonate 
DHC Dehydrocorticosterone  
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid  
EDTA Ethylene diamine tetraacetic acid  
ELISA Enzyme-linked immunosorbent assay  
ERK Extracellular signal-regulated kinase 
FDPase Fructose-1,6-diphosphatase 
FITC Fluorescein isothiocyanate 
G6Pase Glucose-6-phosphatase  
GABA Gamma-aminobutyric acid  
xix 
 
GK Glycerol kinase 
GLUT Glucose transporter 
GR Glucocorticoid receptor 
GRE Glucocorticoid response element 
GTT Glucose tolerance test  
h Hour 
HAT Histone acetyl transferase 
HDAC Histone deacetylase 
HEK293 Human embryonic kidney cell line 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
Hop Hsp organizing protein 
HSL Hormone sensitive lipase 
Hsp Heat shock protein  
ICAM Inter-cellular adhesion molecule 
i.p. Intraperitoneal  
IL Interleukin 
IκB Inhibitor of nuclear factor kappa-B 
xx 
 
IKK Inhibitor of nuclear factor kappa-B kinase 
IRS Insulin receptor substrate 
JNK c-Jun N-terminal kinase 
KO Knock-out 
LB Luria Bertani 
LPL Lipoprotein lipase 
LPS Lipopolysaccharide 
Luc Luciferase 
MAPK Mitogen-activated protein kinase 
MCP Monocyte chemoattractant protein 
MKP MAPK phosphatase 
MMTV Mouse mammary tumour virus 
MR Mineralocorticoid receptor 
MW Molecular weight 
NAD Nicotinamide adenine dinucleotide  
NADP Nicotinamide adenine dinucleotide phosphate  
NCoR Nuclear receptor corepressor 
xxi 
 
NEFA Non-esterified fatty acid 
NFκB Nuclear factor-kappa B  
OFN Oxygen-free nitrogen 
PBS Phosphate buffered saline  
PCR Polymerase chain reaction  
PE Phycoerythrin  
PEPCK Phosphoenolpyruvate carboxykinase  
PerCP/Cy5.5 Peridinin chlorophyll protein complex/Cy5.5 
PMNT Phenylethanolamine-N-Methyl Transferase 
POMC Pro-opiomelanocortin 
RAW264.7 Murine macrophage cell line 
RT-PCR Reverse transcriptase polymerase chain reaction  
SGRM Selective glucocorticoid receptor modulator  
SMRT Silencing mediator of retinoic acid and thyroid hormone 
receptor 
SPA Scintillation proximity assay  
SRC Steroid receptor coactivator 
STAT Signal transducer and activator of transcription 
xxii 
 
SV Simian virus  
TAT Tyrosine aminotransferase 
TBS Tris-buffered saline 
TLR Toll-like receptor  
TNF Tumor necrosis factor  
TPA 12-O-Tetradecanoyl-phorbol-13-acetate 
Tris Trisma base 
TF Transcription factor 









Nixon M, Yang CA, Duffin R, Rossi AG, Walker BR and Andrew R (2011). Anti-
inflammatory properties of 5α-Reduced Glucocorticoids: Potential Dissociated 
Steroids. Endocrine Abstracts 22, 0303. 
 
Nixon M, Duffin R, Rossi AG, Walker BR and Andrew R (2010). Anti-inflammatory 
properties of 5α-Reduced Glucocorticoids: Potential Dissociated Steroids. Program 
of Scottish Society for Experimental Medicine 2010. 
 
Nixon M, Livingstone DEW, Andrew R, and Walker BR. (2010). Salicylate-induced 
insulin sensitisation in obesity is mediated through downregulation of omental 
adipose 11-hydroxysteroid dehydrogenase type 1. Program of the 92
nd
 Meeting of the 
Endocrine Society, OR30-6. 
 
Nixon M, Livingstone DEW, Andrew, R, and Walker BR. (2010). Down-regulation 
of adipose 11βHSD1 mediates the insulin sensitising effects of salicylate in obesity. 
CRF Conference 2010 Diabetes and Obesity, Royal Society of Edinburgh. 
 
Nixon M, Livingstone DEW, Andrew, R, and Walker BR. (2010). Down-regulation 
of adipose 11βHSD1 mediates the insulin sensitising effects of salicylate in obesity. 
Endocrine Abstracts 21, P187. 
 
Nixon M, Livingstone DEW, Andrew R, and Walker BR. (2009). Down-regulation 
of omental adipose 11β-hydroxysteroid dehydrogenase type 1 may mediate the 
insulin sensitising effects of salicylates in obesity. Program of Scottish Society for 























The prevalence of obesity continues to escalate in the western world, with the 
condition also becoming an increasing problem in developing countries. Projections 
by the World Health Organisation indicate that by 2015, approximately 2.3 billion 
people will be overweight, with more than 700 million obese. With this rise in 
obesity comes an increased incidence of obesity-related disorders, including non-
alcoholic fatty liver disease (NAFLD), type 2 diabetes and cardiovascular disease. 
There is increasing evidence that obesity is associated with low-grade inflammation, 
as well as a dysregulation in glucocorticoid metabolism. This chapter will introduce 
the background to the inflammation that is apparent in obesity, as well the roles 
played by glucocorticoids and their metabolism. 
 
1.1 Inflammation in obesity 
In the past decade, it has become clear that inflammation plays a critical role in the 
metabolic dysfunction associated with obesity, namely the development of insulin 
resistance and progression through to type 2 diabetes (Chen 2006). The concept for a 
role of inflammation in obesity first appeared when it was demonstrated that 
expression of the pro-inflammatory cytokine tumor necrosis factor-α (TNFα) was 
increased in obese animals, in both the circulation and the adipose tissue 
(Hotamisligil et al. 1993). Further studies found that, in several obese mouse models, 
functional TNFα-deficiency improved insulin sensitivity (Uysal et al. 1997). Such 
observations were also evident in humans, with increased adipose tissue expression 
of TNFα in obese subjects, followed by a drop in expression after weight loss 
(Hotamisligil et al. 1995; Dandona et al. 1998). This work also raised the possibility 
that other pro-inflammatory molecules aside from TNFα contribute to the 
development of insulin resistance. Indeed, interleukin-6 (IL-6), another pro-
inflammatory molecule, was implicated in obesity-related disorders soon after TNFα 
(Bastard et al. 2002; Sabio et al. 2008). In rodent genetic models of obesity, anti-IL-
6 treatment improves insulin sensitivity (Klover et al. 2005), whilst in humans, 
circulating levels of IL-6 decrease with weight loss and improvement in insulin 
sensitivity (Kopp et al. 2003; Monzillo et al. 2003). 
3 
 
1.1.2 Role of immune cells in the origin of inflammation in 
obesity 
Given their increased levels in obesity, intense work has gone into establishing the 
origin of pro-inflammatory cytokines. Whilst it is now recognised that they are 
released by numerous cell types (Maury and Brichard 2010), the primary source of 
inflammatory mediators within the body remains cells of the immune system, 
including dendritic cells, neutrophils and macrophages (Fain ; Olefsky and Glass 
2010). This suggests that in obesity, there is an activation of the host innate immune 
system, driving an inflammatory response. Inflammation itself is a crucial 
component of tissue repair and involves numerous distinct cell types. However, 
prolonged inflammation is often detrimental, as appears to be the case in metabolic 
diseases. Whilst studies had shown obesity was associated with increased circulating 
levels of pro-inflammatory molecules (Hotamisligil et al. 1993; Hotamisligil et al. 
1995; Uysal et al. 1997; Dandona et al. 1998; Bastard et al. 2002), it was the 
discovery of increased inflammation within the liver, and in particular, adipose 
tissue, that revealed the potential source of the inflammatory response (Chen 2006; 
Hotamisligil 2006). This crucial ‘overlap’ in the metabolic and inflammatory 
pathways may, in part, be explained from an evolutionary viewpoint.  
 
The Drosphilia fat body, which incorporates the mammalian homologues of the liver 
and haematopoietic and immune systems, is thought to be a common ancestral 
structure that controls key metabolic and immune systems (Hotamisligil 2006). This 
fat body acts as the site of co-ordination of responses to pathogens and also senses 
energy and nutrient availability. In higher mammalian organisms, the liver, adipose 
tissue and haematopoietic system have specialized into distinct organ systems. 
However, they have maintained their developmental heritage. This is evident when 
the cell types present in these organs are considered. In the adipose tissue, adipocytes 
are found in close proximity to macrophages, whilst in the liver, specialised 
macrophages, named Kuppfer cells, are present (Chen 2006).  This interface between 
metabolic and immune cells within these tissues provides an environment whereby 




Initially viewed as a passive tissue, functioning only as a site of energy storage, the 
understanding of adipose as a metabolically active tissue that regulates many 
processes has paved the way for greater mechanistic insights into obesity-related 
conditions (Frayn et al. 2003; Kershaw and Flier 2004; Chen 2006). Whilst the levels 
of several pro-inflammatory cytokines are increased in obesity, it was not clear 
whether this resulted from release from adipocytes or non-fat cells. Over the past 
number of years, numerous studies have attempted to dissect the mechanisms 
underlying inflammation within adipose tissue, with several key factors emerging. 
Perhaps the most exciting discovery was that obese adipose tissue is infiltrated by 
macrophages and that these infiltrated immune cells are a major source of pro-
inflammatory cytokine release (Weisberg et al. 2003). Whilst ‘resident’ macrophages 
are present within adipose, obese adipose is characterised by a large increase in the 
number of bone-marrow-derived macrophages. Indeed, some reports in obese rodents 
and humans have suggested that up to 40% of total adipose cell content consists of 
macrophage cells, compared to approximately 10% in lean counterparts (Weisberg et 
al. 2006). However, despite the infiltration of these cells, the mechanisms that recruit 
and retain macrophages in obese adipose remained unclear.   
 
In order to recruit macrophages, it was speculated that there must by a ‘signal’ to 
guide them. Considerable evidence has since accumulated that monocyte-
chemoattractant protein-1 (MCP-1), derived from adipocytes and resident 
macrophages, plays a crucial role in macrophage infiltration (Kamei et al. 2006; 
Kanda et al. 2006; Weisberg et al. 2006). This chemokine plays a key role in the 
development of inflammatory responses and promotes the recruitment of monocytes 
into damaged or inflamed tissues. In obese adipose tissue, MCP-1 expression 
correlates positively with adiposity (Weisberg et al. 2006), whilst mice lacking 
MCP-1 on a high-fat diet have attenuated macrophage accumulation and 
inflammation in adipose tissue, as well as improved insulin sensitivity (Inouye et al. 
2007). This suggests that increased MCP-1 promotes the recruitment of macrophages 




However, the mechanism through which both resident and infiltrated macrophages 
contribute to this cycle of inflammation remained unclear until the discovery that 
saturated fatty acids bind toll-like receptor 4 (TLR4) (Song et al. 2006). TLRs are a 
family of receptors for pathogen-associated molecular patterns (PAMPs) that have 
important roles in innate immunity. They recognise components of foreign objects, 
namely bacterial elements, which distinguish them from the host. In terms of TLR4, 
lipopolysaccharide is recognised as a component of the cell wall of gram negative 
bacteria, stimulating macrophage activation and so initiating an immune response. 
Recent evidence has demonstrated that TLR4 plays an important role in obesity-
induced adipose inflammation, with macrophage expression of TLR4 increased in 
obesity (Song et al. 2006). Furthermore, mice with a myeloid cell-specific deletion of 
TLR4 were protected from high-fat diet-induced insulin resistance, despite being 
fully obese (Suganami et al. 2007; Saberi et al. 2009). The ability of saturated fatty 
acids to act as an endogenous ligand for TLR4 demonstrates a mechanism by which 
macrophages become activated in the lipid rich environment of adipose tissue, 
leading to release of numerous pro-inflammatory molecules. 
 
1.1.3 Role of adipose tissue in obesity 
1.1.3.1 Adipocyte role in inflammation induction 
Clearly, immune cells have an important role to play in obesity as described above. 
However, despite illustrating the infiltration of these cells into adipose tissue, it 
remained unclear as to why such an influx was taking place. Important studies have 
shown that this macrophage infiltration into adipose precedes the development of 
insulin resistance, identifying it as a causal factor behind insulin resistance, not 
merely a consequence (Weisberg et al. 2003; Xu et al. 2003). A recent breakthrough 
has been the discovery that obese adipose tissue is characterised by adipocyte 
hypertrophy (Suganami and Ogawa 2010). Whilst this is an essential process in 
storing extracellular lipids, in the setting of obesity, adipocyte hypertrophy results in 
the initiation of the inflammatory signalling cascade (Hotamisligil 2006). During 
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hypertrophy, multiple pathways are activated in the adipocyte that results in 
activation of inflammatory signalling. These include the activation of the mitogen-
activated protein kinase (MAPK) family of proteins, JNK, p38 kinase and ERK, as 
well as the down-regulation of MAPK-phosphatase-1 (MKP-1) which normally 
functions to rapidly inactivate the MAPKs (Johnson and Lapadat 2002; Bost et al. 
2005). Adipocyte hypertrophy also results in the induction of endoplasmic reticulum 
(ER) stress and increased expression of reactive oxygen species (Ozcan et al. 2004). 
Both these pathways increase inflammatory signalling within adipocytes. 
Hypertrophied adipocytes secrete MCP-1 due to their ‘inflammatory’ state, 
potentially explaining the source of the increase of this chemokine seen in obesity 
(Ito et al. 2007). Further evidence supporting the idea that hypertrophied adipocytes 
are the primary ‘attraction’ for infiltrating macrophages is demonstrated by the 
apparent ‘niche’ within the environment of obese adipose tissue that is involved in 
macrophage activation. Studies have shown that approximately 90% of infiltrated 
macrophages accumulate around dead adipocytes, forming characteristic structures 
known as crown-like structures (CLS) (Cancello et al. 2005; Cinti et al. 2005). These 
structures form as macrophages surround dead or dying adipocytes, reabsorbing the 
lipid remnants of these cells.  
 
Whilst the release of pro-inflammatory cytokines from within adipose is due mainly 
to non-fat cells such as macrophages, adipocytes themselves secrete an array of 
factors, collectively termed adipokines (Maury and Brichard 2010). These adipokines 
regulate energy homeostasis and insulin sensitivity in an autocrine, paracrine and 
endocrine manner, in particular mediating effects in insulin target tissues including 
the liver and muscle. One of the main adipokines is adiponectin. Unlike most factors 
released from adipose tissue, the levels of adiponectin are decreased in obesity, such 
that there is an inverse correlation of adiponectin levels with the development of 
insulin resistance (Arita et al. 1999; Brichard et al. 2003). This adipokine is 
considered an anti-inflammatory factor, which has been shown to reduce weight and 
improve insulin sensitivity (Kadowaki et al. 2006). Both in vitro and in vivo studies 
have demonstrated that insulin downregulates adiponectin secretion in adipocytes 
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(Fasshauer et al. 2002; Yu et al. 2002), and that insulin sensitising agents markedly 
increase adiponectin levels (Yu et al. 2002). Furthermore, the anti-inflammatory 
properties of this adipokine were shown in adiponectin-deficient mice which 
exhibited increased circulating TNFα levels (Maeda et al. 2002). The relationship 
between these two adipokines has been studied extensively, with the overall finding 
being that they appear to regulate each other in a negative manner (Abbasi et al. 
2004). In inflammatory adipocytes, adiponectin suppressed TNFα release (Ajuwon 
and Spurlock 2005), whilst in humans, TNFα has been shown to reduce adiponectin 
levels in adipose (Hector et al. 2007). A reduction in adiponectin expression in 
obesity would further serve to fuel the inflammatory cycle within adipose, yet 
adiponectin also has effects in other tissues. In the liver, adiponectin prevents lipid 
accumulation by increasing β-oxidation and suppressing de novo lipogenesis (You et 
al. 2005). Mouse models of liver fibrosis treated with adiponectin attenuates the 
condition, indicating a protective effect of this adipokine (Kamada et al. 2008). This 
is of particular importance when one considers the condition of the liver in the 
metabolic syndrome. NAFLD is the hepatic manifestation of obesity-induced 
metabolic dysfunction, characterised mainly by the excessive hepatic deposition of 
non-esterified fatty acids (NEFAs) and triglycerides. However, over recent years, 
evidence has accumulated that pro-inflammatory cytokines contribute to the 
development of NAFLD, and that these cytokines are derived from adipose tissue 
(Tsochatzis et al. 2009). Increased expression of TNFα has been shown in several 
studies investigating patients with NAFLD (Valenti et al. 2002; Poniachik et al. 
2006). The role of IL-6 is less clear, with contrasting reports on its expression levels 
in NAFLD (Tsochatzis et al. 2009). However, it appears that inflammation within the 
liver plays a role in the underlying pathogenesis of obesity-related liver disorders. 
 
1.1.3.2 Differential effects of adipose depots 
Whilst obesity is the underlying risk factor for the development of conditions such as 
NAFLD and type 2 diabetes, it is not generalised obesity per se, but rather the 
regional distribution of adipose in the body that is more closely associated with such 
metabolic disorders (Bjorntorp 1992; Wajchenberg 2000). Upper body, visceral 
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adiposity is positively correlated with metabolic dysfunction, as opposed to lower 
body, subcutaneous (S.C.) adipose. Numerous studies have found that, independent 
of body mass index, waist circumference (a marker of visceral adiposity) was 
strongly associated with the prevalence of type 2 diabetes (Garg 2004; Alberti et al. 
2005; Klein et al. 2007). The reason for this lies in the heterogenous nature of 
adipose tissue, with distinct differences in the biology of adipocytes from visceral 
adipose and S.C adipose. Indeed, accumulating evidence indicates that S.C adipose 
may be a ‘metabolic sink’ that prevents accumulation of detrimental visceral adipose 
tissue (Sam et al. 2008). Given the fact that, even in the obese state, visceral adipose 
represents a relatively small proportion of total body adipose, it is reasonable to ask 
why it has such a big influence on whole body metabolism. One possible reason for 
this is that the venous drainage of visceral adipose is directly into the portal 
circulation, which in turn drains directly to the liver. As such, the release of factors 
including NEFAs and pro-inflammatory cytokines from visceral adipose would have 
direct effects on hepatic metabolism. In support of this, studies have shown that 
visceral adipose correlates closely with increased liver fat content (Nguyen-Duy et 
al. 2003), and that reductions in visceral adipose are associated with reduced liver fat 
content (Barzilai et al. 1999).  
 
The correlation between pro-inflammatory levels and visceral adiposity has seen 
these central adipose depots come under intense scrutiny in terms of deciphering the 
underlying cause of adipose inflammation. As mentioned above, adipocyte 
hypertrophy appears a crucial step in initiating the immune response. It has been 
suggested that adipocyte size is the crucial factor in determining the fate of the 
adipocyte (Weisberg et al. 2003). The smaller adipocytes seen in visceral adipose 
compared to S.C adipose is believed to render them more susceptible to hypertrophy 
(Murano et al. 2008). Indeed, comparison of visceral and S.C. adipose depots in 
obese rodents has demonstrated that visceral depots are more prevalent sites of 
adipocyte death. Supporting the greater adipocyte hypertrophy in visceral adipose, a 
recent paper showed preferential macrophage infiltration in visceral versus S.C. 
adipose in obese humans (Harman-Boehm et al. 2007).  Furthermore, in a study 
9 
 
investigating CLS in visceral and S.C. adipose depots of obese rodents, CLS density 
was shown to be greater in visceral adipose (Strissel et al. 2007). 
 
 
1.1.4 Mechanisms of inflammation-induced insulin resistance 
In order to understand how inflammation induces insulin resistance in both liver and 
adipose tissue, numerous studies have focused on intracellular signalling pathways 
that may be disrupted. Under normal conditions (Figure 1.1a), insulin acts through 
the membrane-bound insulin receptor (IR). Upon ligation, the transmembrane 
subunits of the IR are auto-phosphorylated on three tyrosine residues (Tyr-1158, Tyr-
1162, and Tyr-1163). The activated IR functions as a kinase to recruit insulin 
receptor substrate-1 (IRS-1) through its Src homology 2 (SH2) domain, resulting in 
the phosphorylation of tyrosine residues on IRS-1. This enables activation of 
downstream pathways, including the phosphoinositide-3 kinase (PI3K) pathway, 
which leads to the activation of the serine/threonine kinase AKT2. In adipose tissue, 
this signalling cascade leads to the recruitment of the glucose transporter 4 (GLUT4) 
to the plasma membrane of muscle cells and adipocytes, resulting in the enhanced 
glucose uptake form the blood. In the liver, AKT2 phosphorylates the forkhead box 
O1 (FOXO1) transcription factor, preventing its nuclear translocation. This inhibits 
gluconeogenic gene expression, therefore suppressing hepatic glucose production 
(White 1998).  
 
Several serine/threonine kinases are activated by inflammatory stimuli (Figure 1.1b), 
such as TNFα binding to its cognate receptor or the binding of saturated fatty acids to 
TLR4 (Aguirre et al. 2000; Gao et al. 2002; Hirosumi et al. 2002; Draznin 2006). 
The two main kinases implicated in contributing to insulin resistance are the c-Jun N-
terminal kinase (JNK) and the inhibitor of nuclear factor κ-B kinase subunit β 
(IKKβ). JNK belongs to the MAPK family and regulates the pro-inflammatory 
transcription factor activator protein-1 (AP-1). Activation of JNK normally occurs 










Figure 1.1 Proposed model of insulin signalling. Under normal physiological condition (a), insulin binds to the insulin receptor (IR), 
autophosphorylating it. This recruits insulin receptor substrate-1 (IRS-1), which is in turn phosphorylated on a tyrosine residue. This results 
in activation of downstream signalling pathways with different endpoints dependent upon the target tissue. In an inflammatory activated 
insulin target cell (b), saturated fatty acids (FA) and/or pro-inflammatory cytokines such as tumor necrosis factor-α (TNFα) act via toll-like 
receptor-4 (TLR4) and TNFα-receptor (TNFR) respectively to activate intracellular inflammatory kinases. Activation of c-Jun N-terminal 
kinase (JNK) and inhibitor of NF-κB kinase β (IKKβ) results in the inhibitory phosphorylation of IRS-1 on a serine residue, blocking 
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fatty acids have also been shown activate JNK (Aguirre et al. 2000; Hirosumi et al. 
2002). In obesity, JNK activity is increased in both liver and adipose tissue, most 
likely as a result of the combined increase in pro-inflammatory cytokines and 
saturated fatty acids. This in turn leads to the inhibitory phosphorylation of IRS-1 on 
a serine residue (Ser-307), which prevents normal tyrosine phosphorylation, thus 
preventing normal insulin signalling. The importance of this pathway is 
demonstrated by models where loss of JNK1, one of the two isoforms of JNK, 
prevents the development of insulin resistance in rodent models of obesity (Hirosumi 
et al. 2002). Similar to JNK, IKKβ also phosphorylates Ser-307 on IRS-1, inhibiting 
normal insulin signalling (Gao et al. 2002). The IKKβ pathway, which is activated 
by TNFα, plays a key role in inflammation through activation of the pro-
inflammatory transcription factor nuclear factor-κB, (NF-κB). Targeted disruption of 
IKKβ has been shown to improve insulin sensitivity, whilst overexpression in 
cultured cells attenuates insulin signalling (Yuan et al. 2001). Furthermore, liver- 
specific deletion of IKKβ resulted in improved hepatic insulin sensitivity when fed a 
high-fat diet (Arkan et al. 2005).  
 
1.1.5 Anti-inflammatory salicylates  
Although significant work has been carried out in the past number of years to 
establish the relationship between insulin resistance and inflammation, the idea itself 
is not a new concept. Indeed, initial clues date back more than century ago, when it 
was discovered that high doses of sodium salicylate, an anti-inflammatory drug 
related to aspirin, were capable of diminishing glycosuria in diabetic patients 
(Williamson 1901). This effect was rediscovered in 1957 when an insulin-treated 
diabetic patient was given high dose aspirin to treat arthritis (Reid et al. 1957). The 
result was that the patient no longer required daily insulin injections.  Despite this, it 
was not until recently that the mechanisms behind the hypoglycemic effects of 




Both sodium salicylate and aspirin are non-steroidal anti-inflammatory drugs widely 
used to treat conditions including rheumatic pain, yet their anti-inflammatory 
mechanisms are distinct. Whilst aspirin was initially shown to suppress prostaglandin 
production through inhibition of the cyclooxygenase enzymes (COX-1 and 2), non-
acetylated salicylates do not inhibit these enzymes. However, at high concentrations, 
both forms inhibit the IKKβ/NF-κB axis. It is the effects on this pathway that led to 
the investigation of salicylates in treating inflammation-induced insulin resistance. 
Unlike the acetylated aspirin, which increases the risk of bleeding, the non-acetylated 
salicylate does not inhibit platelet aggregation, reducing such risk. Initial studies in 
genetically obese rodents found that salicylate treatment resulted in a reduction in 
both fasting blood glucose levels and insulin concentration (Yuan et al. 2001). 
Further work also demonstrated that lipid-induced insulin resistance in rodents was 
also attenuated with salicylate treatment (Kim et al. 2001).  
 
The promise in these studies led to the effects of salicylates being investigated in 
humans. Initial studies with aspirin found that, in healthy lean men, lipid-induced 
insulin resistance was improved with aspirin pre-treatment, although no beneficial 
effect was observed in the control group (without lipid infusion) (Mohlig et al. 
2006).  Furthermore, in diabetic patients, a two week course of high dose aspirin 
improved insulin sensitivity (Hundal et al. 2002). However, such high doses over an 
extended period of time have potentially grave side effects. Whilst salicylates are not 
associated with increased spontaneous bleeding risk, they do induce gastric irritation 
when administered at high dose. To overcome this issue, trials have switched to the 
more tolerable form of salicylate, namely salsalate, a drug composing of two 
salicylate molecules bound by an ester bond. Due to its insolubility in gastric acid, it 
is not absorbed in the stomach, therefore putatively causing less irritation. However, 
the alkaline conditions present within the intestine break the ester bond, freeing the 
two salicylate molecules and allowing them to be absorbed.  In obese, non-diabetic 
patients, treatment with salsalate had no effect on body weight, reduced glucose 
levels, but increased insulin levels (Koska et al. 2009). In this study, the glucose-
lowering effects of salsalate were determined to be a result of increased systemic 
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insulin concentrations. A similar study in obese young adults found that one month 
salsalate treatment reduced glucose and NEFA levels, with no changes in insulin 
(Fleischman et al. 2008). However, this group did find reduced insulin clearance 
following treatment, which may account for the improved glucose disposal. Another 
study, this time investigating the effects in diabetic patients, also found beneficial 
effects of salsalate treatment in reducing glucose levels (Goldfine et al. 2008). Whilst 
these studies identified a potential role for salsalate as a treatment option, their 
conclusions were limited by the small numbers of patients in each study, as well as 
the short duration of drug administration. To address this, a large randomised trial, 
Targeting Inflammation using Salsalate for Type 2 Diabetes (TINSAL-T2D), began 
in 2008 (Goldfine et al. 2010). The recently published findings from the initial part 
of this study found that a 14 week administration of salsalate at several doses (3.0, 
3.5, 4.0g per day) were well tolerated in patients with type 2 diabetes, and improved 
measures of glycaemic control, as well as increasing circulating adiponectin levels.  
 
The results of the TINSAL-T2D trial clearly support targeting inflammation within 
the setting of metabolic syndrome as a therapeutic option. However, the molecular 
mechanisms underlying the glucose lowering actions remain undefined. Given the 
ability of salicylate to inhibit NF-κB action via IKKβ inhibition, and the role that 
both these molecules play in altering insulin signalling, this inflammatory pathway 
has been identified as a potential molecular target of salicylate. Indeed, insulin 
resistance induced in mice through overexpression of hepatic IKKβ was attenuated 
by salicylate treatment (Cai et al. 2005). Despite this, studies in humans have 
suggested the beneficial effects are a result of increased insulin concentrations 
(Fernandez-Real et al. 2008). As a result, the mechanisms of salicylate-induced 
insulin sensitisation remain to be fully elucidated. In this thesis, a role for modulation 






Glucocorticoids are steroid hormones that function as regulators of metabolic and 
immune status. Like other steroids, they are based on the 
cyclopentanoperhydrophenanthrene structure (Figure 1.2), consisting of three 
cyclohexane rings and a single cyclopentane ring. The unique properties of each 
steroid are achieved through substitution of chemical groups at various positions. 
 
1.2.1 Biosynthesis of glucocorticoids 
Glucocorticoids are derived from the precursor cholesterol within the zona 
fasciculate of the adrenal cortex. This synthetic pathway is catalysed by members of 
the cytochrome P450 oxidative enzyme family, as well as 3β-hydroxysteroid 
dehydrogenase (Figure 1.3). In humans, the active glucocorticoid is cortisol, whilst in 
rodents, the absence of 17α-hydroxylase results in corticosterone being the active 
glucocorticoid (Chung et al. 1987; Luu-The et al. 2005).  
 
1.2.2 Regulation of glucocorticoids 
Endogenous levels of circulating glucocorticoids are controlled by the hypothalamic-
pituitary-adrenal (HPA) axis. The synthesis of glucocorticoids in the adrenal glands 
is regulated by adrenocorticotrophic hormone (ACTH), which is secreted from the 
anterior pituitary. Within these corticotropes, ACTH is cleaved from the pre-cursor 
pro-opiomelanocortin (POMC), under the control of corticotrophin releasing 
hormone (CRH). CRH, secreted from within the paraventricular nucleus of the 
hypothalamus, is produced in response to various physical and psychological 
stressors. Such stressors include factors released by the immune system if the body is 
fighting infection, including pro-inflammatory cytokines. The HPA axis itself is 
regulated through several negative feedback systems. Elevated circulating levels of 
glucocorticoids act upon the pituitary to inhibit transcription of POMC, as well as 
preventing cleavage of POMC, thus preventing production of ACTH. Furthermore, 
the increased levels of glucocorticoids act upon two main regions of the brain, 

















Figure 1.2 Glucocorticoid cyclopentanoperhydrophenanthrene structure. The 
three cyclohexane rings and the single cyclopentane ring are identified by letters and 





































































































Figure 1.3 Biosynthesis of glucocorticoids. Pathways involved in production of 
glucocorticoids in the adrenal cortex. HSD = hydroxysteroid dehydrogenase. 
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hippocampus, reducing stimulation of CRH release from the hypothalamus (Stewart 
2002). A further level of glucocorticoid regulation is evident in the 24 hour circadian 
rhythm of circulating glucocorticoid levels. In humans, glucocorticoid levels are 
highest in the morning (Lupien et al. 1998). In nocturnal animals, such as rodents, 
glucocorticoid levels are lowest in the morning, rising during the day to reach a peak 
in the evening (Windle et al. 1998). 
 
1.2.3 Glucocorticoid activation of glucocorticoid receptor 
The actions of glucocorticoids are mainly mediated through interactions with two 
nuclear hormone receptors, namely the glucocorticoid receptor (GR) and the 
mineralocorticoid receptor (MR) (Lu et al. 2006). Alternative splicing of the pre-
mRNA generates multiple isoforms of the GR, with GRα, the most functional 
isoform, expressed throughout the body. GRβ does not bind glucocorticoids and so 
has been less extensively researched. However, its ability to bind to DNA means that 
it may act in a dominant-negative inhibitor of glucocorticoid action by interfering 
with GRα binding to DNA. (Given that glucocorticoids have been shown to exert 
effects only via the GRα isoform, mention of GR from this point on refers to GRα). 
Whilst the physiological and pharmacological actions are primarily mediated via the 
GR, glucocorticoid binding and activation of other receptors exerts other effects. MR 
is part of the same superfamily of nuclear receptors as GR, with a high affinity for 
glucocorticoids. Yet glucocorticoid action via MR is often prevented by inactivation 
of the glucocorticoid by specific enzymes, discussed in detail later. Other nuclear 
receptors that glucocorticoids bind with include the steroid and xenobiotic receptor 
(SXR), which also responds to a wide range of endogenous steroids (Blumberg et al. 
1998). SXR was initially established as a sensor that regulated xenobiotic clearance 
within the liver and intestine, yet over the past few years, research has revealed a role 
for SXR in inflammation, as well as lipid and energy homeostasis (Zhou et al. 2009). 
Like other steroid receptors, the modular structure of GR contains three major 
domains (Figure 1.4), namely the N-terminal domain, the central DNA-binding 
domain (DBD) and the C-terminal, ligand-binding domain (LBD) (Beck et al. 2009). 








Figure 1.4 Structure of glucocorticoid receptor. The three domain structure of 
glucocorticoid receptor is shown, namely the N-terminal activation function 1 (AF-
1), the DNA-binding domain (DBD) and the ligand-binding domain (LBD). The 














 nuclear receptors, and contains a transactivation domain, activation function-1 (AF-
1). The importance of this AF-1 region in activation has been well established, with 
much of the GR’s transcriptional activity dependent upon this region. AF-1 interacts 
with several transcription factors, including TATA-binding protein (TBP) and 
CREB-binding protein (CBP) (Kumar and Thompson 2005). The N-terminal domain 
also serves as a site of coregulatory protein binding. The DBD is highly conserved in 
terms of amino acid sequence, and serves two main functions; firstly it confers 
receptor recognition for specific DNA sequences within the promoter region of 
glucocorticoid-regulated genes. Secondly, the DBD has two zinc finger regions 
which are crucial for GR dimerisation. Furthermore, the DBD interacts with other 
proteins, including the c-Jun subunit of the AP-1 complex. The LBD consists of 11 
helices that fold into a globular structure that forms the ligand-binding pocket 
(Bledsoe et al. 2002). This hydrophobic ligand-binding site establishes a unique 
hydrogen bond network between the receptor and the bound ligand, ensuring 
specificity between the two. However, the ligand itself also has an important role to 
play in determining the downstream consequences of GR activation. The ligand 
binding pocket contains a branched side pocket critical for high affinity binding of 
ligands. The structure of the ligand is important as it determines the conformation 
that the receptor assumes after ligand binding. Such changes in conformation result 
in changes to the receptor surface, including DNA-binding surface, the dimerisation 
surface and also the ligand-binding surface. The LBD also contains a second 
transactivation domain (AF-2) located within helix 11. This region binds a number of 
coregulatory proteins (discussed later), which are often essential for transcriptional 
activation. 
 
In the resting state, the GR molecule is held in the cytoplasm as part of a large multi-
protein chaperone complex consisting primarily of heat-shock proteins (Hsp) (Pratt 
et al. 2006). These include Hsp90 and Hsp70, as well as several Hsp90-binding 
proteins that serve to stabilise the complex, including p23, Hop, FKBP51, FKBP52 
and CyP-40. This complex binds to the LBD domain, inducing a conformational 
state favourable to high-affinity ligand binding. Given their small hydrophobic 
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nature, glucocorticoids readily diffuse across the membrane of their cellular targets, 
although they may also be actively transported into the cell (Fant et al. 1983). Upon 
binding to the cytosolic GR, the chaperone complex dissociates, inducing a 
conformational change which unmasks the nuclear localisation signal. Two nuclear 
localisation sites have been identified within the GR (Smoak and Cidlowski 2004). 
The ligand-independent NL1 is located with the DBD, whilst the ligand-dependent 
NL2 is located in the LBD. The activation of these nuclear localisation sites 
facilitates translocation to the nucleus of the cell, where importin-α and importin-β 
are involved in the nuclear import of GR (Freedman and Yamamoto 2004). The 
export of GR from the nucleus is believed to involve calreticulin- and exportin-1-
based mechanisms. However, the GR itself may determine its maintenance within the 
nucleus through the nuclear retention signal.  
 
1.2.4 Glucocorticoid receptor-mediated effects on 
transcription 
Following glucocorticoid binding and nuclear translocation, the activated GR acts 
through several mechanisms to modulate transcriptional activity in a positive 
(transactivation) or negative (transrepression) manner (Figure 1.5) (De Bosscher et 




Transactivation is primarily mediated by the binding of GR homodimers to 
glucocorticoid response elements (GREs) within the promoter region of target genes 
(Figure 1.5a). These consensus GREs contain imperfect palindromic sequences (5’ 
GGT ACA nnn TGT TCT 3’) consisting of two hexameric half-sites separated by 
three base pairs of any nucleotide (n) (Newton and Holden 2007; Beck et al. 2009). 
















Figure 1.5 Nuclear actions of glucocorticoid receptor (GR). Mechanisms of 
positive transcriptional activation (Transactivation, a-c) and negative transcriptional 
activation (Transrepression, d-e). GR can dimerise and bind to glucocorticoid 
response elements (GRE) within promoter of target gene, inducing transcription (a). 
GR monomer can bind to GRE half-sites in the DNA sequence that are located 
beside transcription factor (TF) binding sites, acting synergistically to induce gene 
transcription (b). Alternatively, GR monomers can bind directly to TFs, without 
binding to DNA, inducing (c) or inhibiting (e) gene transcription. Direct repression 
of gene transcription also occurs through GR monomer binding to negative GREs 










explains transactivation of simple GREs, which contain consensus GRE sites, such as 
is the case for the mouse mammary tumour virus (MMTV) promoter, the tyrosine 
aminotransferase (TAT) promoter and the glucose-6-phosphatase promoter (De 
Bosscher et al. 2003; Beck et al. 2009). Whilst this has classically been viewed as 
the mechanism behind GR-mediated activation of target genes, it is now known that 
numerous other genes are upregulated through alternative mechanisms. In particular, 
recent work has highlighted that dimerisation of GR is not essential, utilising 
dimerisation-deficient GR to demonstrate an equal ability to transactivate gene 
expression of phenyl-N-methyl-transferase (PMNT) as wild-type GR (Adams et al. 
2003). Although dimerisation is not essential, DNA-GR interactions, either directly 
or indirectly, are crucial. In these situations, GR monomers bind to single or multiple 
GRE half-sites, often in combination with transcription factors, which act in a 
collaborative manner to enhance gene activation (Figure 1.5b) (De Bosscher et al. 
2003).  
 
A further transactivation mechanism does not involve direct DNA-binding, but rather 
‘tethering’ of the GR monomer to DNA-bound transcription factors. An example of 
this is GR monomer binding to signal transducer and activator of transcription 3 
(STAT3), enhancing its transcriptional activity and increasing gene expression of IL-
10 (Figure 1.5c) (Beck et al. 2009). 
 
1.2.4.2 Transrepression 
Similar to transactivation, GR-mediated transrepression is regulated through both 
direct and indirect DNA-binding mechanisms. Binding of GR monomers to negative 
GREs mediates the direct DNA binding mechanism, for example in glucocorticoid-
mediated repression of osteocalcin (Figure 1.5d) (Meyer et al. 1997). However, only 
a handful of genes have been shown to contain negative GREs. In terms of 
inflammatory gene promoters, there is a distinct absence of consensus sequences to 
which GR can bind. Instead, these promoters contain binding sites for the pro-
inflammatory transcription factors NF-κB and AP-1. The proposed predominant 
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mechanism of transrepression involves tethering of GR monomers to transcription 
factors, inhibiting their transcriptional activity (Beck et al. 2009). Indeed, this 
mechanism has been shown to be important for repressing pro-inflammatory gene 
transcription through tethering of GR to NFκB and AP-1 (Figure 1.5e). However, 
whilst DNA-binding is not required in this mechanism, the DBD of the GR still 
appears to be crucial for repression of some inflammatory pathways. This was 
demonstrated in studies utilising a GR with a mutation within the second zinc finger 
of the DBD, when repression of AP-1 transcription was observed, but repression of 
NFκB was prevented (Bladh et al. 2005). 
 
1.2.4.3 Role of coregulators 
The ability of GR to act as a transcriptional activator or repressor depends not only 
upon the presence of specific transcription factors, but also the presence of 
coregulators. The role of these coregulators has only emerged in recent years, and 
remains an area under extensive investigation. These molecules act as signalling 
proteins between the DNA-bound GR and local transcription machinery, 
reorganising the chromatin environment upon recruitment by the GR (De Bosscher 
and Haegeman 2009; Barnes 2010). Coregulator molecules are designated as 
coactivators or corepressors based on their ability to facilitate or repress 
transcription. Once recruited, coactivators such as transcription intermediary factor-2 
(TIF-2), steroid receptor coactivator-1 (SRC-1) and p300 enhance transcriptional 
activity through several mechanisms, including recruitment of basal transcription 
machinery (Coghlan et al. 2003; De Bosscher and Haegeman 2009). Furthermore, 
coactivators have been shown to possess histone acetyl transferase (HAT) activity, 
reorganising the chromatin structure in such a way that recruited transcriptional 
machinery has greater access to DNA (Barnes 2010). Corepressors, such as nuclear 
receptor corepressor (NCoR), and silencing mediator of retinoic acid and thyroid
 
hormone receptor (SMRT), negatively regulate gene expression. Primarily, 
corepressors are bound to unliganded receptors, preventing gene expression in the 
absence of the cognate ligand. However, corepressors also bind to receptors in the 
presence of their respective antagonists, actively repressing gene expression. These 
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corepressors have histone deacetylase (HDAC) activity, reorganising the chromatin 
into a restrictive structure that prevents access of transcriptional machinery (De 
Bosscher and Haegeman 2009; Barnes 2010). One such example of the importance 
of these coregulators proteins was recently shown in muscle cells. Treatment of these 
cells with dexamethasone, a more potent, synthetic analogue of cortisol, induces 
cellular proteolysis. This is attenuated by treatment with the GR antagonist RU486, 
demonstrating the effects are GR-mediated (Yang et al. 2007). However, the effects 
are also attenuated upon gene silencing of the coregulatory protein p300. 
Furthermore, in cells transfected with a mutant form of p300 lacking HAT activity, 
dexamethasone-mediated proteolysis was suppressed (Yang et al. 2007). 
 
1.2.4.4 Non-genomic effects of glucocorticoids 
The genomic actions of glucocorticoids are responsible for transactivation and 
transrepression of target genes. However, there are also multiple, rapid non-genomic 
effects exerted by glucocorticoids that are believed to occur in major tissues 
throughout the body. Firstly, glucocorticoids affect membrane fluidity through direct 
interactions with lipids in both plasma and mitochondrial membranes. High 
concentrations of glucocorticoids have been shown to incorporate into membranes, 







 channels (Stahn et al. 2007). These changes could contribute to the anti-
inflammatory effects of glucocorticoids by inhibiting ATP production (Song and 
Buttgereit 2006). Secondly, glucocorticoids have been shown to associate with 
membrane-bound receptors, distinct from classical glucocorticoid receptors. These 
include gamma-aminobutyric acid (GABA) receptors (Majewska 1987) and low-
affinity glucocorticoid receptors (LAGs) (Roszak et al. 1990), as well as membrane-
bound GR (mGR) (Bartholome et al. 2004), a variant of the classical cytosolic GR.  
Glucocorticoids also have rapid effects on caveolin, a scaffolding protein implicated 
in the organisation of signalling molecules. Glucocorticoids have been shown to alter 
phosphorylation levels of caveolin, resulting in activation of protein kinase B 
(PKB)/Akt pathways, in a rapid, non-genomic manner (Matthews et al. 2008). A 
final class of non-genomic effects involves binding of cytosolic GR. This ligation 
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releases proteins, including Src, which in turn interacts with lipid membranes, 
blocking arachidonic acid production (Croxtall et al. 2000). This molecule is a 
precursor for prostaglandins and leukotrienes, which contribute to the inflammatory 
response. As such, inhibition of arachidonic acid production represents a further non-
genomic, anti-inflammatory mechanism of glucocorticoids (Alangari 2010). 
 
1.2.5 Physiological effects of glucocorticoids 
Glucocorticoids exert a broad range of effects throughout the body. They act upon 
multiple target systems to increase energy substrate availability, as well as to 
modulate the immune response, allowing for adaptation to the changing 
environment.  
 
1.2.5.1 Lipid, carbohydrate and protein metabolism 
In an environmental situation of starvation or perceived danger, glucocorticoids act 
to provide energy substrates for the body in the form of glucose and NEFAs, thus 
opposing the effects of insulin, which acts to lower blood glucose and store fuel 
(Andrews and Walker 1999). The molecular mechanisms behind these effects are 
believed to mainly involve transactivation of target genes. In the liver, 
glucocorticoids activate gluconeogenic pathways through increased transcription of 
enzymes involved in this pathway such as phosphoenolpyruvate carboxykinase 
(PEPCK) (Sugiyama et al. 1998), glucose-6-phosphatase (G6Pase) (van Schaftingen 
and Gerin 2002) and tyrosine aminotransferase (TAT) (Dostert and Heinzel 2004). 
Furthermore, they simultaneously enhance glycogen synthase and glycogenolysis, 
described as ‘futile’ cycling, serving to prime the body for more effective release of 
fuel during times of stress or starvation (Macfarlane et al. 2008). In peripheral 
tissues, including skeletal muscle and adipose, glucose uptake is reduced, whilst 
breakdown of energy substrates is increased (Buren et al. 2002). In skeletal muscle, 
proteolysis is induced to release amino acids into the circulation, providing a 
substrate for gluconeogenesis (Jackman and Kandarian 2004). In adipose tissue, the 
effects of glucocorticoids on fatty acid metabolism are dependent upon the presence 
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of other hormones, namely insulin and catecholamines. In times of stress and 
starvation, when insulin is low and catecholamines elevated, glucocorticoids promote 
lipolysis, producing NEFAs which serve as a fuel source for peripheral tissues. 
Conversely, in an environment of high insulin and lower catecholamines in which 
lipolysis is suppressed, glucocorticoids promote lipid storage (Coppack et al. 1994; 
Macfarlane et al. 2008).  
 
1.2.5.2 Immunomodulatory effects 
Whilst commonly perceived as anti-inflammatory, physiological levels of 
glucocorticoids are more accurately immunomodulatory in action. Glucocorticoids 
act to suppress the production of pro-inflammatory cytokines, including TNFα, IL-6 
and IL-1β, inhibiting the inflammatory response (Barnes 1998). However, 
glucocorticoids also modulate the recruitment of inflammatory cells to sites of 
inflammation (McEwen et al. 1997; Tuckermann et al. 2007). This occurs primarily 
through suppressing the release of chemokines, including MCP-1, IL-8 and 
macrophage-inflammatory protein-1α (MIP-1α), but also suppressing the expression 
of adhesion molecules involved in lymphocyte extravasation, including intracellular 
adhesion molecule-1 (ICAM-1) and E-selectin (Tuckermann et al. 2007). These 
suppressive effects are mediated through both transrepressive mechanisms, whereby 
GR binds to the pro-inflammatory transcription factors NF-κB and AP-1, preventing 
transcription, and transactivation mechanism, namely an increase in the levels of 
MKP-1, which inactivates intracellular inflammatory signalling pathways, and IκBα, 
which retains NF-κB in an inactive form in the cytoplasm (De Bosscher et al. 2003; 
Beck et al. 2009). Aside from inhibiting production of pro-inflammatory molecules, 
glucocorticoids also promote the resolution of inflammation. This is achieved 
through the induction of anti-inflammatory gene expression, namely IL-1 receptor 
antagonist, IL-4, IL-10 and annexin-1 (Beck et al. 2009), and also on a cellular level 
through induction of leukocyte apoptosis and enhanced phagocytic clearance of such 




1.2.5.3 Blood pressure 
Glucocorticoids act upon the both the kidney and vasculature through multiple 
mechanisms to regulate blood pressure. They induce nitric oxide-mediated 
vasodilation of afferent and efferent arterioles in the kidney, as well as increasing salt 
and water retention (De Matteo and May 1997; Whitworth et al. 2000). These effects 
are mediated through both GR and MR. Whilst MR has a 10-fold higher affinity for 
cortisol and corticosterone than GR (Nishi and Kawata 2007), and MR is enriched 
within the kidney, activation of this receptor within the kidney is protected by the 
enzyme 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2 described 1.2.7.1). 
This enzyme inactivates glucocorticoids, thus preventing activation of MR (Roland 
et al. 1995). In conditions of 11βHSD2-deficency, glucocorticoids induce 
hypertension due to inappropriate activation of MR.  In vascular smooth muscle, 
glucocorticoids increase vascular tone primarily through GR-mediated mechanisms 
(Walker and Williams 1992). Levels of the calcium-activated potassium channel, 
which acts to allow relaxation of vascular smooth muscle cells through efflux of 
potassium, is reduced by glucocorticoids, resulting in vasoconstriction of vessels 
(Brem 2001). Glucocorticoids also activate the renin-angiotensinogen system 
through upregulation of both angiotensinogen and angiotensin-converting enzyme, 
which also results in vasoconstriction (Sato et al. 1994). Furthermore, 
glucocorticoids reduce the levels of several vasodilator proteins, including nitric 
oxide through suppression of endothelial and inducible nitric oxide synthase 
(Mitchell and Webb 2002), and prostaglandin I2 (Falardeau and Martineau 1989).  
 
1.2.5.4 Bone remodelling 
Glucocorticoids suppress the proliferation of osteoblasts through transcriptional 
inhibition of osteocalcin, a key protein in bone formation, via glucocorticoid action 
on the negative GRE within the promoter of this gene (Meyer et al. 1997). Apoptosis 
of both osteoblasts and osteocytes is also induced by glucocorticoids, reducing the 
number of bone cells, whilst the differentiation of osteoclasts is increased, enhancing 




1.2.6 Pharmacological effects of glucocorticoids 
The anti-inflammatory properties of glucocorticoids were first reported over half a 
century ago (Hench et al. 1949), leading to extensive research into their therapeutic 
benefits. In this time, the pharmaceutical industry has developed a number of 
synthetic glucocorticoids, including dexamethasone, betamethasone, triamcinolone, 
prednisone, prednisolone and methylprednisolone. This has led to glucocorticoids 
becoming one of the most commonly prescribed agents for the treatment of 
inflammatory and immune diseases (Saklatvala 2002). Indeed, glucocorticoids are 
very effective in the treatment of inflammatory conditions such as rheumatoid 
arthritis and  inflammatory bowel disease. However, the pharmacological doses of 
glucocorticoids often required to control inflammation in patients often result in the 
development of detrimental side effects. These include osteoporosis, growth 
retardation, muscle wasting and mood disorders (Saklatvala 2002; Schacke et al. 
2002). Furthermore, perhaps the most serious side effect resulting from excess 
glucocorticoids is the development of diabetes and cardiovascular disease. Indeed, 
there is considerable evidence for the development of these conditions after 
glucocorticoid therapy. Transplant patients are often treated with glucocorticoids due 
to their immunosuppressive properties, and this is believed to be responsible for the 
development of post-transplant diabetes mellitus (PTDM) (Schacke et al. 2002). 
Treatment is associated with the risk of hyperglycemia in patients without pre-
existing diabetes mellitus, and worsened glycemic control of diabetic patients. 
Recent population-based studies found that the use of glucocorticoids was associated 
with an increased risk of cardiovascular events (Wei et al. 2004). In particular, high 
dose glucocorticoid treatment resulted in patients being 2.5 times more likely to have 
a cardiac event. These side effects are thought to be mainly a result of 
glucocorticoid-induced transactivation of metabolic genes, including key enzymes in 




1.2.6.1 Dissociated glucocorticoids 
The demonstration that transactivation could account for the development of the 
metabolic side effects associated with glucocorticoid therapy, coupled with the anti-
inflammatory effects being controlled by primarily by transrepression, led to intense 
research into the development of ligands that could distinguish between 
transactivation and transrespression, namely dissociated steroids and selective GR 
modulators (SGRMs) (De Bosscher 2010). 
 
Initial work focussed on altering known steroid ligands in an attempt to separate out 
transactivation and transrepression mechanisms. Several synthetic glucocorticoids 
were developed that dissociated these pathways in vitro, namely RU24782, RU24858 
and RU40066 (Vayssiere et al. 1997). These compounds displayed a reduced 
transactivation ability compared to both dexamethasone and prednisolone, whilst 
demonstrating impressive anti-inflammatory properties. Utilising in vivo models of 
inflammation, including croton-oil induced ear oedema, these compounds were 
tested and compared to prednisolone. RU40066 had no in vivo effects on 
inflammation. However, both RU24782 and, in particular, RU24858 were effective 
at reducing inflammation (Vayssiere et al. 1997). Despite this initial promise, the 
reduced transactivation effects shown in vitro were not recapitulated in vivo (De 
Bosscher 2010). The reason for the discrepancies between in vitro and in vivo work 
is believed to result from metabolism of these compounds within the body. However, 
perhaps a more telling observation is the growing evidence that distinguishing 
between deleterious side effects and beneficial anti-inflammatory effects is not as 
simple as separating transactivation from transrepression. Indeed, several anti-
inflammatory molecules are induced by glucocorticoids, such as IL-10, MLP-1 and 
IκBα, which contribute significantly to the overall anti-inflammatory effect.  
 
The continued development of side effects from the above steroids resulted in a 
focussing of attention on non-steroidal compounds. In particular, two SGRMs have 
shown promise, namely AL-438 and CpdA. AL-438 is a modified form of a synthetic 
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progestin, which was shown to reduce inflammation in an in vivo model of asthma, 
but had reduced effects on hyperglycemia compared to classic glucocorticoid ligands 
(Coghlan et al. 2003). Further work on this compound found that key differences 
exist in the ability of AL-438-bound GR to interact with coregulatory molecules 
compared to glucocorticoid-bound GR. In particular, AL-438-bound GR did not 
associate with the coactivator peroxisome proliferator-activated receptor-  
coactivator-1 (PGC-1), which plays a role in the ability of glucocorticoids to induce 
hepatic gluconeogenic gene expression. This suggests that AL-438 induces 
conformational changes within the GR, specifically within the LBD, that alter its 
ability to interact with coregulatory proteins (Coghlan et al. 2003).  
 
CpdA is a plant-derived compound that was shown to display dissociated 
characteristics in vitro (De Bosscher et al. 2005). Further work revealed that CpdA 
induced a conformational change in GR that favoured monomer over dimer 
formation, as is seen with classic glucocorticoids (Robertson et al. 2010). Several in 
vivo models of inflammation, including arthritis and experimental autoimmune 
encephalomyelitis (EAE), have confirmed the anti-inflammatory potential of this 
SGRM, as well as demonstrating that beneficial effects were not accompanied by 
changes in metabolic parameters (Dewint et al. 2008; van Loo et al. 2010). However, 
whilst CpdA does not exert the same level of GR-dependent side effects as classic 
glucocorticoids, it does exert GR-independent effects, inducing apoptosis in several 
cell types, including lymphocytes and neuronal cells (Wust et al. 2009). This has 
been proposed to result from the metabolism of CpdA in vivo into aziridine 
derivatives, which have strong pro-apoptotic and neurotoxic properties. Nonetheless, 
these agents provide hope that manipulation of GR ligands may yet yield a safer 
pharmaceutical alternative to classic glucocorticoids.  
 
Potential alternatives to glucocorticoids are produced endogenously through a series 
of metabolising pathways (described 1.2.7), and it may be that these compounds, in 
particular 5α-reduced glucocorticoids, have the potential to be dissociated steroids. 
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1.2.7 Metabolism of glucocorticoids 
The levels of glucocorticoids in the body are kept in balance through a series of 
production and clearance mechanisms. The HPA axis is responsible for regulating 
circulating levels of glucocorticoids, with negative feedback mechanisms controlling 
synthesis and release of these hormones from the adrenal gland. However, the 
concentrations of glucocorticoids available for action are also regulated by 
metabolism within tissues. These steroids can be activated or inactivated locally by 
various mechanisms within target tissues, thus regulating access of the hormone to its 
receptor at a local level (Figure 1.6). The clearance of glucocorticoids is 
predominantly a hepatic process involving A-ring reduction by several enzymes 
within the A-ring reductase family, including 5α- and 5β-reductases and 3α-
hydroxysteroid dehydrogenase (3αHSD) (Walker and Andrew 2006).  Another major 
route of metabolism in numerous tissues involves 11β-hydroxysteroid 
dehydrogenases (11βHSDs), which, depending on the isozyme involved, generates or 
inactivates local glucocorticoids (Walker and Andrew 2006). 
 
1.2.7.1 11β-Hydroxysteroid dehydrogenases (11βHSDs) 
There are two isozymes of 11βHSD, type 1 and 2, which catalyse the interconversion 
of active glucocorticoids and their inert 11-keto derivatives. Both enzymes are 
microsomal membrane-bound proteins, which act to modify local exposure to 
glucocorticoids. 
In cell homogenates, 11βHSD type 1 (11βHSD1) is bidirectional, whereas in intact 
cells, it functions predominantly as a reductase, regenerating active glucocorticoids 
from their inactive 11-keto metabolites. The determination of reductase activity is 
dependent upon hexose-6-phosphate dehydrogenase (H6PDH). Within intact cells, 
H6PDH co-localises with 11βHSD1 at the ER lumen, providing it with the reduced 
form of nicotine adenine disphosphonucleotide (NADPH) as a cofactor, thus driving 
reductase activity (Figure 1.7) (Morton 2009).  Indeed, the importance of H6PDH is 
shown in H6PDH-deficient mice which lack 11βHSD1 reductase activity (Lavery et 
al. 2006). 11βHSD1 is expressed in a wide variety of tissues, including liver, adipose 







Figure 1.6 Glucocorticoid metabolism. Various pathways and enzymes involved in 
















































































Figure 1.7 Reductase activity of 11βHSD1. In intact cells, 11βHSD1 functions as a 
reductase, converting inactive glucocorticoids, 11-dehydrocorticosterone in rodents, 
to the active form, corticosterone in rodents. For the reaction to proceed in this 
direction requires the presence of the cofactor nicotine adenine disphosphonucleotide 
(NADPH). The colocalised enzyme hexose-6-phosphate dehydrogenase (H6PDH) is 
responsible for converting glucose-6-phosphate (G6P)
 
to 6-phospho-gluconolactone 














now established that 11βHSD1 provides an important intracellular amplification of 
glucocorticoids, as well as contributing to circulating levels of the hormone (Walker 
2007). In particular, given the anti-inflammatory effects of glucocorticoids, increased 
expression of 11βHSD1 is evident during inflammation (Chapman et al. 2009). 
11βHSD type 2 (11βHSD2) is the NADP
+
-dependent isozyme that functions in the 
dehydrogenase direction, inactivating glucocorticoids (Morton and Seckl 2008). The 
expression pattern of 11βHSD2 is distinct in that it is abundantly expressed in 
mineralocorticoid target tissues such as the distal nephron, salivary glands and 
colonic mucosa. This is important as 11βHSD2 protects MR from inappropriate 
activation by glucocorticoids, which can activate mineralocorticoid pathways, 
causing sodium and water retention, leading to hypertension (Morton and Seckl 
2008). Consistent with this, 11βHSD2 is often colocalised with MR at the 
endoplasmic reticulum membrane within cells (Odermatt et al. 2001). 
 
1.2.7.2 5α-Reductases 
5α-Reductases catalyse the reduction of ∆
4,5
 double bonds in a number of steroid 
substrates, yielding 5α-dihydro metabolites. Two isozymes exist, type 1 and type 2, 
which are the products of two different genes, SRD5A1 and SRD5A2 respectively 
(Andersson and Russell 1990; Andersson et al. 1991). Both the tissue distribution 
and substrate affinities differ between the two isozymes. In humans, 5αR1 (type 1) 
predominates in liver, adipose tissue, brain and non-genital skin, whilst 5αR2 (type 
2) is the principal isozyme in male reproductive tissues such as the prostate, 
epididymis and seminal vesicle (Doering et al. 2002). In rodents, it has been shown 
that 5αR1 has a much greater affinity (10-20 fold higher) for corticosterone, 
androgens and progesterones than 5αR2 (Normington and Russell 1992). Tissue 
specific distribution has important physiological implications. 5αR2 is crucial for 
normal development of human male sexual characteristics, as shown in conditions of 
male pseudohermaphroditism (Andersson et al. 1991). This condition, characterised 
by normal development of urogenital tracts, but delayed development of external 
genitalia in males, is a result of a mutation in 5αR2, which converts testosterone to 
its more potent metabolite, 5α-dihydrotestosterone (5αDHT). 5α-Reduction of 
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steroids renders their 3-oxo groups more susceptible to reduction by 3α-HSD. Such 
modifications reduce the affinity of the steroid for binding proteins, and so it was 
believed that 5αR1 participated in the catabolism and inactivation of steroid 
substances (Carlstedt-Duke et al. 1977). However, following the finding that 5αDHT 
is a more potent steroid at the androgen receptor than testosterone (Siiteri and Wilson 
1974), further investigations revealed that 5α-reduced metabolites of  progesterone 
(Kenyon 1985), aldosterone (Smith et al. 1998), and more recently glucocorticoid 
(McInnes et al. 2004), also activate their cognate receptors .  
 
1.2.7.3 5β-Reductase 
Similar to 5α-reductases, 5β-reductase (5βR) catalyses the reduction of the ∆
4,5
 
double bond within the A-ring of steroids. However, unlike 5α-reductases, this yields 
cis 5β-dihydro steroids. Expression of 5βR is mainly restricted to the liver, with 
small amounts detected in kidney tissues (Okuda and Okuda 1984). The predominant 
function of 5βR involves bile acid metabolism within the liver, as demonstrated by 
congenital defects in this metabolism pathway resulting from mutations in 5βR 
(Palermo et al. 2008). However, in terms of steroid metabolism, it is believed that 
5βR participates in catabolism of steroids, with 5βR metabolites thought to be 
biologically inactive as they fail to activate classic steroid receptors (McInnes et al. 
2004). However, it should be noted that 5β-reduced steroids are effective SXR 
activators (Blumberg et al. 1998). 
 
1.2.7.4 3α-Hydroxysteroid dehydrogenases 
Following 5α- or 5β-reduction of steroids, 3αHSDs rapidly reduce these 5α- or 5β-
dihydro metabolites, forming 5α- or 5β-tetrahydro steroids. In the rat, only one 
isozyme has been identified and cloned (akr1c9) (Lin et al. 1999). In humans, four 
isozymes have been cloned from four different genes, namely 3αHSD type 1 
(AKR1C4), 3α(17β)HSD type 2 (AKR1C3), 3αHSD type 3 (AKR1C2) and 20α(3α)-
HSD (AKR1C1) (Penning 1999). Distinct tissue distribution of these isozymes is 
apparent in humans, with both brain and liver expressing all four, lung tissue 
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expressing all except 3αHSD type 1 and prostate predominantly expressing 3αHSD 
type 3 and 3α(17β)HSD type 2 (Penning 1999). 3αHSDs are believed to participate 
in catabolism of steroids, for example in human liver, 3αHSD type 1 reduces the 
active 5αDHT to the inactive 5α-tetrahydro form (Khanna et al. 1995). However, 
3αHSDs function in vivo in both directions, dependent on the availability and ratio of 
NADP
+
/NADPH. In human prostate, 3αHSD type 3 acts in the reverse direction as 
an oxidative enzyme, generating the active 5αDHT (Penning 1999). Therefore, the 
direction and activity of 3αHSD may critically influence the availability of active 5α-
steroids. 
 
1.2.8 Glucocorticoids in metabolic syndrome 
The potential roles of glucocorticoid signalling in obesity and the associated 
metabolic syndrome are shown in Figure 1.8. The importance of glucocorticoids is 
exemplified in the clinical settings of deficiency, namely Addison’s disease 
(Kyriazopoulou 2007), and excess, namely Cushing’s syndrome (Boscaro et al. 
2001).  Addison’s disease is characterised by hypotension, weight loss and 
hypoglycaemia, whereas patients suffering from Cushing’s syndrome display 
hypertension, central obesity and hyperglycaemia. The striking similarities between 
glucocorticoid excess and the metabolic syndrome led to investigation into whether 
altered levels of glucocorticoids was responsible for the development of insulin 
resistance. Initial studies in idiopathic obesity revealed that whilst cortisol secretion 
is increased compared to lean subjects, circulating levels of glucocorticoids are 
unchanged due to enhanced metabolic clearance (Walker 2007). However, the 
discovery of intracellular metabolism of glucocorticoids as a modulator of receptor 
activation invoked much research into the roles of the 11βHSDs and the A-ring 
reductases in this disorder. 
 
Elevated intra-adipose levels of glucocorticoids have been proposed to be a major 
determinant of obesity and the metabolic syndrome (Seckl and Walker 2001; Walker 
and Andrew 2006; Cooper and Stewart 2009). The enzyme 11βHSD1 regenerates 
active glucocorticoid from its inert 11-keto metabolite, thereby providing an elegant 
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system through which local levels of glucocorticoids could be increased. As such, the 
levels of this enzyme were investigated in both genetic models of rodent obesity, as 
well as human obesity, revealing an increase in adipose expression of 11βHSD1 
(Livingstone et al. 2000; Masuzaki et al. 2001; Rask et al. 2001; Lindsay et al. 2003; 
Wake et al. 2003). Subsequent transgenic rodent models have further demonstrated 
the potential role this enzyme plays in metabolic dysregulation. Adipose-specific 
overexpression of 11βHSD1 in mice results in elevated adipose levels of 
corticosterone alongside all the major features of the metabolic syndrome (Masuzaki 
et al. 2001). In contrast, mice with a targeted disruption of 11βHSD1 show improved 
glucose tolerance and insulin sensitivity when fed a high-fat diet (Kotelevtsev et al. 
1997; Morton et al. 2001; Morton et al. 2004). However, the detrimental effect of 
enhanced 11βHSD1 expression is not solely in adipose. Transgenic overexpression 
of 11βHSD1 in liver tissue also leads to the development of insulin resistance and 
dyslipidemia, but not obesity (Paterson et al. 2004).  
 
Recent studies have suggested a possible link between the inflammation seen in 
obesity and the altered levels of 11βHSD1, with pro-inflammatory cytokines shown 
to increase expression and activity of 11βHSD1 in primary adipocytes (Tomlinson et 
al. 2001; Tomlinson et al. 2004). This work provides a potentially crucial 
mechanistic insight into the dysregulation of glucocorticoid metabolism in obesity.  
 
Given the association of increased 11βHSD1 expression in obese subjects, a 
compelling case is made for targeted inhibition of 11βHSD1 as a therapeutic strategy 
to combat the metabolic complications associated with obesity. Numerous 11βHSD1 
inhibitors have been tested in rodent models of obesity and insulin resistance, with 
varying results. However, several groups have reported compounds that lower 
plasma glucose and insulin levels in both diet-induced and genetic models of obesity 
(Alberts et al. 2002; Alberts et al. 2003). Translation of these inhibitors into human 
patients has recently been undertaken, with the results providing much promise. In a 
randomised, placebo-controlled study, patients with type 2 diabetes who had 
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insufficient glycaemic control with metformin treatment were given the 11βHSD1 
inhibitor INCB13739 (Rosenstock et al. 2010). Over 12 weeks, it was found that 
treatment with the inhibitor improved hyperglycaemia in a dose-dependent manner, 
indicating that 11βHSD1 is a valid therapeutic target for the treatment of the 
metabolic syndrome. 
 
Given that glucocorticoid secretion is increased in obesity, yet circulating levels are 
unchanged, it raises the question of whether there are alterations in the clearance 
mechanisms of glucocorticoids in obesity. Hepatic levels of 11βHSD1 are reduced in 
obesity, both in rodent models and in human subjects, lowering the regeneration of 
active glucocorticoids (Morton and Seckl 2008). However, the main route of 
glucocorticoid clearance is believed to involve A-ring reduction (Andrew et al. 1998; 
Walker and Andrew 2006; Morton and Seckl 2008). Investigation into the levels of 
A-ring reductases revealed that hepatic levels of 5αR1 are increased in obese humans 
and rodents, resulting in increased clearance of glucocorticoids, as demonstrated by 
increased excretion of 5α-reduced metabolites (Andrew et al. 1998; Livingstone et 
al. 2005). Given the detrimental effects that glucocorticoids have on insulin 
sensitivity, it would appear that increasing the clearance of these steroids could be an 
adaptive response employed by the liver to protect it from these effects. Support for 
this theory is shown by recent studies in 5αR1 knockout mice, which develop fatty 
liver and glucose intolerance, possibly due to accumulation of the parent 
glucocorticoid (Livingstone 2008). However, one might speculate that the recent 
discovery that 5α-reduced metabolites of glucocorticoids are able to activate GR 
alters this theory. As such, it became important to characterise these 5α-reduced 
metabolites in terms of their biological activity.  
 
Work looking at the binding affinities of A-ring reduced metabolites of 
corticosterone for GR, as well as the level of receptor activation, found that 5α-
reduced glucocorticoid metabolites are capable of displacing dexamethasone in 
competitive binding studies (McInnes et al. 2004). Recent work has shown that 
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whilst 5αTHB was unable to transactivate the gluconeogenic genes TAT and 
PEPCK, it was able to suppress the release of pro-inflammatory cytokines IL-6 and 
TNF-α in lipopolysaccharide (LPS) treated bone marrow derived macrophages, 
although to a much lesser extent than corticosterone (Yang 2009). This evidence 
suggests that 5αTHB is capable of retaining the anti-inflammatory properties of the 
parent glucocorticoid, without inducing the adverse metabolic effects. This lends 
support to the theory that increased 5αR1 expression in obesity is a protective 
















Figure 1.8 Overview of signalling in obesity. In adipose tissue (a), obesity is associated with adipocyte hypertrophy. This stimulates secretion of 
monocyte chemoattractant protein-1 (MCP-1), which results in the macrophage recruitment. Subsequent macrophage activation releases inflammatory 
mediators including tumor necrosis factor-α (TNF α) and interleukin-6 (IL-6), which directly affect insulin signalling. Increased glucocorticoid (GC) 
levels, via increased regeneration through 11βHSD1, are also known to affect insulin signalling. This thesis will assess potential roles for inflammatory 
regulation of adipose 11βHSD1 (shown by red dotted line). In liver (b), obesity increases the flux of adipose-derived mediators, including non-esterified 
fatty acids (NEFAs) to this tissue. this is associated with increased hepatic triglyceride accumulation, reduced insulin signalling and increased levels of 
the enzyme 5αR1, which reduces GCs into their 5α-metabolites. This altered GC metabolism has initially been viewed as a protective pathway, limiting 
the metabolic effects of GCs on the liver. However, the full range of actions of 5α-reduced GC metabolites has yet to be explored, and so effects on the 
liver are not fully understood (red dotted line). This thesis will explore the potential anti-inflammatory actions of 5α-reduced GC metabolites. 
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Given that glucocorticoid metabolism is altered in obesity and associated insulin 
resistance and might influence local glucocorticoid levels and hence inflammation, 
and that  inflammation plays a prominent role in the development of these metabolic 
disorders and is implicated in regulation of 11-HSD1, it is possible that these events 
may regulate each other, contributing to the overall disease state. The hypotheses of 
this thesis are outlined below: 
 
1) Salicylate treatment alters glucocorticoid metabolism, suppressing 11-HSD1 in 
adipose tissue. 
2) Suppression of adipose 11βHSD1 mediates the insulin-sensitising effects of anti-
inflammatory salicylates in obesity. 
3) 5α-Reduced glucocorticoid metabolites exert anti-inflammatory effects in a 
similar manner to the parent glucocorticoid. 



































All chemicals and reagents were from Sigma-Aldrich, Dorset, UK, unless otherwise 
stated. All steroids were from Steraloids, RI, USA. Room temperature (RT) is 
defined as 18-22°C. 
 
2.2 Buffers and Solutions 
2.2.1 Molecular biology 
2.2.1.1 DEPC-treated water 
Diethylpyrocarbonate (DEPC; 5 drops) was added to distilled water (500ml), mixed, 
left for 24 hours prior to autoclaving and stored at RT. 
 
2.2.1.2 10xTBE Buffer 
Tris base (890mM), boric acid (890mM) and EDTA (0.5M, 40ml) were dissolved in 
distilled water (800ml). The pH was adjusted to 8.0 through addition of KOH (10M) 
and volume adjusted to 1L with distilled water. The solution was autoclaved and 
stored at RT. 
 
2.2.1.3. 0.5xTBE Buffer 
10xTBE (50ml) was diluted in distilled water (950ml) and stored at RT. 
 
2.2.1.4 Protein Lysis Buffer (2x) 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 1M, pH 7.5, 50ml), 
NaCl (137mM), MgCl2 (1mM), CaCl2 (1mM), NaF (10mM), EDTA (2mM) and 





2.2.1.5 Protein Lysis Buffer (1x) 
Octylphenoxypolyethoxyethanol (IGEPAL CA-630, 1% v/v), glycerol (l0% v/v), 
NaVO4 (2mM), protease inhibitor cocktail tablet (Roche, West Sussex, UK; x1) and 
lysis buffer (2x, 5ml) were added to distilled water (2.8ml). This was prepared 
immediately prior to use. 
 
2.2.1.6 Running Buffer (10x) 
Tris base (250mM), sodium dodecyl sulphate (SDS, 35mM) and HEPES (1M) were 
dissolved in distilled water (1L) and stored at RT. A working solution was used at 1x 
concentration. 
 
2.2.1.7 Transfer Buffer 
Tris base (25mM) and glycine (186mM) were dissolved in distilled water (900ml), 
before addition of methanol (100ml) and stored at 4°C. 
 
2.2.1.8 TBS (10x) 
Tris base (250mM), KCl (27mM) and NaCl (1.5M) were dissolved in distilled water 
(800ml). The pH was adjusted to 7.4 with concentrated HCl (37%), before the 
volume was adjusted to 1L with distilled water and stored at RT. 
 
2.2.1.9 TBST (1x) 
10xTBS (100ml) was diluted in distilled water (900ml), with the addition of Tween-




2.2.1.10 Blocking Milk (5%) 
Blotting grade blocker, non-fat, dry milk (Biorad, CA, USA, 5g) was dissolved in 1x 
TBST (100ml) and stored at 4°C. 
 
2.2.1.11 BSA (5%) 
Bovine serum albumin, (BSA, Fraction V, 5g) was dissolved in TBST (1x, 100ml) 
and stored at 4°C. 
 
2.2.1.12 KREBS Buffer 
MgSO4.7H2O (1.19mM), KCl (3.80mM), KH2PO4 (1.19mM), CaCl2 (2.54mM), 
NaHCO3 (25mM) and NaCl (118mM) were added to distilled water (76ml). The pH 
was adjusted to 7.4 with concentrated HCl (37%) and the solution stored at 4°C. 
 
2.2.1.13 Borate buffer 
Boric acid (66mM), NaOH (33mM), BSA (Fraction V, 0.5% w/v) and concentrated 
HCl (1.75ml) were dissolved in distilled water (500ml) and stored at -20°C. 
 
2.2.1.14 Luciferase lysis buffer 
Tris phosphate (25mM, pH 7.8), dithiothreitol (2mM), Triton x100 (1% v/v) and 
glycerol (10% v/v) were added to distilled water (21.5ml) and stored at -20°C. 
 
2.2.1.15 Luciferase assay buffer (2x) 
Tricine (59mM), dithiothreitol (66mM), EDTA (0.2mM), MgCO3 (2mM), MgSO4 
(0.5mM) and Coenzyme A (0.26mM) were added to distilled water (48ml). The pH 




2.2.1.16 Luria Bertani (LB) broth 
LB (25g) was dissolved in distilled water (1L). 
 
2.2.1.17 LB/ ampicillin agar 
Agarose (1.5g, Lonza, Berkshire, UK) was dissolved in LB broth (100ml, 2.2.1.16), 
before addition of ampicillin (100μg/ml). 
 
2.3 Cultured cells 
All cells were from the European Collection of Cell Cultures (ECACC), unless 
otherwise stated. All reagents for cell culture were from Lonza, Berkshire, UK, 
unless otherwise stated. 
 
2.3.1 HEK293 (human embryonic kidney cells) 
HEK293 cells were cultured in 75cm
2
 flasks in Dulbecco’s Modified Eagle’s 
Medium (DMEM), supplemented with 10% (v/v) heat-inactivated foetal bovine 
serum (FBS), penicillin (100 IU/ml), streptomycin (100μg/ml) and L-glutamine 
(200mM). Cells were incubated in a humidified atmosphere in 95% air and 5% CO2 
at 37°C.  
Cells were routinely passaged when confluent, usually twice a week. For 
subculturing, cells were washed with sterile phosphate buffered saline (PBS, 7ml) 
and then cells incubated with trypsin/EDTA (2ml, 1-2 min, 37°C). The flasks were 
shaken until cells were released from the flask surface. Cells were resuspended in 
medium (10ml). 1/10 to 1/4 of cells were left for maintenance in the flasks, and the 
rest were aspirated or transferred to other containers. The medium (12ml final 
volume) was added to the flasks before cells were incubated in the conditions 




2.3.2 RAW264.7 (murine macrophage cells) 
RAW264.7 cells were cultured 75cm
2
 flasks under the same conditions as those 
described for HEK293 cells (2.7.1.1), however subculturing was slightly different. 
Cells were washed with sterile PBS (7ml) and fresh culture media added (9ml). Cells 
were detached from the surface of the flask and resuspended in normal culture media 
using a sterile scrapper. The remaining subculture protocol was as described for 
HEK293 cells (2.4.1). 
 
 
2.4 In vitro experimental procedures 
 
2.4.1 Luciferase reporter plasmids 
The luciferase reporter plasmids 3x(NFκB)tk-luc and MMP1-luc (-517/+63col-luc) 
were kind gifts from L.G. Bladh (Karolinska Institutet, Sweden) and have been 
described previously (Bladh et al. 2005). The plasmids pGEM (inert DNA) and 
pGL3-basic (empty vector) were purchased from Promega (Hampshire, UK). The 
plasmids pSV2-luc (positive luciferase control) and pVL342 (glucocorticoid 
receptor) were kindly supplied by Prof. Karen Chapman (University of Edinburgh).  
 
2.4.2 Plasmid preparation 
The plasmids described above (2.8.1) were grown in Escherichia coli HB101 cells. A 
single colony of cells were grown overnight (37°C) in LB broth (5ml, 2.2.1.16). This 
overnight culture of cells was diluted 1/100 into LB broth (50ml) and incubated (2 
hours, 37°C). Cells underwent centrifugation (6000g, 5 min, 4°C). The pellet formed 
was resuspended in calcium chloride (20ml, 0.1M) and incubated (10 min, 4°C). The 
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cells underwent further centrifugation (6000g, 5 min, 4°C), and the pellet formed 
was resuspended in calcium chloride (20ml, 0.1M) and incubated (4°C). 
For each plasmid, DNA (1μl) was added to HB101 cells (200μl) and incubated (30 
min, 4°C). Cells were heat-shocked (50 sec, 42°C) and incubated (2 min, 4°C), 
before being plated out on LB/ ampicillin agar plates (2.2.1.17) and incubated 
(overnight, 37°C). A single colony was selected and grown in LB broth with 
ampicillin (overnight, 37°C). 
Plasmid purification was carried out using the Plasmid Maxi Kit (Qiagen). Overnight 
cultures were subjected to centrifugation (8000g, 10 min, 4°C), with the pellet 
formed resuspended thoroughly in Buffer P1 (10ml). Addition of Buffer P2 (10ml) 
and thorough mixing ensured lysis of cells. Following incubation (10 min, RT), 
Buffer P3 (10ml) was added, mixed thoroughly and incubated (10 min, 4°C) to 
precipitate out SDS. The suspension was subjected to centrifugation (16000g, 30 
min, 4°C) and the supernatant added to a QIAGEN-tip, where DNA binds to the 
column. The QIAGEN-tip was washed twice with Buffer QC (30ml each), before 
DNA was eluted with Buffer QF (15ml). DNA was precipitated out by addition of 
0.7x volume (10.5ml) isopropanol and subjection to centrifugation (15000g, 30 min, 
4°C). The resulting pellet was washed with ethanol (5ml, 70% v/v) and subjected to 
centrifugation (15000g, 10 min, 4°C). The pellet formed was air-dried (5 min) and 
resuspended in distilled water (500μl), before DNA was quantified using a Nanodrop 
Spectrophotometer as described for RNA (2.6.1.4), with the exception that the ratio 






2.4.3 Transfection of cells 
Cells were seeded on 6-well plates at a concentration of approximately 2-3 x 10
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cells/ml and incubated for 24 hours. For each well to be transfected, the following 
transfection complex was made up: 
 Plasmid DNA (1.2μg, outlined below) 
 Opti-MEM Reduced Serum Medium (50μl, GIBCO, Parsley, UK) 
 FuGENE HD Transfection Reagent (2μl, Roche, West Sussex, UK) 
This transfection complex was incubated (15 min, RT), before addition to 
appropriate wells. Plasmid DNA was setup as outlined in Table 2.1. The plasmid 
pGEM, containing inert DNA, was used to as a negative control. The plasmid pSV2-
luc was used as a positive control to confirm the success of each batch of 
transfection. The plasmid pGL3-basic was an empty vector control which was a 
luciferase reporter vector without promoter or enhancer. When the luciferase activity 
of cells transfected with pSV2-luc was >500 times higher than that of pGL3-basic, 
the transfection was deemed successful.  
 
2.4.4 Cell lysate preparation 
The growth medium from cells was removed, and then cells were rinsed carefully 
with sterile PBS (1ml). Lysis buffer (2.2.1.14, 100µl per well) was added and the 
culture plates rocked to ensure complete coverage of the cells with lysis buffer. The 
cells were then scraped from wells and transferred to an eppendorf tube prior to 
centrifugation (12000g, 2 min, RT) to precipitate any remaining undissolved cell 







pGEM pSV2 pGL3 
With GR Without GR 
NFκB AP-1 NFκB AP-1 
pGEM 1.2 - - - - - - 
pSV2-luc - 1.2 - - - - - 
pGL3-basic - - 1.2 - - - - 
3x(NFκB)tk-luc - - - 1 - 1.2 - 
-517/+63col-luc - - - - 1 - 1.2 
pVL342 - - - 0.2 0.2 - - 
 




2.4.5 Luciferase assay 
Luciferase activity was quantified on a 96-well plate (Nunclon Surface, Denmark). 
The following were added to each well: sample (duplicate; 40µl), assay buffer 
(2.2.1.15; 100µl) and ATP (0.1M; 5µl). The plate was placed into a Microplate 
Luminometer (Orion II, Berthold, Hertfordshire, UK), in which luciferin (1mM; 
100µl) was injected to each well. The reaction between the substrate luciferin and co-
substrate ATP Mg
2+
 was catalyzed by the firefly luciferase when present within the 
cells, forming the product of oxyluciferin. During the oxidation of luciferin, light was 
produced by converting the chemical energy derived from an electron transition. 
Using the programme Simplicity 4.1 (Berthold, Hertfordshire, UK), the 
luminescence from each well was read with a 2.05 sec delay after injection, and each 
measurement lasted for 10 sec. When the luciferase activity of cells transfected with 
pSV2-luc was 500 times higher than that of pGL3-basic, the transfection was deemed 
successful. Activity from pGEM was subtracted from all values as a measure of 
background activity. Duplicates were acceptable if they differed from mean <10%. 
 
2.5 In vivo procedures 
2.5.1 Animal Maintenance 
Animals were maintained under controlled conditions of light (lights on 0700h – 
1900h) and temperature (18-20°C) and allowed free access to standard chow (RMI 
801002; Special Diet Services, Witham, UK) and drinking water, unless otherwise 
stated. All experiments were performed under the following project licence (JR 
Seckl, PPL No: 60/3962) and personal licence (Nixon, PIL No: 60/11505) and under 




2.5.2 Mini-pump Implantation 
2.5.2.1 Mini-pump loading 
Solutions of vehicle or drug were made up immediately prior to loading of mini-
pumps. Osmotic mini-pumps (Model 2004, Alzet, CA, USA) were loaded with 
appropriate solution following manufacturer’s instructions and primed in saline at 
37°C for 24 hours before surgery. These pumps perform due to differences in 
osmotic pressure between the loading compartment within the pump and the tissue 
environment in which the pump is implanted. This causes an influx of water into the 
area around the loading compartment, displacing the test solution from the pump at a 
controlled rate (0.25μl/hr). 
 
2.5.2.2. Surgery 
Animals were injected subcutaneously with carprofen (5mg/kg body weight, 1 in 10 
diluted in saline (0.9% w/v, B.Braun Melsungen AG, Germany)) and anaesthetised 
with isoflurane (Merial Animal Health Ltd, Essex, UK). Loaded osmotic mini-pumps 
were implanted subcutaneously between the scapulae through dorsal incisions which 
were closed with staples. Following surgery, animals were allowed to recover on a 
heat mat before being transferred to individual clean cages. 
 
2.5.3 Thioglycollate-induced peritonitis 
Thioglycollate (0.5ml, 10% v/v in distilled water) was administered by 
intraperitoneal injection at 1100h. Animals were decapitated 4 hours after induction 
of peritonitis (1500h) and within 1 min of disturbing the cage. Trunk blood was 
collected in ETDA-treated tubes (0.5M). Plasma was prepared from blood samples 
by centrifugation (10000g, 5 min, 4°C) and stored at -20C.  Peritoneal lavage was 
performed immediately after decapitation with sterile PBS (4ml). Lavage fluid was 




2.5.4 Glucose tolerance test 
Mice were fasted for 6 hours (0800h – 1400h) before initiation of glucose tolerance 
test. Glucose (40% w/v in distilled water) was administered by intraperitoneal 
injection to give a dose of 2g glucose per kg body weight.  Blood was collected via 
tail nick before glucose injection and at 15, 30, 60 and 90 min post-injection. 
Following this procedure, animals were transferred to clean cages with free access to 
food and water. 
 
2.5.5 Terminal procedures 
Animals were decapitated on the morning (0800h – 1000h) of final day within 1 min 
of disturbing the cage. Trunk blood was collected in EDTA (0.5M)-treated tubes. 
Plasma was and stored as above (2.5.3). The following tissues were removed, 
weighed and snap frozen on dry ice; thymus, spleen, liver, kidney, adrenal, omental 
adipose, mesenteric adipose, retroperitoneal adipose, epididymal adipose and 
subcutaneous adipose. Tissues were then stored at -80°C. 
 
 
2.6 Molecular Biology 
2.6.1 RNA 
All kits for RNA extraction and reverse transcription were from Qiagen, West 
Sussex, UK. 
 
2.6.1.1 RNA extraction from liver 
RNA was extracted from liver using the Qiagen RNeasy Mini Kit. Tissue (~30mg) 
was homogenised in Buffer RLT (600μl). The samples were subjected to 
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centrifugation (16,000g, 3 min, 4ºC). The supernatant was removed into an equal 
volume of 50% ethanol and mixed. This solution was placed in the RNeasy spin 
column and subjected to centrifugation (12,000g, 30sec, 4ºC). The eluate was 
discarded and the column washed with Buffer RW1 (700μl) and Buffer RPE (500μl) 
sequentially. In each case, the eluate was discarded following centrifugation 
(12,000g, 30 sec, 4ºC). Buffer RPE (500μl) was added to wash the membrane, 
followed by a further centrifugation step (12,000g, 2 min, 4ºC). The spin column was 
then placed in a fresh 2ml collecting tube and subjected to centrifugation (16,000g, 1 
min, 4ºC) to eliminate any Buffer RPE carryover. The spin column was then placed 
in a fresh 1.5ml eppendorf, RNase-free water (30μl) added and RNA eluted by 
centrifugation (12,000g, 1 min, 4ºC). Eluted RNA was stored at -80°C. 
 
2.6.1.2 RNA extraction from adipose 
RNA was extracted from adipose using the same method as with liver, except for 
tissue homogenisation. Tissue (~30mg) was homogenised in Qiazol Lysis Reagent 
(600μl, Qiagen) and incubated (5 min, RT). Chloroform (200μl) was added, mixed 
and subjected to centrifugation (12,000g, 15 min, 4˚C). The supernatant was 
removed into an equal volume of ethanol (70% v/v) and mixed. At this stage, the 
solution was placed in the RNeasy spin column, with the remainder of the procedure 
being the same as for liver tissue shown above (2.6.1.1). 
 
2.6.1.3 RNA extraction from cultured cells 
RNA was extracted from cells using the Qiagen RNeasy Mini Kit. Cells were 
washed in sterile PBS (1ml) before addition of Buffer RLT (350μl per well) to lyse 
the cells. Cells were incubated (15 min, 4°C) and then scraped into eppendorfs. 
Lysates were transferred to the QIAshredder spin column and subjected to 
centrifugation (16000g, 2 min, 4ºC). The supernatant was removed into an equal 
volume of 70% ethanol and mixed. At this stage, the solution was placed in the 





2.6.1.4 RNA quantification 
RNA was quantified using a Nanodrop Spectrophotometer (Thermo Fisher, West 
Sussex, UK). Concentration was determined by the absorbance at 260nm wavelength 
(A260), and the purity assessed by the ratio of RNA/DNA (A260/A280), which was 
deemed acceptable if between 1.9 and 2.1. 
 
2.6.1.5 RNA quality 
Quality of RNA was assessed by electrophoresis on a denaturing agarose (Lonza, 
Berkshire, UK) gel (1.2% w/v in 0.5x TBE). Samples (2μl) were prepared by adding 
loading dye (Promega, WI, USA; 1 in 5 diluted in distilled water; 10μl). Prepared 
samples (12μl) were electrophorosed on the gel (100V, 1hr) and RNA integrity 
assessed on basis of 18S and 28S ribosomal RNA (rRNA) bands. RNA integrity was 
deemed satisfactory if sharp, clear 28S and 18S  rRNA bands were present without 
smearing, and if 28S rRNA band was approximately twice as intense as 18S rRNA 
band. 
 
2.6.1.6 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
Total RNA (liver 1μg, adipose 0.25μg) was reverse transcribed using the QuantiTect 
Reverse Transcription Kit. RNA (12μl) was added to gDNA Wipeout Buffer (2μl) 
and incubated (42ºC, 2 min) to eliminate any contaminating genomic DNA. To each 
sample, Quantiscript RT Buffer (4μl, containing dNTPs), RT Primer Mix (1μl, 
containing oligo-dT and random primers) and Quantiscript Reverse Transcriptase 
(6μl) were added. Two negative controls were prepared as above, one with water 
instead of RNA to identify any RNA contamination in reagents and one without the 
reverse transcriptase enzyme in order to detect the presence of contamination by 
genomic DNA. Samples were incubated (42ºC, 15 min; 95ºC, 3 min) in a PCR 
machine (G-Storm, GRI Lid, Essex, UK), before being chilled to 4ºC. The resultant 
cDNA was stored at -20ºC. 
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2.6.1.7 Polymerase Chain Reaction (PCR) 
PCR was carried out using Qiagen Multiplex PCR Kit. cDNA samples (1μl) were 
added to Qiagen water (7μl), primer mix (containing forward and reverse primers 
(Table 2.1), 2pmoles/μl for each primer, 2μl) and Qiagen Mastermix (10μl). A 
negative control was prepared with Qiagen water added in place of cDNA to confirm 
absence of DNA contamination. Thermal cycling was performed in a PCR machine 
(G-Storm, GRI Lid, Essex, UK). Samples were heated for initial denaturation (95°C, 
5 min), then underwent 30 cycles of PCR amplification, which consisted of 
denaturation (95°C, 30 sec), primer annealing (55°C, 90 sec) and elongation (72°C, 
60 sec). Upon completion of the PCR programme, samples were incubated to ensure 
elongation of products to full length (72°C, 5 min) and chilled to 10 °C. Cresol red 
loading dye (4mg/ml cresol red in 40% w/v sucrose; 5μl) was added to each sample, 
mixed and analysed by electrophoresis on an agarose (Lonza, Berkshire, UK) gel 
(1.2% w/v in 0.5x TBE). A 100 base pair (bp) DNA ladder (Promega, WI, USA; 
range 100 – 1000bp) was also included to allow identification of products based on 










For CTA CAG GAG CTG CCT TCA AT
Rev CTT TGC ACG TAG TGG ATC AG
For AAC ACA GCG AGA GTG TGT CG
Rev GAG AAG AGA CCC AGC AGC AC
For ATG CCG CCT ATG TTT ACC AC
Rev ATG TGC GAC AAT GAC GAT GT
For AAT TGG TCC GAT CTT GCT TG
Rev CCA CCC AGA TTT TGT CTC GT
For ATG GTG AAG GTC GGT GTG AAC
Rev GCC TTG ACT GTG CCG TTG AAT
258
Srd5a2                               
(5α-reductase 2)                       
NM_053188
Akr1d1                              
(5β-reductase)                       
NM_145364
Akr1c6                              
(3α-HSD)                       
NM_030611
Gapdh                                   
(GAPDH)                                 
NM_008084.2
Primer sequence
Srd5a1                               








Table 2.2 Details of primers for PCR amplification (For, forward; Rev, reverse; bp, 




2.6.1.8 Real-time PCR 
Abundance of mRNA was quantified using a LightCycler 480 (Roche Applied 
Science, Burgess Hill, UK). Primers (Table 2.3; Invitrogen Ltd., Paisley, UK) were 
designed to match intron-spanning probes within the Roche Universal Probe Library. 
cDNA was diluted (liver, 1 in 40; adipose, 1 in 20; cultured cells, 1 in 20) in 
LightCycler H2O. Diluted cDNA samples (2μl) were added to each well, followed by 
Master Mix (8μl), consisting of the following components: 
LightCycler H2O (2.7μl) 
Forward and reverse primers (20μM, 0.1µl each) 
Corresponding probe (10μM, 0.1µl) 
Roche Probes Master (5μl) 
 
Samples were heated for initial denaturation (95ºC, 5min), then underwent 50 cycles 
of PCR amplification, which consisted of denaturation (95ºC, 10 sec), annealing 
(60ºC, 30 sec) and elongation (72ºC, 1 sec). Upon completion of the PCR 
programme, samples were cooled (40ºC, 30 sec). All samples were analysed in 
triplicate and amplification curves plotted (y axis fluorescence, x axis cycle number). 
Triplicates were deemed acceptable if the standard deviation of crossing point (Cp) < 
0.5 cycles. A standard curve (y axis crossing point, x axis log concentration) for each 
gene was generated by serial dilution of cDNAs pooled from different samples and 
fitted with a straight line and deemed acceptable if reaction efficiency was between 












For TCT ACA AAT GAA GAG TTC AGA CCA G
Rev GCC CCA GTG ACA ATC ACT TT
For GGG AAA CTG GAT ACA AAA TAC CC
Rev CCA CGA GCT CCC CAA AAT A
For CGA CCT CCT GAC TTG GAT AGA
Rev AAA GGG TGG GCA GCT TGT
For CTG TAG CCC ACG TCG TAG C
Rev TTG AGA TCC ATG CCG TTG
For GGA GAG AAA GGA GAT GCA GGT
Rev CTT TCC TGC CAG GGG TTC
For CTC GCT CTC AGA TGC CCT AC
Rev GGT TGT GTT GCT TGC CAT T
For GCG CTG GAG GAG TGT TTT T
Rev CCG CTC TCC AGT TGA ACC
For CCT CTC GAA GGC TCT CTT CC
Rev GGT CCT TTG GTT CCA CAC AG
For CTC AAC ACG GGA AAC CTC AC
Rev CGC TCC ACC AAC TAA GAA CG
For GGG GAG CTG TGA TGT GAA GT
Rev CCA GGA AAT AAT TVT GGC TCA
Primer sequence
Adipoq               
(Adiponectin)                                   
NM_009605.4






Agt                                     
(Angiotensinogen)                       
NM_007428.3
62
Lip                                       
(Hormone sensitive lipase) 
NM_001039507.1
Pnpla2                    
(Adipose triglyceride lipase) 
NM_025802.2
Rn18s                                  
(18S)                                        
NR_003278.1
17
Tbp                                      
(TATA-binding protein) 
NM_013684.3
Srd5a1                               
(5α-reductase 1)                       
NM_175283
41
Hsd11b1               




Tnf                                     






Table 2.3 Details of primers for real-time PCR for use with Roche Universal Probe 





2.6.2.1 Protein extraction from tissue 
Tissue (adipose, 60mg) was homogenised using a rotor-blade in KREBS (2.2.1.12; 
1.8ml) subjected to centrifugation (1000g, 1 min, RT) to pellet cellular debris. The 
supernatant containing the protein was then harvested and stored at -20°C. 
 
2.6.2.2 Protein extraction from cultured cells 
Cells were washed with sterile PBS (1ml). Lysis buffer (2.2.1.5; 100μl per well) was 
added and incubated (15 min, 4°C). Cells were scraped into an eppendorf, mixed and 
further incubated (5 min, 4°C), before being subjected to centrifugation (13000g, 20 
min, 4°C) to generate a pellet composed of heavy membranes. The supernatant 
containing cytosolic protein was stored at -20°C. 
 
2.6.2.3 Protein assay 
Protein concentrations of samples were determined using a Bio-Rad kit (Bio-Rad 
Laboratories Ltd., Hertfordshire, UK). The absorbance maximum for the acidic 
solution of Coomassie® Brilliant Blue G-250 dye shifts from 465nm to 590nm when 
binding to protein occurs. The absorbance at 590mn is proportional to the 
concentration of protein present. Standards were prepared from a stock solution in 
KREBS (2.2.1.12; adipose) or protein lysis buffer (2.2.1.5; cultured cells). Samples 
(10μl) were added in duplicate to wells of a 96-well plate before addition of Biorad 
acidic dye reagent (1 in 5 dilution in distilled water; 240μl). Absorbance of samples 
and standards were recorded at 590nm. Data from the standards were used to 
construct standard curves (y axis absorbance, x axis concentration) which were 
deemed acceptable if r
2






11βHSD1 functions as a reductase in vivo, converting inactive 11-
dehydrocorticosterone to corticosterone. However, in vitro, dehydrogenase activity 
predominates, so velocity of 11βHSD1 activity in adipose was quantified through 
conversion of corticosterone to 11-dehydrocorticosterone. 
Enzyme kinetics were determined from whole tissue homogenate, with first order 
kinetics determined by ensuring conversion <30%. Adipose homogenates (100 or 
300μg/ml) were incubated (37ºC) in KREBS buffer containing glucose (1% w/v), 
NADP (2mM), 1,2,6,7-[
3
H]4-corticosterone (10nM, GE Healthcare Life Sciences, 
Buckinghamshire, UK) and unlabelled corticosterone (adipose, 1.99 or 9.99μM). 
Steroids were extracted after a fixed period of incubation (adipose, 16 or 24 hours) 
with 10x volume ethyl acetate and the organic phase evaporated under oxygen free 
nitrogen at 60
o
C. The dried extracts were then dissolved in mobile phase (600μl: 
60% H2O; 15% acetonitrile; 25% methanol). Steroids were injected using a 717plus 
Autosampler (Water, Hertfordshire, UK) and analysed by high performance liquid 
chromatography. Steroids were eluted (600 Controller pump, Waters, Hertfordshire, 
UK) with mobile phase (1.5ml/min, 45ºC) from a C18 Sunfire column (length 15cm; 
internal diameter, 4.6mm, pore size 5µm; Waters, Hertfordshire, UK) and quantified 
by on-line scintillation counting after mixing with Goldstar scintillation fluid 
(2ml/min; Meridian, Surrey, UK) using a scintillation pump (Berthold, Hertfordshire, 
UK). The proportion of corticosterone converted to 11-dehydrocorticosterone was 
calculated by integrating the peak areas of the analytes in the radiochromatograms 
using Chromeleon software (Dionex, CA, USA). Assays were performed in duplicate 
and deemed acceptable if differed from mean < 10%. Minimum peak height was set 
at 3x background.  
 
2.6.2.5 Western blotting 
2.6.2.5.1 Gel electrophoresis 
Protein samples (30μg) were added to equal volume of loading mix, consisting of 
NuPAGE LDS sample loading dye (Invitrogen, Paisley, UK, 4x) and NuPAGE 
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sample reducing agent (Invitrogen, 1x). Samples were mixed and incubated (5 min, 
95°C) to denature protein. Samples were separated by electrophoresis on a 12% 
Pierce Precise protein gel (Thermo Fisher Scientific, Northumberland, UK) using the 
XCell Surelock™ Mini-Cell (Invitrogen). The XCell tank was filled with 1x running 
buffer (2.2.1.6) and run at 80V for 1 hour at RT. 
 
2.6.2.5.2 Gel transfer 
Gels were transferred to nitrocellulose membranes (GE Healthcare, 
Buckinghamshire, UK) using the Mini Trans-Blot
 
Electrophoretic Transfer Cell 
(Biorad, CA, USA). A gel sandwich was prepared within the cassette consisting of 
fiber pad, filter paper, gel, nitrocellulose membrane, filter paper and fiber pad. The 
gel sandwich cassette was placed within the transfer module and tank, which was 




After transfer, nitrocellulose membrane was blocked with milk (2.2.1.10, 1 hour, 
RT). The membrane was washed three times (10 min each) with TBST (2.2.1.9). The 
membrane was then incubated (overnight, 4°C) with primary antibody at a 
concentration of 1:1000 (unless otherwise stated) in BSA (2.2.1.11). The membrane 
was washed three times as before prior to incubation with secondary antibody at a 
concentration of 1:10000 (unless otherwise stated) in milk (2.2.1.10) for 1 hour. A 
final series of washes was performed as above, before the blot was developed. 
 
2.6.2.5.4 Blot development 




2.7 Biochemical assays 
All spectrophotometric measurements were carried out with an OPTImax Tunable 
Microplate Reader (Molecular Devices, CA, USA). 
 
2.7.1 Quantification of insulin in plasma by enzyme-linked 
immunosorbent assay (ELISA) 
Insulin was quantified using an Ultra Sensitive Mouse Insulin ELISA Kit (Crystal 
Chem Inc., Illinois, USA). A series of dilutions of insulin were prepared (0.1 – 6.4 
ng/ml) from the standard using sample diluent according to the kit. Samples 
(singlicate due to paucity of sample; 5μl) and standards (duplicate; 5μl) were added 
to wells pre-coated with primary guinea pig anti-insulin antibody along with sample 
diluent (95μl). Sample diluent was used as a blank measurement. After incubation (2 
hours, 4˚C), the plate was washed five times in wash buffer supplied (diluted 1 in 20 
in distilled water) to remove unbound insulin. Horse-radish peroxidise (HRP)-
conjugated anti-insulin antibody conjugant (100μl) was added to each well and 
incubated (30 min, RT). The plate was washed a further seven times using the diluted 
wash buffer to remove unbound excess HRP-conjugate before addition of enzyme 
substrate solution (100μl) containing tetramethylbenzidine (TMB) to each well. The 
plate was incubated in the dark (40 min, RT) before addition of sulphuric acid (0.5M, 
100μl) to each well to stop the reaction. The difference in absorbance between 
630nm and 450nm was measured spectrophotometerically (values at 630nm are 
deemed to be a result of scratches or artefacts on the plate and are therefore 
subtracted to give a more accurate reading). A standard curve was constructed (y axis 
absorbance, x axis concentration) and a straight line fitted and deemed acceptable if 
r
2





2.7.2 Quantification of glucose in plasma by hexokinase 
assay 
Glucose levels were quantified using an Infinity Glucose Hexokinase Liquid Stable 
Reagent (Thermo Electron, Pittsburgh, USA) based on the following reactions. The 
reagent supplied contained hexokinase, which catalysed the phosphorylation of 
glucose by ATP, producing ADP and glucose-6-phosphate. The latter was then 
oxidised to 6-phosphogluconate with the associated reduction of NAD
+
 to NADH by 
glucose-6-phosphate dehydrogenase. The amount of NADH formed was proportional 
to the concentration of glucose in the sample.  
Serial dilutions of glucose were prepared (50 – 400mg/dl) from the standard using 
distilled water, with distilled water used as a blank.  Samples (singlicate due to 
paucity of sample; 2μl) and standards (duplicate; 2μl) were added to wells of 96-well 
plates, followed by addition of the reagent (200μl). The plate was incubated in the 
dark (15 min, RT). The absorbance at 340nm was measured spectrophotometrically. 
A standard curve was constructed (y axis absorbance, x axis concentration) and a 
straight line fitted and deemed acceptable if r
2
 > 0.98. Duplicates of standards were 
deemed acceptable they differed from mean < 10%. 
 
2.7.3 Quantification of non-esterified fatty acid (NEFA) in 
plasma 
NEFAs were quantified using a 96-well Serum/Plasma Fatty Acid Kit (Zen-Bio, NC, 
USA) based on the following reactions. NEFAs and CoA were firstly converted to 
fatty acyl-CoA thiol esters, in the presence of acyl-CoA synthetase, which 
subsequently reacted with oxygen in the presence of acyl-CoA oxidase, producing 
hydrogen peroxide. Thereafter 3-methyl-N-ethyl-N-(β-hydroxyethyl) -aniline and 4-
aminoantipyrine were oxidized by hydrogen peroxide in the presence of peroxidase 
and produced a purple product with an absorbance of 550 nm.  
Serial dilutions of NEFAs were prepared (1.4 - 333µM) from a NEFA Standard 
using distilled water, with distilled water used as a blank. Samples (singlicate due to 
paucity of sample; 5μl) and standards (duplicate; 5µl) were added to wells of 96-well 
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plate, followed by Dilution Buffer (45µl). NEFA Reagent A (100µl) was added to 
each well and plate incubated (10min, 37C°). NEFA Reagent B (50µl) was added to 
each well and plate incubated (10min, 37C°). Following incubation, the plate was 
allowed to equilibrate (5min, RT) before absorbance was read at 540nm. A standard 
curve was constructed (y axis absorbance, x axis concentration) and a straight line 
fitted and deemed acceptable if r
2
 > 0.98. Duplicates of standards were deemed 
acceptable if they differed from mean < 10%. 
 
2.7.4 Quantification of triglycerides in plasma 
Plasma triglyceride levels were assessed using Infinity Triglyceride Liquid Stable 
Reagent (Thermo Electron, Pittsburgh, USA) based on the following reactions. 
Triglycerides were hydrolysed to glycerol and NEFAs by lipoprotein lipase. Glycerol 
was phosphorylated by ATP with glycerol kinase, producing ADP and glycerol-3-
phosphate. The latter is then oxidised by glycerolphosphatase to produce hydrogen 
peroxide. Hydrogen peroxide reacts with 4-aminoantipyrine and 3, 5-dichloro-2-
hydroxybenzene sulfonate to produce a red coloured dye. The absorbance of this dye 
was proportional to the concentration of triglycerides in the sample. 
Serial dilutions of triglyceride were prepared (0.565 – 11.3mmol/l) from the standard 
calibrator using distilled water, with distilled water used as a blank. Samples 
(singlicate due to paucity of sample; 2μl) and standards (duplicate; 2μl) were added 
to wells of 96-well plate, followed by addition of the reagent (200μl). The plate was 
incubated in dark (5 min, 37ºC) before the difference in absorbance was read 
between 600nm and 500nm. A standard curve was constructed (y axis absorbance, x 
axis concentration) and a straight line fitted and deemed acceptable if r
2
 > 0.98. 




2.7.5 Quantification of corticosterone in plasma by 
radioimmunoassay (RIA) 
Plasma corticosterone was quantified using an in-house assay (Al-Dujaili et al. 
1981). Plasma was diluted (10% v/v) with borate buffer (2.2.1.13) and incubated (30 
min, 80˚C) to denature corticosteroid-binding globulin (CBG).  Serial dilutions of 
corticosterone were prepared (0.6 – 320nM) from a standard using borate buffer. 
Sample and standards (20μl) were added to wells of 96-well plate. A mix of primary 
antibody-
3
[H]4-corticosterone was prepared as follows: [
3
H]4-corticosterone (3μl) 
was added to borate buffer (6ml), followed by addition of rabbit anti-mouse primary 
antibody (60μl, 1 in 100 dilution), a kind gift from Dr Christopher Kenyon, 
University of Edinburgh (MacPhee et al. 1989). Primary antibody-
3
H-corticosterone 
mix (50μl) was added to each well. 50μl of SPA beads (GE Healthcare Life Sciences, 
Buckinghamshire, UK) coated with anti-rabbit secondary antibody were added to 
each well and the plate incubated in the dark (16 hours, RT). Scintillation occurred 
when the SPA beads bound to that fraction of primary antibody which was associated 
with [
3
H]4-corticosterone. Due to the competition between binding of unlabelled and 
labelled corticosterone to the primary antibody, the extent of scintillation decreased 
as the concentration of unlabelled corticosterone increases. The degree of 
scintillation was quantified using a liquid scintillation counter (Microbeta Plus, 
Wallac 1450, Turku, Finland), and data (Bound/Bound at zero) used to construct a 
semi-log standard curve from which the concentration of corticosterone in each 
sample was calculated. Standard curves were deemed acceptable if r
2
 > 0.98. 
Duplicates of standards were deemed acceptable if they differed from mean < 10%. 
 
2.7.6 Quantification of β-hydroxybutyrate in plasma 
Plasma β-Hydroxybutyrate (β-HB) was analysed using a β-Hydroxybutyrate Assay 
Kit (BioVision, CA, USA) based on the following reaction.  β-HB was converted to 
acetoacetate by the enzyme β-hydroxybutyrate dehydrogenase. This product has an 
absorbance that is read at 450nm.  
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Serial dilutions were prepared (1 – 20mM) from the β-Hydroxybutyrate Standard 
using distilled water. Samples (singlicate due to paucity of sample; 5μl) and 
standards (duplicate; 5μl) were added to wells of 96-well plate, followed by addition 
of Reaction Mix (50µl). The plate was incubated in dark (5 min, RT) before 
absorbance was read at 450nm. A standard curve was constructed (y axis absorbance, 
x axis concentration) and a straight line fitted and deemed acceptable if r
2
 > 0.98. 
Duplicates of standards were deemed acceptable if they differed from mean < 10%. 
 
2.7.7 Quantification of cytokines by ELISA 
Cytokine levels in cell media was quantified using the ELISA Ready-SET-Go! Kit 
(eBioscience, Hatfield, UK). All reagents were supplied by the kit unless stated. The 
96-well plates provided were coated with Capture Antibody (100μl per well) and 
incubated (overnight, 4°C). The plates were washed five times with Wash Buffer 
(250μl per well) to remove unbound antibody and then blocked with 1x Assay 
Diluent (200μl per well, 1 hour, RT). The plates were washed five times as above. A 
series of dilutions of the specific cytokine were prepared using 1x Assay diluents 
(IL-6, 4pg/ml – 500pg/ml; TNFα, 8pg/ml – 1000pg/ml), with 1x Assay diluent used 
as a blank. Samples and standards (duplicate, 100μl) were added and incubated 
(overnight, 4°C). Following incubation, the plates were washed five times as above, 
Detection Antibody added (100μl per well) and plates incubated (1 hour, RT). The 
plates were washed five times as above, Avidin-HRP solution added (100μl per well) 
and incubated (30 min, RT). The plates were washed seven times with Wash Buffer 
(250μl per well), Substrate Solution added (100μl) and incubated (15 min, RT), then 
stop solution was added (50μl per well). The change in absorbance between 570nm 
and 450nm was measured spectrophotometrically. A standard curve was fitted 
according to manufacturer’s instructions and deemed acceptable if r
2
 > 0.98. 





Data are presented as mean ± SEM and were analysed by Student’s t-tests, One-way 
Analysis of Variance (ANOVA), or Two-way ANOVA followed by post-hoc tests as 
appropriate. Statistical significance was taken at the 5% level. Calculations were 
















Effects of anti-inflammatory 
salicylates on glucocorticoid 












In recent years, a plethora of evidence has accumulated indicating that inflammation 
is a key component in the underlying mechanism through which obesity causes 
insulin resistance (Mathieu et al. 2010; Olefsky and Glass 2010). Obese adipose 
tissue is viewed as being in a state of chronic, low-grade inflammation, with the 
levels of the pro-inflammatory cytokines TNFα and IL-6 positively correlated with 
the degree of obesity-linked insulin resistance.  It is therefore reasonable to 
hypothesise that suppressing inflammation in this tissue may be beneficial. Non-
steroidal anti-inflammatory drugs, such as sodium salicylate and aspirin, are amongst 
the most widely used medications in the world for treatment of inflammatory 
conditions such as rheumatoid arthritis. These effects are mediated by blocking 
production of pro-inflammatory molecules through several mechanisms, namely 
inactivation of COX-1 and COX-2 (Loll et al. 1995) and the more recently 
discovered inhibition of NFκB-mediated transcription (Kopp and Ghosh 1994). 
However, despite the discovery over half a century ago of their beneficial effects in 
the treatment of hyperglycaemia, it was not until recently that the mechanisms 
behind these glucose-lowering abilities of salicylates were re-investigated. Both 
rodent and human data have demonstrated the ability of salicylate compounds such 
as sodium salicylate, acetylsalicylic acid (aspirin) and salsalate to lower blood 
glucose levels in obesity and type 2 diabetes (Kim et al. 2001; Yuan et al. 2001; 
Hundal et al. 2002; Mohlig et al. 2006; Fleischman et al. 2008; Goldfine et al. 2008; 
Koska et al. 2009; Goldfine et al. 2010). These studies have implicated inflammatory 
pathways, particularly the IKKβ/NFκB system as the target of these compounds. 
However, the precise mechanism remains to be elucidated.  
 
The clinical similarities between the excessive glucocorticoid levels seen in 
Cushing’s syndrome and the metabolic consequences of obesity and insulin 
resistance led to the belief that dysregulation of glucocorticoid action was central to 
the pathogenesis of the metabolic syndrome. It has since been discovered that the 
levels of the glucocorticoid-regenerating enzyme 11βHSD1 are altered in obesity. In 
human obesity, 11HSD1 mRNA levels and activity are decreased in liver, but 
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increased in subcutaneous adipose tissue, resulting in elevated intra-adipose cortisol 
regeneration (Rask et al. 2001; Lindsay et al. 2003; Wake et al. 2003). In genetically 
obese rodents, 11βHSD1 is increased in visceral adipose (Masuzaki et al. 2001; 
Livingstone et al. 2005), whilst adipose-specific overexpression of 11βHSD1 results 
in increased glucocorticoid action and recapitulates the obese and insulin resistance 
state (Paterson et al. 2004). In contrast, targeted disruption of Hsd11b1 protects 
against insulin resistance and central obesity on high fat feeding (Kotelevtsev et al. 
1997; Morton et al. 2001; Morton et al. 2004). Studies investigating potential 
therapeutic effects of 11βHSD1 inhibition have demonstrated improved insulin 
sensitivity in animal models of obesity and insulin resistance (Alberts et al. 2002; 
Alberts et al. 2003). A recent study using a selective 11βHSD1 inhibitor to treat type 
2 diabetes found treatment resulted in significantly reduced fasting blood glucose, as 
well as improvements in measures of insulin resistance (Rosenstock et al. 2010). 
 
The mechanism of tissue-specific dysregulation of 11HSD1 in obesity remains 
uncertain, however, given the roles that both inflammation and 11βHSD1 have in the 
underlying pathogenesis of obesity-linked insulin resistance, it appears that the two 
may be linked. Indeed, in vitro studies have demonstrated that pro-inflammatory 
cytokines including TNF and IL-6 up-regulate 11HSD1 in several cell types 
including in human pre-adipocytes (Tomlinson et al. 2001; Tomlinson et al. 2004). 
These observations raise the possibility that increased intra-adipose 11HSD1 
expression is a manifestation of the pro-inflammatory state in obesity. This chapter 




The hypothesis of this chapter is that a salicylate-induced improvement in insulin 





The aims of this chapter were to investigate: 
1)  Whether salicylates improve insulin sensitivity in diet-induced obesity.  
2) Whether improved insulin sensitivity is associated with reduced adipose 





3.2 Materials and methods 
3.2.1 Investigation of salicylate effects on glucocorticoid 
metabolism in vivo 
 
3.2.1.1 Experimental outline 
Mice were continuously infused with sodium salicylate (120mg/kg/day) or vehicle 
(distilled water) via subcutaneously implanted osmotic mini-pumps for 4 weeks. 
Mice were weighed twice weekly throughout the course of the experiment. Glucose 
tolerance tests were carried out on Day 23 or 24. On Day 27 or 28, mice were culled 
with blood and tissues collected. 
 
3.2.1.2 Animal Maintenance 
Adult male C57Bl6 mice were obtained (Harlan, Olac, UK) at 12 weeks of age. Mice 
were maintained as described (2.5.1). Upon arrival, they were allowed to acclimatise 
to the new environment for at least one week before any experiments were initiated. 
Two cohorts of mice were studied: 
 A ‘lean’ cohort of C57Bl/6 mice was maintained on standard chow diet (RMI 
801002; Special Diet Services, Witham, UK) over the course of the 
experiment.  
 A diet-induced obese (‘DIO’) cohort of C57Bl/6 mice was generated by ten 
weeks of feeding with high fat diet (58% fat, 12% sucrose; D12331, Research 
Diets, NJ, USA). The mice were maintained on this diet thereafter until the 
experiment was complete.  
 
3.2.1.3 Mini-pump implantation 
To ensure a dose of 120mg/kg/day was administered, two different concentrations of 
sodium salicylate were made up dependent upon the weight of the mice. For ‘lean’ 
74 
 
mice, sodium salicylate (1.16g) was dissolved in distilled water (2ml). For obese 
(‘DIO’) mice, sodium salicylate (1.52g) was dissolved in distilled water (2ml). 
Vehicle groups received distilled water. Osmotic mini-pumps were loaded as 
described (2.5.2.1). Mice were operated on Day 0 using the surgical procedures 
described (2.5.2.2). 
 
3.2.1.4 Glucose tolerance test 
Glucose tolerance tests were carried out as described (2.5.4) on Day 23 or 24. 
 
3.2.1.5 Terminal procedures 
Animals were culled on Day 27 or 28 as described (2.5.5). 
 
3.2.1.6 Quantification of mRNA expression 
Total RNAs were isolated from snap frozen livers (2.6.1.1), subcutaneous adipose, 
mesenteric adipose and omental adipose (2.6.1.2) before RNA quantification 
(2.6.1.4). First strand cDNA was synthesised by RT-PCR (2.6.1.6). The mRNA 
abundances of 11βHSD1, angiotensinogen (AGT), adiponectin (AdiQ), tumor 
necrosis factor-α (TNFα), hormone sensitive lipase (HSL), adipose triglyceride lipase 
(ATGL) and lipoprotein lipase (LPL) were quantified by real-time PCR (2.6.1.8) and 
normalised against the mean of the transcript levels of a combination of house-
keeping genes as outlined in Table 3.1. These combinations of house-keeping genes 










in DIO Mice 
P 
value 
Liver TBP + Cyc 0.14 18S + TBP   0.79 
Omental adipose 18S + TBP + Cyc 0.28 18S + Cyc 0.22 
Mesenteric adipose 18S   0.35 18S + Cyc 0.69 
Subcutaneous adipose 18S + TBP   0.14 18S + TBP   0.35 
     
  
Table 3.1 Housekeeping genes used for each tissue for real-time PCR. DIO = 
diet-induced obese; 18S = 18S ribosomal RNA; TBP = TATA-binding protein; Cyc 
= cyclophilin A. P value indicates results of student’s t-test between Vehicle- and 




11βHSD1 reductase activity was measured in mesenteric and subcutaneous adipose 
as described (2.6.2.4). In mesenteric adipose, samples from ‘lean’ mice were 
incubated with protein concentration (100μg/ml) and substrate concentration (2μM) 
for 16 hours. Obese ‘DIO’ samples were incubated with protein concentration 
(300μg/ml) and substrate concentration (10μM) for 24 hours. In subcutaneous 
adipose, paucity of tissue in ‘lean’ mice prevented assessment of activity in these 
animals. In obese ‘DIO’ mice, samples were incubated with protein concentration 
(100μg/ml) and substrate concentration (2μM) for 22 hours. 
 
3.2.1.8 Quantification of glucose in plasma 
Glucose in plasma collected during the glucose tolerance test was quantified by 
hexokinase assay as described (2.7.2). 
 
3.2.1.9 Quantification of insulin in plasma 
Insulin in plasma collected during the glucose tolerance test was quantified by 
ELISA as described (2.7.1). 
 
3.2.1.10 Quantification of triglycerides in plasma 
Fasting plasma triglyceride levels from ‘0’ time point during glucose tolerance test 
were quantified as described (see 2.7.4). 
 
3.2.1.11 Quantification of NEFAs in plasma 
NEFAs in plasma collected during the first two time points of the glucose tolerance 




3.2.1.12 Quantification of β-hydroxybutyrate in plasma 
Fasting plasma β-hydroxybutyrate levels from ‘0’ time point during glucose 
tolerance test were quantified as described (see 2.7.6). 
 
3.2.2 Statistics 
Data are presented as mean ± SEM and were analysed by unpaired student’s t-tests, 
One-way Analysis of Variance (ANOVA) with Tukey post-hoc tests, or Two-way 




3.3.1 Salicylate effects on 11βHSD1 in lean and diet-induced 
obese (DIO) mice 
 
3.3.1.1 Body and tissue weights 
In both lean C57Bl/6 and DIO mice, salicylate did not induce changes in body 
weight compared to vehicle treatment (Table 3.2). In lean mice, salicylate did not 
significantly alter tissue weights, however, there were trends towards increased 
subcutaneous (S.C.) adipose (P=0.06) and decreased liver weight (P=0.07). In DIO 
mice, there was an increase in the ratio of S.C. to omental adipose depots weights 
with salicylate, as well as a trend for increased S.C. adipose (P=0.09). 
 
3.3.1.2 Glucose tolerance test 
To investigate the effects of salicylate on insulin sensitivity, plasma glucose and 
insulin levels were quantified during a glucose tolerance test (Figure 3.1). In lean 
mice, salicylate increased insulin levels (Figure 3.1b and d), but did not alter glucose 
levels (Figure 3.1a and c). Plasma glucose levels in DIO mice were significantly 
elevated compared to lean mice, an effect that was attenuated by salicylate treatment 
(3.1a and c). Insulin levels in DIO mice, whilst significantly higher than in lean mice, 












Table 3.2 Body and tissue weights of lean and diet-induced obese (DIO) mice following salicylate or vehicle treatment for 4 weeks. 
No significant differences in body weight were observed between vehicle and salicylate treated groups prior to or after treatment. In lean 
mice, no significant differences were observed in tissue weights (expressed as percentage of body weight) following salicylate treatment. In 
DIO mice, there was a significant increase in the ratio of S.C. adipose to omental adipose following salicylate treatment. Data are mean ± 
SEM for n=7-8 per group. Comparisons between Vehicle and Salicylate were by Student’s t-test.  
Body Weights 
 Lean DIO 
 Vehicle Salicylate p Value Vehicle Salicylate p Value 
Weight at start (g) 28.8 ± 0.6 29.2 ± 0.5 0.67 38.0 ± 1.2 39.4 ± 1.6 0.51 
Weight at end (g) 29.2 ± 0.8 29.5 ± 0.7 0.8 39.0 ± 1.4 40.3 ± 2.3 0.65 
       
Tissue Weights 
 Lean DIO 
Tissue     Weight as % Body Weight p Value     Weight as % Body Weight p Value 
 Vehicle Salicylate  Vehicle Salicylate  
Liver 4.38 ± 0.13 4.05 ± 0.10 0.07 3.51 ± 0.08 3.65 ± 0.10 0.29 
S.C. Adipose 0.79 ± 0.05 0.94 ± 0.06 0.06 0.96 ± 0.12 1.29 ± 0.14 0.09 
Omental Adipose 0.04 ± 0.01 0.04 ± 0.01 0.92 0.15 ± 0.03 0.12 ± 0.02 0.34 
Mesenteric Adipose 0.69 ± 0.09 0.73 ± 0.10 0.83 1.36 ± 0.15 1.589 ± 0.25 0.44 
Retroperitoneal Adipose 0.43 ± 0.05 0.47 ± 0.06 0.6 0.81 ± 0.07 0.92 ± 0.08 0.28 
Epididymal Adipose 1.52 ± 0.14 1.79 ± 0.15 0.21 2.62 ± 0.22 2.74 ± 0.13 0.65 
Quadricep Muscle 0.50 ± 0.05 0.49 ± 0.04 0.97 0.31 ± 0.03 0.28 ± 0.03 0.50 
Adrenal 0.02 ± 0.001 0.02 ± 0.001 0.86 0.01 ± 0.001 0.01 ± 0.001 0.34 




Figure 3.1 Salicylate improved glucose tolerance in DIO mice. Plasma glucose (a) 
and insulin (b) levels over the course of a glucose tolerance test, with areas under the 
curve (AUC) shown underneath (c and d respectively), were measured 
spectrophotometrically. Squares denote lean mice, whilst triangles denote DIO mice. 
Open symbols/bars denote vehicle treatment, whilst closed symbols/bars denote 
salicylate treatment.  In lean mice, salicylate had no effect on plasma glucose (c), but 
significantly increased plasma insulin levels (d). Compared to lean mice, diet-
induced obese (DIO) had significantly elevated plasma insulin (d), and glucose levels 
(c) over the course of the test. Salicylate treatment in DIO mice reduced plasma 
glucose levels (c). Data are mean ± SEM for n=7-8 per group for individual time 
points and for area under the curve. Comparisons for AUC were by two-way 










































































3.3.1.3 Plasma NEFA levels 
In lean mice, salicylate did not alter fasting plasma NEFA levels or their suppression 
15 min after glucose infusion (Figure 3.2). DIO mice had significantly elevated 
fasting plasma NEFA levels compared with lean mice (Figure 3.2a) and a greatly 
reduced ability to suppress NEFA release following a glucose bolus (Figure 3.2b). In 
this obese setting, salicylate reduced fasting plasma NEFA levels (Figure 3.2a), as 
well as increasing NEFA suppression following a glucose bolus (Figure 3.2b). 
 
3.3.1.4 Plasma triglyceride levels 
In lean mice, salicylate treatment did not alter fasting plasma triglyceride levels 
(Figure 3.3). Compared to lean, DIO mice had significantly elevated fasting 
triglyceride levels and there was a trend towards a reduction in triglyceride levels 
(P=0.06) with salicylate treatment. 
 
3.3.1.5 Plasma β-hydroxybutyrate levels 
Salicylate did not alter fasting β-HB levels in lean mice (Figure 3.4). DIO mice had 
significantly elevated fasting β-HB levels compared to lean mice, with salicylate 
















Figure 3.2 Salicylate altered NEFA levels in DIO mice. Fasting plasma non-
esterified fatty acids (NEFA) levels (a) and 15 min post-glucose challenge NEFA 
suppression (b) in lean and diet-induced obese (DIO) mice were measured 
spectrophotometrically. Open bars denote vehicle treatment, whilst closed bars 
denote salicylate treatment. In lean mice, salicylate had no effect on fasting NEFA 
levels (a) or on post-glucose NEFA suppression (b). Compared to lean mice, DIO 
mice had significantly elevated fasting NEFA levels (a), as well as significantly 
reduced post-prandial NEFA suppression (b). In DIO mice, salicylate significantly 
reduced fasting NEFA levels (a) and improved post-prandial NEFA suppression (b). 
Data are mean ± SEM for n=7-8 per group. Comparisons were by two-way ANOVA 

















































Figure 3.3 Salicylate did not alter triglyceride levels. Fasting plasma triglyceride 
levels in lean and diet-induced obese (DIO) mice were measured 
spectrophotometrically. Open bars denote vehicle treatment, whilst closed bars 
denote salicylate treatment. Salicylate did not affect fasting triglyceride levels in lean 
mice. DIO mice had significantly elevated triglyceride levels compared to lean mice. 
Whilst salicylate had no significant effect on triglyceride levels in DIO mice, there 
was a trend towards a reduction following salicylate treatment (P=0.08). Data are 
mean ± SEM for n=7-8 per group. Comparisons were by two-way ANOVA with 
Bonferroni post-hoc tests: 
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Figure 3.4 Salicylate reduced β-hydroxybutyrate (β-HB) levels in DIO mice. 
Fasting plasma β-HB levels in lean and diet-induced obese (DIO) mice were 
measured spectrophotometrically. Open bars denote vehicle treatment, whilst closed 
bars denote salicylate treatment. In lean mice, salicylate had no effect on fasting β-
HB levels. Compared to lean, DIO mice had significantly elevated β-HB levels, with 
salicylate treatment normalising the levels. Data are mean ± SEM for n=7-8 per 
group. Comparisons were by two-way ANOVA with Bonferroni post-hoc tests: 
























 3.3.1.6 11βHSD1 expression and activity 
To investigate whether salicylate reduced abundance of 11βHSD1 mRNA, transcript 
levels were analysed in liver and several adipose depots (Figure 3.5). In lean mice 
(Figure 3.5a), salicylate did not significantly alter mRNA levels of 11βHSD1 in 
liver, S.C. adipose or mesenteric adipose, however, there was a trend towards 
reduced expression in omental adipose (P=0.08). In DIO mice (Figure 3.5b), 
salicylate significantly reduced mRNA levels of 11βHSD1 in omental adipose, with 
an accompanying trend towards a reduction in mesenteric adipose (P=0.06). 
The activity of 11βHSD1 was further assessed in adipose tissue to confirm if changes 
in transcript levels were matched with changes in protein (Figure 3.6). Paucity of 
omental adipose tissue prevented assessment of enzyme activity in this depot, and so 
mesenteric adipose was assessed instead (Figure 3.6a). In both lean and DIO mice, 
salicylate treatment significantly reduced 11βHSD1 activity in mesenteric adipose. 
The necessity for a much greater substrate concentration in DIO mice (10μM vs 
2μM) in order to detect equivalent turnover of substrate, due to suppression of 
11βHSD1, meant a direct comparison of conversion rates was not possible. However, 
extrapolation using the Michaelis-Menten equation and previously reported Vmax 
and Km values for the enzyme (Mitic 2009) allowed a comparison of reaction 
velocity in both groups, revealing that 11βHSD1 enzyme activity in the mesenteric 
adipose of DIO mice was significantly downregulated compared to lean mice (Figure 
3.6a). In S.C. adipose (Figure 3.6b), shortage of tissue in lean mice prevented 
assessment of enzyme activity in these animals. However, in DIO mice S.C. adipose 






Figure 3.5 Salicylate reduced 11βHSD1 transcript levels in omental adipose. 
mRNA levels of 11βHSD1 in liver, omental adipose (Om Fat), mesenteric adipose 
(Mes Fat) and subcutaneous adipose (SC Fat) were determined by real-time PCR in 
lean (a) and diet-induced obese (DIO) (b). In lean mice (a), salicylate treatment 
(black bars) had no significant effect on 11βHSD1 transcript levels, however there 
was a trend towards reduced expression in omental adipose (P=0.08). In DIO mice 
(b), salicylate significantly reduced 11βHSD1 expression in omental adipose 
compared to vehicle (open bars), with an accompanying trend in mesenteric adipose 
(P=0.06). Data are mean ± SEM, expressed as % of the respective Vehicle mean. 
N=6-8 per group. Comparisons were by Student’s unpaired t-test: *P<0.05 vs 
Vehicle on same diet. 
 
 






































































































Figure 3.6 Salicylate reduced mesenteric adipose 11βHSD1 activity. Enzyme 
velocity was measured in mesenteric adipose (a) and subcutaneous (S.C) adipose (b). 
In mesenteric adipose, salicylate significantly reduced 11βHSD1 activity in both lean 
and diet-induced obese (DIO) mice. DIO mice had significantly reduced activity in 
mesenteric adipose compared to lean mice (a). In S.C. adipose (b), salicylate had no 
effect in DIO mice. Insufficient tissue in lean mice prevented measurement of 
activity in S.C. adipose of these animals. Data are mean ± SEM for n=7-8 per group. 
Comparisons were by two-way ANOVA with Bonferroni post-hoc tests: *P<0.05, 















































3.3.1.7 Adipokine expression in adipose tissue 
In lean mice, salicylate had limited effects on adipokine expression in adipose tissue. 
In omental adipose (Figure 3.7a), salicylate significantly reduced TNFα mRNA 
levels, but had no effect on adiponectin (AdiQ), lipoprotein lipase (LPL), adipose 
triglyceride lipase (ATGL) or hormone sensitive lipase (HSL) mRNAs. In mesenteric 
adipose (Figure 3.8a), salicylate significantly increased adiponectin mRNA levels, 
but had no effect on any other transcripts. In S.C. adipose (Figure 3.9a), salicylate 
significantly increased mRNA levels of TNFα, with a trend towards reduced AdiQ 
(P=0.06). In DIO mice, salicylate had much more pronounced effects on adipokine 
transcript expression, predominantly within the visceral adipose depots including 
omental and mesenteric. In omental adipose (Figure 3.7b), salicylate significantly 
reduced mRNA levels of AGT, TNFα, LPL and ATGL, whilst increasing AdiQ. In 
mesenteric adipose (Figure 3.8b), a similar pattern resulted from salicylate treatment. 
In addition to AGT and ATGL transcript levels being significantly reduced by 
salicylate, there were trends towards reduced TNFα (P=0.06), as well as increased 
AdiQ (P=0.06), whilst LPL, in contrast to omental adipose, appeared to be increased 
although not significantly (P=0.07). In S.C. adipose (Figure 3.9a), salicylate 
significantly increased both AdiQ and LPL mRNA levels, but had no effect on the 





 Figure 3.7 Salicylate altered omental adipose transcript levels. mRNA levels of 
angiotensinogen (AGT), adiponectin (AdiQ), tumor necrosis factor-α (TNFα), 
lipoprotein lipase (LPL), hormone sensitive lipase (HSL) and adipose triglyceride 
lipase (ATGL) were determined by real-time PCR in lean (a) and diet-induced obese 
(DIO) (b) mice. In lean mice (a), salicylate significantly reduced TNFα mRNA 
levels. In diet-induced obese mice (b), salicylate significantly reduced TNFα, LPL 
and ATGL, whilst increasing adiponectin mRNA levels. Data are mean ± SEM, 
expressed as % of the respective Vehicle mean. N=6-8 per group. Comparisons were 
by Student’s unpaired t-test: *P<0.05 vs Vehicle. 
 


























































































Figure 3.8 Salicylate alters mesenteric adipose transcript levels. mRNA levels of 
angiotensinogen (AGT), adiponectin (AdiQ), tumor necrosis factor-α (TNFα), 
lipoprotein lipase (LPL), hormone sensitive lipase (HSL) and adipose triglyceride 
lipase (ATGL) were determined by real-time PCR in lean (a) and diet-induced obese 
(DIO) (b) mice. In lean mice (a), salicylate significantly increased adiponectin 
expression. In DIO mice (b), salicylate significantly reduced ATGL expression, with 
trends towards reduced TNFα (P=0.06) as well as increased adiponectin (P=0.06) 
and LPL (P=0.07). Data are mean ± SEM, expressed as % of the respective Vehicle 
mean. N=6-8 per group. Comparisons were by Student’s unpaired t-test: *P<0.05, 
**P<0.01 vs Vehicle. 
 


























































































Figure 3.9 Salicylate alters subcutaneous (S.C.) adipose transcript levels. mRNA 
levels of angiotensinogen (AGT), adiponectin (AdiQ), tumor necrosis factor-α 
(TNFα), lipoprotein lipase (LPL), hormone sensitive lipase (HSL) and adipose 
triglyceride lipase (ATGL) were determined by real-time PCR in lean (a) and diet-
induced obese (DIO) (b) mice. In lean mice (a), salicylate significantly increased 
TNFα expression. In DIO mice (b), salicylate significantly increased adiponectin and 
LPL expression. Data are mean ± SEM, expressed as % of the respective Vehicle 
mean. N=6-8 per group. Comparisons were by Student’s unpaired t-test: *P<0.05 vs 
Vehicle. 
 





























































































Whilst recent years have seen tremendous progress in understanding the relationship 
between inflammation and insulin resistance, many of the underlying mechanisms 
remain unclear. Initial clues as to the role of inflammation in insulin resistance date 
back to over a century ago, when it was discovered that high doses of sodium 
salicylate, an anti-inflammatory drug, were capable of diminishing glycosuria in 
diabetic patients (Reid et al. 1957). Despite this, it was not until recently that the 
mechanisms behind this hypoglycemic effect were reinvestigated. In this chapter, we 
have demonstrated that the ability of salicylate to improve insulin sensitivity in diet-
induced obese mice is associated with a reduction in 11βHSD1 expression and 
activity. 
 
Salicylate compounds, including sodium salicylate and acetylsalicylic acid, improve 
insulin sensitivity in both rodent and human conditions of insulin resistance (Yuan et 
al. 2001; Alberts et al. 2003; Goldfine et al. 2010; Rosenstock et al. 2010). Rodent 
models used to demonstrate this to date include genetically obese ob/ob mice (Yuan 
et al. 2001) and lipid infusion in rats (Kim et al. 2001). Given that human obesity is 
predominantly polygenic in origin, C57Bl/6 mice fed a high-fat diet are commonly 
used as they are considered more representative of the human nature of the condition, 
although this model has, to our knowledge, not previously been used to investigate 
the potential of salicylates to improve insulin sensitivity. It is suggested that 
inhibition of inflammatory pathways, specifically via IKKβ and NFκB, are crucial in 
salicylate action (Yuan et al. 2001). To investigate the mechanism behind the 
possible insulin sensitising effects of salicylates, mice were infused over a 4 week 
period with a high dose of sodium salicylate (120mg/kg/day), with insulin sensitivity 
being measured though a glucose tolerance test (GTT). This dose and treatment 
period was chosen as it has previously been shown to be effective in improving 





Initial work in lean mice revealed that, contrary to improving insulin sensitivity, 
salicylate induced mild insulin resistance, evidenced by an increase in insulin levels 
without a change in glucose levels over the course of the GTT. Whilst this was 
unexpected, it is perhaps not entirely unsurprising. Despite numerous reports of 
salicylate-induced improvements in insulin sensitivity, the metabolic effects of 
salicylates still remain somewhat contentious. There are several reports describing an 
increase in insulin concentration following salicylate treatment, due to both increased 
secretion and impaired clearance (Newman and Brodows 1983; Bratusch-Marrain et 
al. 1985). This is not associated with hypoglycaemia, suggesting that salicylates can 
induce insulin resistance. A possible mechanism by which salicylates may induce 
insulin resistance is through inhibition of prostaglandin production. Prostaglandins 
function as a negative feedback mechanism, inhibiting TNFα production, and so their 
inhibition could increase TNFα levels (Netea et al. 2001). However, what appears 
more than likely is that a lack of underlying insulin resistance plays a role in the 
inability of salicylate to improve insulin sensitivity. In healthy men, lipid infusion 
induces an insulin resistant state that is improved with acetylsalicylic acid treatment 
(Mohlig et al. 2006). However, acetylsalicylic acid treatment in the absence of lipid-
induced insulin resistance has no beneficial effect (Mohlig et al. 2006). A similar 
study in rats again found that treatment with salicylate ameliorated insulin resistance 
induced by lipid infusion, yet salicylate treatment alone had no effect (Park et al. 
2007). Furthermore, this study found that salicylate treatment reversed the decrease 
in anti-inflammatory markers in muscle and the inhibitory serine phosphorylation of 
IRS-1 in the liver induced by lipid infusion. However, salicylate treatment alone had 
no effect on these parameters. This evidence supports what was found in our study, 
that in the lean state, salicylate treatment does not improve insulin sensitivity. This 
presents a similar scenario to the use of PPARγ agonists, such as thiazolidinediones, 
which only have beneficial effects in improving insulin sensitivity in the obese state 
(Ribon et al. 1998). 
 
To investigate whether obesity-induced insulin resistance was necessary in order to 
observe beneficial effects of salicylate, mice were fed a high-fat diet for 10 weeks 
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prior to initiation of salicylate treatment. Compared to lean mice, these diet-induced 
obese (DIO) mice exhibited a phenotype typical of the metabolic syndrome, with 
hyperinsulinemia, hyperglycemia and dyslipidemia. In contrast to their lean 
counterparts, DIO mice responded favourably to salicylate, with reduced plasma 
glucose levels following treatment, indicating improved glucose tolerance and 
insulin sensitivity. Although there were no statistically significant differences in 
individual tissue weights seen following treatment, there was an increased ratio of 
S.C. to omental adipose, indicating that salicylate may cause a subtle redistribution 
of body fat, causing these mice to store fat preferentially in S.C. depots.  
 
One of the main aims of this chapter was to investigate whether the beneficial effects 
of salicylate were associated with any changes in adipose expression of the 
glucocorticoid-regenerating enzyme 11βHSD1. In lean mice, no significant changes 
were seen in mRNA levels of 11βHSD1 in various adipose depots or indeed the 
liver, although there was a trend towards reduced expression in omental adipose. A 
lack of tissue meant that 11βHSD1 activity could not be analysed in omental adipose, 
and so this was instead assessed in a similar central depot, mesenteric adipose, and 
found to be significantly reduced. Despite this depot-specific downregulation of 
11βHSD1, no improvements were seen in insulin sensitivity. However, this may 
simply be due to the fact that these were healthy, lean animals, with no further 
benefits to be gained from reducing 11βHSD1 levels. In contrast to lean mice, an 
improvement in insulin sensitivity in DIO mice following salicylate treatment was 
associated with a downregulation of 11βHSD1 mRNA levels in both omental and 
mesenteric adipose depots. Enzyme activity was also significantly reduced in 
mesenteric adipose following salicylate treatment. This salicylate-induced 
downregulation of 11βHSD1 demonstrates an in vivo link between inflammation and 
11βHSD1 levels within adipose tissue, consistent with the theory that inflammatory 
mediators may regulate the expression of this enzyme. However, the lack of 
salicylate-induced changes in 11βHSD1 mRNA expression or enzyme activity in 
peripheral, S.C. adipose, indicates that salicylate effects on 11βHSD1 appear 
localised to visceral adipose depots.  
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In order to understand the reason behind these depot-specific effects, it is important 
to consider the heterogeneous nature of adipose tissue. Visceral adipose tissue is 
known to be more metabolically important than peripheral depots due to its strong 
association with insulin resistance, type 2 diabetes and cardiovascular disease 
(Wajchenberg 2000; Mathieu et al. 2010). Even in those who are not overweight, a 
centralised distribution of adiposity leads to increased risk of metabolic disease. 
Depot-specific differences between omental and S.C. adipose have been documented 
for triglyceride uptake, lipolysis, adipocyte size and number, as well as density of 
GR (Wajchenberg 2000). Furthermore, the inflammatory state of these various 
adipose depots has been shown to be distinct. Accumulating evidence suggests that 
visceral adipose is a major source of inflammatory molecules (Fain 2010). In obese 
individuals with higher visceral adiposity, there is greater infiltration of macrophages 
into visceral adipose than subcutaneous adipose, enhancing production of pro-
inflammatory cytokines in this depot (Cancello et al. 2006; Lee et al. 2009). 
Additionally, previous work has shown that pro-inflammatory cytokines are capable 
of increasing 11βHSD1 expression in both omental and S.C. adipose stromal cells 
(Tomlinson et al. 2001). Given the greater levels of inflammation in obese visceral 
adipose tissue, it may be that salicylates exert a greater influence on 11βHSD1 
expression and activity due to their improved anti-inflammatory properties in 
visceral adipose. Indeed, in our study, mRNA levels of the pro-inflammatory 
cytokine TNFα were significantly reduced in omental adipose, with a strong trend 
towards an accompanying reduction in mesenteric adipose as well, supporting the 
anti-inflammatory efficacy of salicylate. However, changes in mRNA profiles of 
inflammatory mediators were not seen in S.C. adipose. Whether this lack of effect in 
S.C. adipose is attributable to a lack of a direct effect of salicylate upon 
inflammatory cytokines or a consequence of a lack of downregulation of 11βHSD1 
remains to be elucidated. 
 
In terms of changes in the transcript levels of other genes in the various adipose 
depots, one can only speculate as to whether these are a result of reducing 
inflammation or a result of reduced glucocorticoid action. Certainly, glucocorticoids 
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are capable of directly influencing expression of these molecules, and given the 
greater density of GR in visceral adipose (Bjorntorp 1995), any changes in 11βHSD1 
expression or activity would likely have more pronounced effects in such central 
depots. Adiponectin is one of the major proteins released by adipose, with circulating 
levels principally controlled by production in adipose (Arita et al. 1999; Kadowaki et 
al. 2006; Takemura et al. 2006). Expression of this adipokine is inversely associated 
with obesity and insulin resistance, suggesting alteration in adiponectin homeostasis 
may play a role in the development of insulin resistance. Both glucocorticoids and 
TNFα have been shown to have effects on adiponectin expression (Fasshauer et al. 
2002; Fontana et al. 2007; Hector et al. 2007). In vitro studies in murine adipocytes 
illustrated that dexamethasone reduces adiponectin gene expression (Fasshauer et al. 
2002). A study investigating effects of both exogenous and endogenous 
glucocorticoid exposure on adiponectin levels in men revealed that administration of 
glucocorticoids to healthy humans reduced circulating adiponectin levels (Fallo et al. 
2004). Furthermore, a comparison between non-obese Cushing’s patients and their 
non-obese controls demonstrated endogenous hypercortisolism reduces adiponectin 
levels (Fallo et al. 2004).  In terms of TNFα, studies in murine adipocytes have also 
shown that this pro-inflammatory mediator suppresses adiponectin expression, whilst 
the anti-inflammatory properties of adiponectin were also demonstrated as it 
suppressed release of TNFα, indicating that these molecules negatively regulate each 
other (Fasshauer et al. 2002). In our study, transcript levels of adiponectin in 
salicylate-treated DIO mice were significantly increased in both omental and S.C. 
adipose, with a strong trend towards upregulation in mesenteric adipose. Given the 
decrease in TNFα expression in visceral adipose, it is possible that a reduction in 
inflammation facilitates the increase in adiponectin. Alternatively, reduced 
expression and activity of 11βHSD1 in visceral adipose reduces exposure to 
glucocorticoids, which would normally act to suppress adiponectin levels. Whilst one 
of these pathways may explain changes in visceral adipose depots, it does not offer 
an explanation for the increased adiponectin expression in S.C. adipose, given that 
neither TNFα nor 11βHSD1 expression was altered. However, this rise in S.C. 





Perhaps the most striking depot-specific differences in DIO mice were observed in 
the transcript levels of LPL, with a significant increase in S.C. adipose and a 
decrease in omental adipose. This enzyme hydrolyses triglycerides, breaking them 
down into NEFAs and glycerol, thus enabling NEFA uptake by adipose. As such, 
LPL levels correlate positively with adiposity.  In men, the uptake of triglycerides is 
significantly higher in omental compared with subcutaneous adipose (Marin et al. 
1992). Further work revealed that, in men, LPL expression and activity were greater 
in intra-abdominal (visceral) adipocytes than in S.C. adipocytes, perhaps explaining 
the greater tendency for men to accumulate fat in central, visceral depots (Marin et 
al. 1992). In terms of our study, the differential effects on LPL mRNA expression 
would seem to support the subtle redistribution of body fat observed in these 
animals, and may provide an explanation as to why this occurs. Both insulin and 
glucocorticoids act to increase LPL levels, however the effects of insulin are much 
less pronounced in omental adipocytes than S.C. adipocytes (Zierath et al. 1998; 
Karpe and Tan 2005). This, coupled with a reduction in glucocorticoid levels through 
downregulation of 11βHSD1, may explain the reduction in omental LPL transcript 
levels. However, it should be noted whilst these changes in mRNA levels provide 
evidence of altered fatty acid metabolism via LPL, it would be more robust to 
measure activity of this enzyme in order to gain a clearer understanding of the 
changes taking place. 
 
In terms of adipose depot-specific differences in lipolysis, previous work reports that 
catecholamine-stimulated lipolysis is much higher in omental compared to S.C. 
adipose (Wajchenberg 2000; Karpe and Tan 2005). Pro-inflammatory cytokines, 
including TNFα, have been shown to induce lipolysis through two mechanisms. 
Firstly, TNFα elevates intracellular levels of second messenger cyclic adenosine 
monophosphate (cAMP), activating protein kinase A (PKA), which in turn 
phosphorylates and activates HSL and ATGL (Bezaire and Langin 2009).  A second, 
more indirect mechanism through which TNFα enhances lipolysis is achieved 
through serine phosphorylation of insulin receptor substrate-1 (IRS-1) (Gao et al. 
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2002; Draznin 2006). Such phosphorylation results in the inhibition of the insulin 
signalling cascade which would normally act to suppress adipocyte lipolysis. To 
investigate if salicylate had any effects on adipocyte lipolysis, we analysed transcript 
levels of HSL and ATGL in several adipose depots. ATGL mRNA levels were 
significantly reduced in both mesenteric and omental adipose following salicylate 
treatment. This may be a direct effect of salicylate treatment or an indirect effect via 
improved insulin sensitisation. Despite this, it has been shown previously that 
sodium salicylate treatment alters lipolytic activity of these enzymes without altering 
protein levels. As such, it may be that salicylate treatment in this study also reduced 
activity of HSL and ATGL. Whilst enzyme activity was not measured here, it would 
undoubtedly provide a clearer picture of alterations in lipolysis. 
 
With regard to lipolysis, insulin is anti-lipolytic and normally acts as the master 
regulator of lipolysis, ensuring its suppression after a meal. However, as mentioned 
above, its effects are much less pronounced in omental adipose tissue, meaning that 
other hormones are likely to contribute more to regulation of omental adipose 
lipolysis. Glucocorticoids are known to increases lipolysis in adipose through 
induction of the two major lipolytic enzymes HSL and ATGL (Macfarlane et al. 
2008; Xu et al. 2009). This is believed to occur through an elevation in intracellular 
levels of cAMP, which results from glucocorticoid-mediated reduction in PDE3, an 
enzyme responsible for the breakdown of cAMP. Whilst reduced glucocorticoid 
levels in these adipose depots has not been demonstrated, the down-regulation of 
angiotensinogen (AGT) in depots with a concordant down-regulation of 11βHSD1 
provides strong support for a reduction in adipose glucocorticoid levels, as AGT 
contains GREs within its promoter and so is directly affected by the local levels of 
glucocorticoids (Olson et al. 1991).  
 
These changes in the expression levels of enzymes involved in lipolysis may go 
some way to explaining the salicylate-induced reduction in plasma NEFA levels in 





resistance has been well documented, with evidence in both rodents and humans 
indicating that plasma levels are elevated in obesity, with NEFAs being implicated in 
the pathogenesis of insulin resistance (Zierath et al. 1998; Griffin et al. 1999; Karpe 
and Tan 2005). Early studies have demonstrated the ability of salicylates to reduce 
plasma NEFA levels (Reid et al. 1957; Bizzi and Carlson 1965). In our study, DIO 
mice had significantly elevated fasting NEFA levels compared to lean mice, an 
increase that was markedly attenuated with salicylate treatment. Whilst suppression 
of lipolytic enzymes would undoubtedly reduce NEFA release into the circulation, it 
is difficult to argue that such a reduction is solely the result of changes in lipolysis in 
visceral adipose. S.C. adipose contributes to the majority of circulating NEFA levels, 
whilst the contribution of visceral adipose is relatively small (Karpe and Tan 2005). 
However, the anatomical site of visceral adipose lipolysis is believed to be 
significantly more important, as released NEFAs directly enter the portal circulation 
which connects to the liver. To investigate possible changes in liver exposure to 
NEFAs, we analysed circulating levels of the ketone body β-hydroxybutyrate (β-
HB). During the fating state, NEFAs derived from adipose tissue lipolysis serve as a 
fuel other tissues, notably the liver (Sunny et al. 2010). Within hepatocytes, NEFAs 
are converted to acyl CoA, which is either used for the synthesis of triglycerides in 
lipoproteins or transported to the mitochondria for oxidation. Each cycle of β-
oxidation produces acetyl CoA, which is converted, downstream, to β-HB and 
released into the circulation. In a period of extended fasting, this ketone body 
production provides
 
a critical alternative substrate for oxidation by extra-hepatic 
tissues, in particular the central nervous system, which is normally dependent on 
glucose metabolism (Sunny et al. 2010). If we consider a metabolic state in which 
circulating NEFA levels are greatly elevated, such as in obesity, we can see how this 
leads to increased circulating levels of ketone bodies. An increased flux of NEFAs to 
the liver leads to increased production of acetyl CoA, which exceeds cellular energy 
requirement. As such, a greater amount of acetyl CoA is shunted towards β-
oxidation, leading to increased production and release of β-hydroxybutyrate. Indeed, 
it has been shown that in mice fed a high-fat diet, fasting hepatic production of 
ketone bodies was significantly elevated (Sunny et al. 2010). Similarly, in our study, 
we have also shown that obesity increased fasting plasma β-hydroxybutyrate levels, 
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with DIO mice showing significantly higher levels compared to lean mice. 
Interestingly, salicylate treatment in DIO mice attenuated this increase. Two possible 
explanations may exist for this. Firstly, and perhaps more likely, is that the decrease 
in ketone body production is a direct result of reduced circulating NEFA levels, 
meaning reduced NEFA flux to the liver. Another possibility is that salicylate 
directly impacts upon hepatic β-oxidation, reducing expression of genes involved in 
oxidation and ketone body formation, including acetyl coenzyme A carboxylase 
(ACC), malonyl coenzyme A decarboxylase (MCD) and mitochondrial 3-hydroxy-3-
methylglutarate coenzyme A synthase (mHMG CoA synthase). However, this 
appears unlikely given the drop in NEFA levels and so was not explored further. 
 
In summary, treatment of DIO mice with anti-inflammatory salicylate improves 
insulin sensitivity and reduces circulating NEFA levels. Accompanying this 
improved metabolic profile was a reduction in the expression and activity of 
11βHSD1 in central, visceral adipose depots, demonstrating for the first time in vivo, 
that adipose inflammation and glucocorticoid metabolism are linked. However, it 
remains unclear whether the salicylate-induced downregulation of adipose 11βHSD1 
is a result of reduced adipose inflammation, or if salicylates directly reduce 
11βHSD1 expression, which in turn regulates the inflammatory state of adipose. 
Interestingly, recent in vitro treatment of murine 3T3-L1 adipocytes with 
acetylsalicylic acid resulted in a downregulation of 11βHSD1 mRNA levels (C 
Esteves et al., unpublished data). This demonstrates that salicylate suppresses 
11βHSD1 expression in the absence of an underlying inflammatory state, potentially 
indicating that the effects of salicylate on 11βHSD1 are direct, implicating a role for 
this enzyme in the regulation of adipose inflammation. This will be explored further 















The role of 11βHSD1 in the insulin 












As shown in Chapter 3, the anti-inflammatory drug sodium salicylate is capable of 
improving insulin sensitivity in diet-induced obese (DIO) mice, a benefit that occurs 
alongside a down-regulation of both expression and activity of the glucocorticoid-
regenerating enzyme 11βHSD1 in visceral adipose, specifically in the omental and 
mesenteric depots. This raises the possibility that 11βHSD1 is a crucial component in 
the underlying mechanism through which salicylates improve insulin sensitivity. 
However, given that pro-inflammatory cytokines increase 11βHSD1 expression in 
vitro in adipocytes (Tomlinson et al. 2001), it remains to be seen whether salicylate-
induced down-regulation of 11βHSD1 is a result of reduced inflammation, or if the 
effects are direct. This chapter will investigate whether salicylate has the same 




The hypothesis of this chapter is that salicylate will not improve insulin sensitivity in 





The aims of this chapter were to investigate: 
1) Whether salicylate improves insulin sensitivity in DIO mice lacking 11βHSD1. 
2) Which of the downstream effects of salicylate treatment on insulin sensitivity and 




4.2 Materials and methods 
4.2.1 Experimental outline 
The experimental procedure is as described in section 3.2.1. 
 
4.2.2 Animal Maintenance 
Homozygous male 11βHSD1-deficient (HSD1KO) mice were bred from an in-house 
colony (Kotelevtsev et al. 1997) on a C57Bl/6 background (>10 generations back-
cross) with corresponding wild type (WT) controls (Harlan Olac, UK). Diet-induced 
obesity was induced from 12 weeks of age through feeding with high fat diet (58% 
fat, 12% sucrose; D12331, Research Diets, NJ, USA), until body weight was 
matched with DIO mice from 3.2.2.2 (approximately 38g). Mice were maintained as 
described (2.5.1).  
 
4.2.3 Mini-pump implantation 
Osmotic mini-pumps were loaded with solutions of sodium salicylate or vehicle 
(distilled water) (2.5.2.1). Mice were operated on Day 0 using the surgical 
procedures described (2.5.2.2). 
 
4.2.4 Glucose tolerance test 
Glucose tolerance tests were carried out as described (2.5.4) on Day 23 or 24. 
 
4.2.4 Terminal procedures 




4.2.5 Molecular biology: quantification of mRNA abundance 
of genes of interest 
Total RNAs were isolated from snap frozen livers (2.6.1.1), subcutaneous adipose, 
mesenteric adipose and omental adipose (2.6.1.2) before RNA quantification 
(2.6.1.4). First strand cDNA was synthesised by RT-PCR (2.6.1.6). The mRNA 
abundances of 11βHSD1, angiotensinogen (AGT), adiponectin (AdiQ), tumour 
necrosis factor-α (TNFα), hormone sensitive lipase (HSL), adipose triglyceride lipase 
(ATGL) and lipoprotein lipase (LPL) were quantified by real-time PCR (2.6.1.8) and 
normalised against the mean of the transcript levels of a combination of house-
keeping genes as outlined in Table 4.1. These combinations of house-keeping genes 
were selected due to lack of change in expression following treatment. 
 
4.2.6 Enzymology 
11βHSD1 reductase activity was measured in mesenteric and subcutaneous adipose 
of WT-DIO mice as described (2.6.2.4). In mesenteric adipose, samples were 
incubated with protein (300μg) and substrate concentration (10μM) for 24 hours. In 
subcutaneous adipose, samples were incubated with protein (100μg) and substrate 
concentration (2μM) for 22 hours. 
 
4.2.7 Biochemical assays 
4.2.7.1 Quantification of plasma glucose 
Glucose in plasma collected during the glucose tolerance test was quantified by 
hexokinase assay as described (2.7.2). 
 
4.2.7.2 Quantification of plasma insulin 
Insulin in plasma collected during the glucose tolerance test was quantified by 




Tissue Gene Combination P value 
   
Liver TBP 0.31 
Omental adipose TBP + Cyc 0.35 
Mesenteric adipose Cyc 0.49 
Subcutaneous adipose Cyc 0.81 
 
Table 4.1 Housekeeping genes used for real-time PCR. TBP = TATA-binding 
protein; Cyc = cyclophilin. P value indicates results of student’s t-test between 




4.2.7.3 Quantification of plasma triglycerides 
Fasting plasma triglyceride levels in the plasma collected at the ‘0’ time point during 
glucose tolerance tests were quantified as described (see 2.7.4). 
4.2.7.4 Quantification of plasma NEFAs 
NEFAs in plasma collected during the first two time points of the glucose tolerance 
tests (‘0’ and ‘15’ min) were quantified as described in (2.7.3). 
 
4.2.8 Statistics 
Data are presented as mean ± SEM and were analysed by Student’s unpaired t-tests 




4.3.1 Body and tissue weights 
In wild type diet-induced obese (WT-DIO) mice, salicylate reduced weight gain 
compared to vehicle-treated WT-DIO mice (Table 4.2). In contrast in 11βHSD1-
deficient mice fed the same high fat diet (HSD1KO-DIO), salicylate did not alter 
body weight. In WT-DIO mice, salicylate also significantly altered the weights of 
several tissues, with reduction in both omental and epididymal adipose depots, as 
well as a trend towards reduced mesenteric adipose weight. In contrast, salicylate did 
not alter tissue weights in HSD1KO-DIO mice. 
 
4.3.2 Glucose tolerance test 
Plasma glucose and insulin levels were measured during a glucose tolerance test as a 
measure of insulin sensitivity. Compared to WT-DIO mice, HSD1KO-DIO mice had 
significantly lower plasma glucose levels (Figure 4.1b). Salicylate treatment in WT-
DIO mice improved glucose tolerance as demonstrated by reduced plasma glucose 
(Figure 4.1b) and insulin (Figure 4.1a) levels. In contrast, salicylate failed to alter 
plasma glucose or insulin levels in HSD1KO-DIO mice. 
 
4.3.3 Plasma NEFA levels 
In WT-DIO mice, salicylate reduced fasting plasma NEFA levels, as well as 
improving post-prandial NEFA suppression (Figure 4.2). Fasting plasma NEFA 
levels were not different in HSD1KO-DIO mice compared to WT-DIO, however, 
post-prandial NEFA suppression was significantly greater in the HSD1KO-DIO 














Table 4.2 Salicylate-induced changes in body and tissue weights of diet-induced obese wild type mice (WT-DIO) were not observed 
in diet-induced obese 11βHSD1 knockout mice (HSD1KO-DIO). In WT-DIO mice, salicylate attenuated overall weight gain and 
reduced weight of omental and mesenteric adipose depots. No significant changes were seen in HSD1KO-DIO mice following treatment. 
HFD = high-fat diet; S.C. = subcutaneous. Data are mean ± SEM for n=8 per group. Comparisons were by Student’s unpaired t-test.  
Body Weights 
 WT-DIO HSD1KO-DIO 
 Vehicle Salicylate p Value Vehicle Salicylate p Value 
Weight at start (g) 38.9 ± 0.7 37.4 ± 0.5 0.12 38.0 ± 0.8 38.3 ± 0.5 0.81 
Weight at end (g) 41.9 ± 0.9 39.2 ± 0.6 0.02 38.0 ± 0.8 39.0 ± 0.8 0.37 
Time on HFD (weeks)  18.5 ± 1.6   10.8 ± 0.8  
       
Tissue Weights 
 WT-DIO HSD1KO-DIO 
Tissue     Weight as % Body Weight p Value     Weight as % Body Weight p Value 
 Vehicle Salicylate  Vehicle Salicylate  
Liver 3.90 ± 0.27 3.89 ± 0.22 0.96 3.23 ± 0.17 3.39 ± 0.15 0.47 
S.C. Adipose 1.13 ± 0.12 1.10 ± 0.15 0.87 1.29 ± 0.10 1.46 ± 0.12 0.87 
Omental Adipose 0.12 ± 0.01 0.08 ± 0.01 0.01 0.11 ± 0.01 0.12 ± 0.01 0.52 
Mesenteric Adipose 1.41 ± 0.15 1.03 ± 0.09 0.05 1.29 ± 0.08 1.49 ± 0.12 0.21 
Retroperitoneal Adipose 0.74 ± 0.03 0.59 ± 0.08 0.15 0.72 ± 0.03 0.74 ± 0.03 0.65 
Epididymal Adipose 2.51 ± 0.10 1.97 ± 0.19 0.02 2.42 ± 0.09 2.42 ± 0.12 0.99 
Quadricep Muscle 0.52 ± 0.04 0.57 ± 0.02 0.25 0.51 ± 0.05 0.47 ± 0.02 0.55 
Adrenal 0.009 ± 0.001 0.007 ± 0.001 0.34 0.016 ± 0.001 0.008 ± 0.001 0.32 
Ratio S.C:Omental Adipose 9.6 ± 0.5 15.1 ± 1.3 0.001 12.9 ± 1.9 13.9 ± 2.5 0.75 
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Figure 4.1 Salicylate improved glucose tolerance in WT-DIO mice, but had no 
effect in HSD1KO-DIO. Plasma glucose (a) and insulin (b) levels over the course of 
a glucose tolerance test, with areas under the curve (AUC) shown underneath (c and 
d respectively). Squares denote WT-DIO mice, whilst triangles denote HSD1KO-
DIO mice. Open symbols/bars denote vehicle treatment, whilst closed symbols/bars 
denote salicylate treatment. In WT-DIO mice, salicylate treatment significantly 
reduced plasma glucose (c) and insulin (d) levels, but had no effect in HSD1KO-DIO 
mice. HSD1KO-DIO mice had significantly reduced glucose (c) and insulin (d) 
levels compared to WT-DIO mice. Data are mean ± SEM for n=8 per group for 
individual time points and for area under the curve. Comparisons for AUC were by 




























































































Figure 4.2 Salicylate reduced non-esterified fatty acids (NEFAs) levels in WT-
DIO mice, but had no effect in HSD1KO-DIO mice. Fasting plasma NEFA levels 
(a) and 15 min post-glucose challenge NEFA suppression (b) in diet-induced obese 
11βHSD1 knockout mice (HSD1KO-DIO) and diet-induced obese wild type mice 
(WT-DIO) were measured spectrophotometrically. Open bars denote vehicle 
treatment, whilst closed bars denote salicylate treatment. Salicylate treatment 
reduced fasting NEFA levels in WT-DIO mice, but had no effect in HSD1KO-DIO 
mice (a). Post-glucose challenge NEFA suppression was increased in WT-DIO mice 
following treatment and whilst HSD1KO-DIO mice had increased NEFA 
suppression compared to WT-DIO mice, salicylate treatment induced no further 
changes (b). Data are mean ± SEM for n=8 per group. Comparisons were by two-
way ANOVA with Bonferroni post-hoc tests: *P<0.05 vs Vehicle of same genotype; 
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4.3.4 Plasma triglyceride levels 
Salicylate had no effect on plasma triglyceride levels in either WT-DIO or 
HSD1KO-DIO mice, nor were differences observed between genotypes (Figure 4.3). 
 
4.3.5 11βHSD1 expression and activity 
In WT-DIO mice, salicylate did not alter mRNA expression of 11βHSD1 in either 
liver or subcutaneous (S.C.) adipose. A trend towards reduction was seen in omental 
adipose (P=0.09). However, in mesenteric adipose, salicylate significantly reduced 
mRNA levels of 11βHSD1 (Figure 4.4). Enzyme activity was measured in 
mesenteric and S.C. adipose (Figure 4.5). Salicylate significantly reduced enzyme 










Figure 4.3 Salicylate did not influence triglyceride concentrations in WT-DIO or 
HSD1KO-DIO mice. Fasting plasma triglyceride levels in diet-induced obese 
11βHSD1 knockout mice (HSD1KO-DIO) and diet-induced obese wild type mice 
(WT-DIO) were measured spectrophotometrically. Data are mean ± SEM for n=8 per 














Figure 4.4 Salicylate reduced 11βHSD1 transcript levels in WT-DIO mice. 
mRNA levels of 11βHSD1 in liver, omental adipose (Om Fat), mesenteric adipose 
(Mes Fat) and subcutaneous adipose (SC Fat) were determined by real-time PCR. 
Salicylate (closed bars) significantly downregulated 11βHSD1 in Mes fat compared 
to vehicle treatment (open bars), with a trend in Om fat (P=0.09). Data are mean ± 
SEM, expressed as % of the respective Vehicle mean. N=6-8 per group (except Om 
fat salicylate group, n=4). Comparisons were by Student’s unpaired t-test: *P<0.05 
vs Vehicle. 
Figure 4.5 Salicylate reduced 11βHSD1 activity in mesenteric adipose of WT-
DIO mice. Enzyme activity was measured in mesenteric adipose (a) and 
subcutaneous (S.C.) adipose (b) and steroids quantified by high performance liquid 
chromatography. In mesenteric adipose, salicylate (closed bars) significantly reduced 
11βHSD1 activity, compared to vehicle treatment (open bars). In S.C. adipose (b), 
salicylate did not alter enzyme activity. Data are mean ± SEM, expressed as % of the 
respective Vehicle mean. Nn=7-8 per group. Comparisons were by Student’s 


































(b) (a) Mesenteric Adipose S.C. Adipose 












































4.3.6 Adipokine transcript profile 
In omental adipose (Figure 4.6), salicylate significantly increased adiponectin and 
reduced LPL mRNA levels in WT-DIO mice. HSD1KO-DIO mice had significantly 
higher adiponectin and reduced AGT, TNFα, LPL and ATGL mRNA levels 
compared to WT-DIO mice. However, salicylate did not induce changes in the 
abundance of transcripts of these genes in HSD1KO-DIO mice. In mesenteric 
adipose, similar patterns were seen (Figure 4.7), with salicylate significantly 
reducing AGT, TNFα, LPL, HSL and ATGL mRNA levels in WT-DIO mice. Only 
TNFα was significantly different between HSD1KO-DIO and WT-DIO mice, 
however this may be due reduced n numbers in HSD1KO-DIO groups. As in 
omental adipose, salicylate did not alter transcript levels in mesenteric adipose of 
HSD1KO-DIO mice. In S.C. adipose (Figure 4.8), salicylate significantly increased 
adiponectin in WT-DIO mice. HSD1KO-DIO mice had significantly increased 
adiponectin compared to WT-DIO mice. However, salicylate had no significant 




Figure 4.6 Salicylate effects on omental adipose transcript levels in WT-DIO 
mice are not replicated in HSD1KO-DIO mice. mRNA levels of angiotensinogen 
(AGT), adiponectin (AdiQ), tumor necrosis factor-α (TNFα), lipoprotein lipase 
(LPL), hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) were 
determined by real-time PCR. Salicylate treatment in WT-DIO mice (black bars) 
resulted in significant downregulation of AGT and LPL, with significant 
upregulation of AdiQ. HSD1KO-DIO mice (horizontal stripes) had significantly 
downregulated TNFα, LPL and ATGL, as well as upregulated AdiQ compared to 
WT-DIO mice (open bars). Salicylate treatment in HSD1KO-DIO mice (hatched 
bars) had no significant effects. Data are mean ± SEM, expressed as % of the 
respective WT-DIO Vehicle mean for each gene. N=4-8 per group. Comparisons 







P<0.001 vs WT-DIO Vehicle. 
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Figure 4.7 Salicylate effects on mesenteric adipose transcript levels in WT-DIO 
mice are not replicated in HSD1KO-DIO mice.  mRNA levels of angiotensinogen 
(AGT), adiponectin (AdiQ), tumor necrosis factor-α (TNFα), lipoprotein lipase 
(LPL), hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) were 
determined by real-time PCR. Salicylate treatment in WT-DIO mice (black bars) 
significantly downregulated AGT, TNFα, HSL and ATGL. HSD1KO-DIO mice 
(horizontal stripes) had significantly downregulated TNFα and HSL, as well as 
upregulated AdiQ compared to WT-DIO mice (open bars). Salicylate treatment in 
HSD1KO-DIO mice (hatched bars) had no significant effects. Data are mean ± SEM, 
expressed as % of the respective WT-DIO Vehicle mean for each gene. N=4-8 per 
group. Comparisons were by two-way ANOVA with Bonferroni post-hoc tests: 







































































Figure 4.8 Salicylate effects on subcutaneous adipose transcript levels in WT-
DIO mice are not replicated in HSD1KO-DIO mice. mRNA levels of 
angiotensinogen (AGT), adiponectin (AdiQ), tumor necrosis factor-α (TNFα), 
lipoprotein lipase (LPL), hormone sensitive lipase (HSL) and adipose triglyceride 
lipase (ATGL) were determined by real-time PCR. Salicylate treatment in WT-DIO 
mice (black bars) significantly upregulated AdiQ compared to Vehicle (open bars). 
HSD1KO-DIO mice (horizontal stripes) had significantly upregulated AdiQ 
compared to WT-DIO mice, but this was not affected by salicylate (hatched bars). 
Data are mean ± SEM, expressed as % of the respective WT-DIO Vehicle mean for 
each gene. N=6-8 per group. Comparisons were by two-way ANOVA with 























































In this chapter, 11βHSD1-deficient mice were utilised to investigate whether changes 
in the expression and activity of this enzyme are crucial to the insulin sensitising 
effects of salicylate in diet-induced obesity. In contrast to wild type mice, these 
transgenic mice showed no improvements in insulin sensitivity following salicylate 
treatment. This lack of efficacy supports a key role for downregulation of 11βHSD1 
in salicylate’s mechanism of action. 
 
Previous reports on 11βHSD1-deficient mice fed a high fat diet demonstrated marked 
protection to the development of insulin resistance (Kotelevtsev et al. 1997; Morton 
et al. 2001; Morton et al. 2004). The phenotype displayed in these mice bears a 
striking resemblance to that seen in the salicylate-treated DIO mice in Chapter 3, 
with reduced plasma glucose and NEFA levels. As such, it was not unexpected to 
find a decrease in adipose levels of 11βHSD1 in salicylate-treated mice.  Given the 
evidence that pro-inflammatory mediators are capable of inducing 11βHSD1 
expression in vitro (Tomlinson et al. 2001), one might therefore postulate that 
salicylate treatment attenuated the inflammation within adipose tissue, which 
resulted in reduced expression and activity of 11βHSD1. Such a reduction in 
11βHSD1 levels would consequently improve the metabolic profile, as has been 
demonstrated through the use of 11βHSD1 inhibitors (Alberts et al. 2002; Alberts et 
al. 2003). However, the data from Chapter 3 only show an association between the 
effects of salicylate and reduced 11βHSD1 expression. Removing 11βHSD1 from 
the equation would allow us to determine whether the insulin sensitising effects of 
salicylate were due specifically to downregulation of the enzyme, or due to an 
enzyme-independent effect such as reduced pro-inflammatory markers within 
adipose tissue.  
 
In order to investigate this, 11βHSD1-deficient mice (HSD1KO-DIO) were fed a 
high-fat diet and weight matched to wild-type C57Bl/6 controls also on a high-fat 
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diet (WT-DIO). In glucose tolerance tests, it was evident that HSD1KO-DIO mice 
were more insulin sensitive at baseline than their weight-matched wild-type controls, 
demonstrated by lower plasma insulin and glucose levels. This was expected, and 
confirmed the protected metabolic state of 11βHSD1-deficient mice. However, at the 
outset of the experiment, weight matching was chosen over matching for insulin 
resistance as the latter would have been difficult to achieve, and weight-matching 
ensured an obese phenotype. In direct contrast to WT-DIO mice, HSD1KO-DIO 
mice treated with salicylate exhibited no improvement in glucose tolerance. One 
could argue that the improved metabolic profile of the HSD1KO-DIO mice may 
mask any potential benefits of salicylate treatment, as was seen for the ‘lean’ cohort 
of mice in Chapter 3. However, if one compares the baseline reading for these mice 
with the ‘lean’ cohort of mice from Chapter 3, it is evident that the HSD1KO-DIO 
mice are not only obese (38.0 ± 0.8 vs 28.8 ± 0.6 g), but hyperinsulinemic in the 
fasting state (2.01 ± 0.15 vs 0.95 ± 0.11 ng/ml) compared to lean mice. Therefore, it 
is unlikely that salicylate failed to induce any effects in these mice due to a lack of 
insulin resistance. In terms of other biochemical improvements in the metabolic 
profile and supporting the results from Chapter 3, a reduction in fasting plasma 
NEFA levels was seen in WT-DIO mice following salicylate treatment, whilst no 
change was observed in HSD1KO-DIO mice. 11βHSD1-deficient mice have 
previously been reported to have reduced fasting plasma NEFA levels compared to 
wild type controls (Morton et al. 2004). However, this was not observed in this 
current cohort of mice. Despite this, an increased suppression of plasma NEFA levels 
was observed post-glucose challenge in HSD1KO-DIO mice compared to WT-DIO 
mice, indicating improved adipose insulin sensitivity. Similar to fasting levels, 
NEFA suppression levels were unaltered by salicylate treatment in HSD1KO-DIO 
mice. The accumulation of this evidence implies that not only is downregulation of 
11βHSD1 associated with the salicylate-mediated ability to improve the metabolic 
profile of DIO mice, but that it is a crucial mediator of this insulin sensitising effect.  
 
Having established the importance of 11βHSD1 in salicylate-induced insulin 
sensitisation, our focus switched to pro-inflammatory cytokine regulation of this 
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enzyme. If one is to consider the general hypothesis of what is believed to occur in 
obese adipose tissue, with marked macrophage infiltration in response to adipocyte 
hypertrophy (Suganami and Ogawa 2010). The resultant release of pro-inflammatory 
mediators could act upon adipocytes to drive an increase in 11βHSD1 expression, 
raising local levels of glucocorticoids and inducing a Cushing’s syndrome-like effect. 
Whilst this is clearly an attractive hypothesis, the main reservation here is the 
apparent lack of anti-inflammatory effects of glucocorticoids upon the inflammatory 
state within adipose tissue. Indeed, elevated 11βHSD1 would be expected to dampen 
any inflammatory response as a result of increasing the local levels of 
glucocorticoids. In our study, HSD1KO-DIO mice had reduced TNFα expression in 
visceral adipose compared to WT-DIO mice, indicating a paradoxical situation 
whereby a reduction in 11βHSD1 actually suppresses inflammation. Furthermore, 
salicylate treatment in WT-DIO mice reduced visceral expression of TNFα, yet a 
similar effect was not observed in HSD1KO-DIO mice. These findings raise the 
possibility that 11βHSD1 is a regulator of the inflammatory response within obese 
adipose, with increased levels of the enzyme driving inflammation. 
 
To understand this paradoxical situation, it is important to note the effects of 
exogenous versus endogenous glucocorticoids, as well the distinction in the 
inflammatory state between the acute response to injury and infection, and the 
chronic, low grade inflammation seen in obesity. Glucocorticoids at pharmacological 
doses are used in the treatment of inflammatory conditions (Saklatvala 2002). 
However, less is known about the physiological effects of endogenous 
glucocorticoids on inflammation. In response to acute injury and inflammation, 
glucocorticoids are known to alter leukocyte trafficking and the differentiation of 
haematopoietic cells (McEwen et al. 1997; Ehrchen et al. 2007; Tuckermann et al. 
2007). They also promote the resolution of inflammation by inducing an anti-
inflammatory phenotype in differentiating monocytes (Liu et al. 1999; Olefsky and 
Glass 2010). These effects on monocyte/macrophage cells are particularly pertinent 
when one considers the role these cells play in obesity-linked insulin resistance, 
given that they are a major source of pro-inflammatory mediators (Fain 2010; 
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Olefsky and Glass 2010). Indeed, the recent discovery that up to 40% of adipose 
tissue cell content in obese rodents and humans is composed of macrophages, 
compared to around 10% in lean adipose, demonstrates the potential impact of these 
cells (Weisberg et al. 2006). Interestingly, the infiltration of macrophages into 
adipose and the resultant increase in the inflammation precede the development of 
insulin resistance, indicating the important role that adipose tissue macrophages may 
play in the pathogenesis of this condition (Weisberg et al. 2003; Xu et al. 2003). A 
major advance here was the recent discovery of 11βHSD1 expression in immune 
cells, in particular that its expression is induced upon differentiation of monocytes to 
macrophages (Thieringer et al. 2001). However, 11βHSD1 expression in 
macrophages is also dependent upon the polarisation of the specific cell. The 
classically activated macrophage phenotype (M1) is highly pro-inflammatory and has 
been shown to have greatly elevated 11βHSD1 mRNA expression and activity 
compared to the anti-inflammatory alternatively activated phenotype (M2) (Martinez 
et al. 2006). Given that resident adipose tissue macrophages are M2, with the 
infiltrated macrophages of the M1 phenotype, this demonstrates the pro-
inflammatory state of obese adipose tissue (Olefsky and Glass 2010). Furthermore, 
this highlights that not only adipocytes, but infiltrated macrophages can contribute to 
the local increase in glucocorticoids within obese adipose tissue through elevated 
11βHSD1. However, this still leaves the paradox whereby increased glucocorticoid 
levels promote rather than suppress the inflammatory response. Recent in vitro 
studies in both macrophages and adipocytes have sought to investigate this, 
demonstrating that inhibition of 11βHSD1 in both pro-inflammatory stimulated 
macrophages and pre-adipocytes attenuated the increase in the release of TNFα, IL-6 
and IL-1β (Ishii et al. 2007; Ishii-Yonemoto et al. 2010). This finding indicates that 
intracellular regeneration of active glucocorticoids by 11βHSD1 exerts pro-
inflammatory effects. Indeed, low, physiological, concentrations of glucocorticoids 
have been shown to induce macrophage expression of pro-inflammatory cytokines, 
including osteopontin (OPN) (Wang et al. 2000) and macrophage migratory 
inhibitory factor (MIF) (Calandra et al. 1995; Leng et al. 2009).  Furthermore, in 
TNFα-stimulated pre-adipocytes, overexpression of 11βHSD1 augmented the release 
of IL-6 and MCP-1 (Ishii-Yonemoto et al. 2010). Perhaps most interestingly, this did 
123 
 
not occur in resting pre-adipocytes, indicating that 11βHSD1 only reinforces 
inflammation under pre-existing inflammatory conditions. This accumulation of data 
suggests that low, physiological levels of glucocorticoids, such as may be seen as a 
result of increased 11βHSD1 activity, actually drive inflammation as oppose to 
suppressing it. 
 
In this chapter, we have shown that salicylates have no beneficial effects in 
11βHSD1-deficient mice. This transgenic model is a global knockout and so it is 
difficult to interpret whether it is the lack of 11βHSD1 in adipose, liver or other 
tissues that is responsible for ‘blocking’ the effects of salicylates. However, having 
seen specific downregulation of visceral adipose levels and activity of 11βHSD1 in 
wild-type mice following salicylate treatment, it suggests that adipose regulation of 
11βHSD1 is crucial to the insulin sensitising effects of anti-inflammatory salicylates. 
Despite this, as we have seen, adipose tissue does not solely consist of adipocytes, 
with pre-adipocytes and macrophages found to be present in increasing numbers in 
obese adipose. As such, it would be of great interest to look more closely at the 
composition of visceral adipose depots treated with salicylates to determine any 
changes in immune cell composition and polarisation. One of the many interesting 
points to arise from this work is the inability of salicylates to suppress inflammatory 
marker transcript levels in the absence of 11βHSD1, indicating that the inflammatory 
state in obese adipose tissue is regulated by this enzyme. Whether or not this is 
determined by adipocyte or macrophage 11βHSD1 remains to be seen, however, the 
creation of myeloid-specific 11βHSD1 knockout mice would be a great tool in 
solving this puzzle. What is evident is that 11βHSD1 appears to act as a central pivot 
in pathways regulating both metabolic and inflammatory signalling, implicating it in 
playing a causative role in the pathogenesis of obesity-linked insulin resistance. As 
















The anti-inflammatory mechanisms 












Within obesity-associated insulin resistance, it is clear that glucocorticoids play a key 
role in the development of the metabolic syndrome, with intracellular levels of 
glucocorticoids altered through metabolising enzymes such as the 11βHSDs. 
However, another important pathway of glucocorticoid metabolism involves A-ring 
reduction, and this is mediated primarily by the rate-limiting enzymes in the reaction, 
5αR1, and also by 3αHSD, resulting in the generation of 5α-reduced metabolites of 
glucocorticoids. Interest in the role these enzymes play was sparked when it was 
discovered that in obesity, there is an increase in hepatic levels of 5αR1 (Livingstone 
et al. 2005). Physiological levels of glucocorticoids have numerous metabolic effects 
within target cells, as described in previous chapters, with an increase in their levels 
leading to the development of insulin resistance. The increased reduction of 
glucocorticoids in the obese setting may represent an adaptive mechanism which 
limits the exposure of the liver to the metabolic consequences of glucocorticoids. 
However, given that the full range of effects of these 5α-reduced glucocorticoid 
metabolites is yet to be established, it is difficult to understand the physiological role 
of this pathway of glucocorticoid metabolism  
 
The parent glucocorticoids exert their numerous metabolic and immunomodulatory 
effects primarily via the GR, an intracellular, ligand-activated transcription factor 
capable of regulating gene transcription through transactivation or transrepression 
(Saklatvala 2002; De Bosscher et al. 2003; Beck et al. 2009). Upon ligand-binding, 
the activated GR dissociates from the heat shock proteins that retain the GR in the 
cytoplasm in an inactive form. This results in a conformational change that unmasks 
the nuclear localisation signal, enabling translocation of the GR to the nucleus 
whereby it acts to induce or repress gene transcription. Previous work in rat 
hepatocytes identified that the 5α-reduced tetrahydro metabolite of corticosterone, 
5αTHB, is capable of displacing dexamethasone from ligand binding sites on GR 
(McInnes et al. 2004). Further work demonstrated that 5αTHB binds and activates 
GR, inducing translocation to the nucleus (Yang 2009). Following translocation, 
activated GRs regulate gene transcription through transactivation or transrepression. 
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The parent glucocorticoid, corticosterone induces transcription of tyrosine 
aminotransferase (TAT) and phosphoenolpyruvate carboxykinase (PEPCK) in H4IIE 
hepatoma cells, however there is conflicting evidence on whether 5αTHB induces 
mRNA expression. One report suggests that this metabolite does induce mRNA 
expression of TAT and PEPCK (McInnes et al. 2004), yet this effect has not been 
reproducible (Yang 2009).  
 
The potent anti-inflammatory effects of glucocorticoids are widely documented, and 
the conventional viewpoint is that these effects are believed to involve GR-mediated 
transrepression (Barnes 1998; De Bosscher and Haegeman 2009; Barnes 2010). In 
particular, GR-protein interactions with pro-inflammatory transcription factors 
including NF-κB and AP-1 are believed to suppress production of pro-inflammatory 
cytokines such as TNFα, IL-6 and MCP-1. However, there is also evidence that 
glucocorticoids induce expression of anti-inflammatory molecules through 
transactivation, for example of IL-10 (Clark 2007; Newton and Holden 2007). 
Previous work has shown that 5αTHB is capable of suppressing release of TNFα and 
IL-6 from LPS-stimulated bone marrow-derived macrophages, as well as inducing 
release of IL-10 (Yang 2009). This has led to speculation that 5α-reduced 
metabolites of corticosterone may act as ‘dissociative’ steroids, maintaining their 
anti-inflammatory properties, but having less detrimental side effects such as 
activation of metabolic pathways. However, the mechanisms behind these anti-
inflammatory effects remain unclear. Parent glucocorticoids have been shown to act 
through blockade of NFκB and AP-1 activation pathways, yet it is unknown whether 
5α-reduced metabolites of glucocorticoids, namely 5αDHB and 5αTHB, act in a 
similar manner, or through a separate mechanism. 
 
Hypothesis 
The hypothesis in this chapter is that 5α-reduced metabolites of corticosterone exert 





The aims of this chapter were to investigate: 
1) Whether 5α-reduced metabolites suppress pro-inflammatory cytokine production 
and pro-inflammatory signalling pathways.  




5.2 Materials and methods 
5.2.1 Maintenance of cell lines and reagent preparation 
5.2.1.1 RAW264.7 (murine macrophage cells) 
RAW264.7 cells were cultured as described (2.3.2). 
 
5.2.1.2 HEK293 (human embryonic kidney cells) 
HEK293 cells were cultured as described (2.3.1) 
 
5.2.1.3 Preparation of stripped-serum medium 
To avoid interference from background concentrations of glucocorticoids found in 
FBS, stripped serum was prepared. Heat-inactivated FBS (500ml) was mixed with 
dextran-coated charcoal (5g) and stirred for 16-24 hours at 4°C. The serum was 
filtered using 5μm and 0.45μm filters (Sartorius, Germany) successively and 
sterilized by filtration (0.20μm filter (Millipore, MA, USA)). The filtered serum was 
dispensed into 50ml aliquots and stored at -20°C. The stripped serum medium was 
prepared with the same components as the normal culture medium for RAW264.7 
cells (2.3.2) with the normal FBS replaced by the stripped serum.  
 
5.2.1.4 Preparation of antibiotic-free, stripped-serum medium 
Antibiotic-free medium was prepared for use with HEK293 cells undergoing 
transfection as antibiotics interfere with this process. Stripped serum was prepared as 
described above (5.2.1.3). The antibiotic-free, stripped serum medium was prepared 
as described for HEK293 cells (2.3.1) with the normal FBS replaced by the stripped-
serum and without the addition of penicillin.  
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5.2.1.5 Preparation of phenol-red free medium 
To avoid spectrophotometric interference in ELISAs, phenol-red free medium was 
prepared for use with RAW264.7 cells. Phenol-red free DMEM was supplemented 
with 10% (v/v) heat-inactivated stripped FBS (5.2.1.3), penicillin (100 IU/ml), 
streptomycin (100μg/ml) and L-glutamine (200mM). 
 
5.2.1.6 Preparation of glucocorticoid treatments 
Corticosterone, 5αDHB and 5αTHB were dissolved separately in ethanol to make 
stock solutions (1M). Solutions were stored at -20°C. A series of dilutions of each 
glucocorticoid was prepared with ethanol. 
 
5.2.1.7 Preparation of modulators of signalling pathways 
Lipopolysaccharide (LPS, 1mg) was suspended in sterile PBS (1ml) to make a stock 
(1mg/ml) and was stored at -20°C. A series of dilutions was prepared with sterile 
PBS. 12-O-Tetradecanoyl-phorbol-13-acetate (TPA, 1mg) was suspended in sterile 
PBS (1ml) to make a stock (1mg/ml) and was stored at -20°C. A series of dilutions 
was prepared with sterile PBS.  The GR antagonist RU486 was dissolved in ethanol 
to make a stock (1mM). 
 
 
5.2.2 Suppression of cytokine release in RAW264.7 cells by 
glucocorticoids 
5.2.2.1 Dose response of LPS to induce cytokine release in RAW264.7 
cells  
The day before the experiment, RAW264.7 cells were plated on 6-well plates at a 
density of 2-3×10
5
 cells per well and incubated in normal medium (2ml) in a 
humidified atmosphere in 95% air and 5% CO2 at 37°C.  
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Twenty four hours later, the medium was removed and the wells washed with sterile 
PBS (1ml). Phenol-red free stripped-serum medium (5.2.1.5, 2ml) was added to each 
well and incubated (1 hour) under the above conditions. 
Cells were incubated (24 hours) with increasing concentrations of LPS (0, 3, 10, 30, 
100ng/ml) before medium was harvested for quantification of cytokine release. Three 
experiments were performed in duplicate for each dose. 
 
5.2.2.2 Dose response of glucocorticoids to suppress cytokine release 
in LPS-stimulated RAW264.7 cells 
RAW264.7 cells were plated on 6-well plates and incubated (24 hours) as described 
above (5.2.2.1). Following change of medium to phenol-red free stripped serum 
medium and incubation (1 hour), cells were treated with increasing concentrations of 
corticosterone, 5αDHB or 5αTHB (0, 0.01, 0.03, 0.1, 0.3, 1, 3μM for each steroid), 
with LPS (30ng/ml) or without (PBS, 2μl). Following treatment, cells were incubated 
(24 hours) under conditions described (2.3.2) before medium was harvested for 
quantification of cytokine release. Three experiments were performed in duplicate 
for each dose. 
 
5.2.2.3 GR-mediated suppression of cytokine release 
RAW264.7 cells were plated  and medium harvested as described above (5.2.2.2), 
however, one hour prior to glucocorticoid treatment, cells were incubated with the 
GR antagonist RU486 (1μM). Only one dose of each glucocorticoid (1μM) was used.  
 
5.2.2.4 Quantification of cytokine release 
The amount of the inflammatory cytokines TNF-α and IL-6 in the medium of 




5.2.3 Suppression of signalling via pro-inflammatory 
pathways in response to glucocorticoids 
5.2.3.1 Treatment of RAW264.7 cells 
RAW264.7 cells were plated on 6-well plates and incubated for 24 hours as 
described above (5.2.2.1). Following change of medium to phenol-red free stripped-
serum medium and incubation (1 hour), corticosterone, 5αDHB, 5αTHB (1μM) or 
Vehicle (100% ethanol, 2μl) were added. Following incubation (1 hour) with 
steroids, cells were treated with LPS (100ng/ml) and incubated (30 min) before being 
lysed and protein extracted (2.5.2.2). 
 
5.2.3.2 Assessment of protein levels in RAW264.7 cells 
Following quantification of protein levels from total cell lysates (2.5.2.3), amounts of 
specific proteins were assessed by Western blotting (2.5.2.5). Primary antibodies 
directed against IκBα, NFκB, JNK, phospho-JNK, p38 and phospho-p38, all raised in 
rabbit, were from Cell Signalling Technology (New England Biolabs, Hertfordshire, 
UK). The antibody directed against MKP-1 (raised in rabbit) was from Santa Cruz 
Biotechnology (Insight Biotechnology, Middlesex, UK). The antibody directed 
against β-tubulin (raised in mouse) was from Millipore (Hertfordshire, UK). 
Secondary fluorescent antibodies directed against rabbit and mouse primary 
antibodies, both raised in goat, were from LI-COR Biosciences. Protein bands of 
interest were visualised using the Licor Odyssey (2.5.2.5.4). 
 
5.2.4 Suppression of pro-inflammatory transcription factor 
activity in response to glucocorticoids 
5.2.4.1 Transcription factor plasmids 
The luciferase reporter plasmids for NFκB (3x(NFκB)tk-luc) and AP-1 (-
517/+63col-luc) (2.7.1) were grown as described (2.7.2) 
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5.2.4.2 Transfection of RAW264.7 cells 
Initially, transfection of RAW264.7 cells with luciferase reporter plasmid for NFκB 
and AP-1 was attempted. However, preliminary experiments using the protocol 
described (2.7.3), revealed that positive control plasmids were not producing 
luciferase activity greater than ‘empty’ negative control plasmids. A number of 
optimisation methods were undertaken to overcome this: 
 The volume of FuGENE HD transfection reagent added to the transfection 
complex was altered. The FuGENE HD reagent forms a complex with the DNA 
and then transports this complex into the cells. Therefore, altering the ratio of 
FuGENE:DNA impacts on complex composition and function. The protocol 
described in 2.7.3 used a FuGENE:DNA ratio of approximately 2:1. In 
attempting to transfect RAW264.7 cells, the following ratios were tried: 3:2, 4:2, 
5:2, 6:2, 7:2 and 8:2.  
 The volume of the transfection complex added to each well was altered. The 
protocol described in 2.7.3 required addition of 50μl transfection complex to each 
well. The following volumes of transfection complex were tested: 75μl, 100μl, 
150μl and 200μl.  
 The incubation time for complex formation was altered. In the protocol described 
in 2.7.3, the transfection complex was added immediately to the cells. In 
attempting to optimise transfection of RAW264.7 cells, the following incubation 
times were tested for the transfection: 15 min, 30 min, 1 hour (all RT). 
 
Despite these attempts, successful transfection was not achieved and so another cell 
line previously used to transfect these plasmids was used as an alternative (Bladh et 
al. 2005). 
 
5.2.4.3 Transfection of HEK293 cells 
Transfection of HEK293 cells was as described (2.4.3).  
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5.2.4.3 Glucocorticoid treatment of TPA-stimulated HEK293 cells 
Twenty four hours after transfection, HEK293 cells were incubated with TPA 
(5ng/ml) or vehicle (PBS, 2μl) to stimulate pro-inflammatory transcription factor-
mediated luciferase activity. Cells were co-incubated with corticosterone, 5αDHB or 
5αTHB (1μM) (24 hours) before luciferase activity was quantified. Three 
experiments were performed in duplicate. 
 
5.2.4.4 Quantification of luciferase activity 
Luciferase activity of transfected HEK293 cells was quantified as described (2.7.4). 
 
5.2.4.5 Data analysis 
Data for the transient transfection study were analysed using the raw data of 
luminescent intensity of the luciferase assay. The values of the luciferase activity 
were calculated by subtraction of the corresponding mean values of the background 
that were produced by transfections with pGEM only. In order to normalise for 
transfection efficiency, a LacZ plasmid (encoding β-galactosidase) under the control 
of the simian virus-40 (SV40) promoter was co-transfected into HEK293 cells. 
However, it was found that TPA-stimulation significantly induced expression of β-
galactosidase and so was not a viable transfection control. A switch was made to the 
Dual Luciferase Assay kit (Promega, Southampton, UK), which utilised a Renilla 
luciferase reporter plasmid under the control of the cytomegalovirus (CMV) 
promoter as an internal control for transfection efficiency. However, TPA treatment 
here also resulted in an upregulation of Renilla luciferase activity. For this reason, 
transfection efficiency was not controlled using an internal control plasmid. Instead, 
all experiments were performed in triplicate, and only deemed acceptable if 
difference from mean for triplicates was <15%. Transfection was only deemed 
acceptable if the luciferase activity of the positive control plasmid was >500 times 
greater than the ‘empty’ plasmid negative control. 
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5.2.5 Assessment of A-ring reductase expression in 
RAW264.7 cells 
5.2.5.1 Treatment of cells 
RAW264.7 cells were plated on 6-well plates and incubated (24 hours) as described 
above (5.2.2.1). Cells were washed with sterile PBS and incubated (1 hour) in their 
respective growth medium containing stripped-serum instead of normal serum. Cells 
were treated with LPS (30ng/ml) or vehicle (PBS) and incubated (24 hours). 
 
5.2.5.2 Molecular biology 
Total RNA was extracted from plated cells (2.6.1.3) before quantification of RNA 
(2.6.1.4). First strand cDNA was synthesised by reverse transcription (2.6.1.6). 
Expression of 5αR1, 5α-reductase-2 (5αR2), 5β-reductase (5βR), 3αHSD and 




Data are presented as mean ± SEM and were analysed by One-way Analysis of 




5.3.1 Cytokine release in LPS-stimulated RAW264.7 
macrophages: LPS dose-response 
LPS-stimulation of RAW264.7 cells resulted in a dose-dependent increase in the 
release of both TNFα (Figure 5.1a) and IL-6 (Figure 5.1b). EC50 values of 
53.89ng/ml for TNFα and 44.41ng/ml for IL-6 were calculated. A submaximal dose 
of 30ng/ml was chosen to assess the effects of steroids upon cytokine release in 
subsequent experiments. 
 
5.3.2 Suppression of cytokine release in LPS-stimulated 
RAW264.7 cells by glucocorticoids 
LPS stimulation of RAW264.7 cells resulted in an increase in the levels of both 
TNFα (Figure 5.2a-c) and IL-6 (Figure 5.2d-f) above control. Corticosterone (B), 
5αDHB and 5αTHB suppressed release of both TNFα and IL-6 in a dose-dependent 
manner. However, at equimolar concentrations, 5αDHB had a significantly weaker 
suppressive effect on TNFα release than both B and 5αTHB In terms of IL-6 
suppression, at equimolar concentrations, 5αTHB had a weaker suppressive effect 
compared to both B and 5αDHB.  
 
5.3.3 Effects of GR antagonism on suppression of cytokines 
by steroids in LPS-stimulated RAW264.7 cells 
The GR antagonist RU486 was incubated with a single concentration (1μM) of each 
steroid and TNFα and IL-6 levels assessed (Figure 5.3a and 5.3b respectively). Co-
incubation with the GR antagonist prevented any reduction in cytokine release by B, 






















Figure 5.1 Dose-dependent increase in cytokine release in LPS-stimulated 
RAW264.7 macrophages. RAW264.7 cells were incubated with increasing 
concentrations of lipopolysaccharide (LPS) for 24 hours and cytokine release into 
culture media quantified by ELISA. LPS-stimulation resulted in a dose-dependent 
increase in TNFα (a) and IL-6 (b) release. Data are mean ± SEM for n=3 in duplicate 
per group.  




























Figure 5.2 Glucocorticoids suppress cytokine release from LPS-stimulated 
macrophages. RAW264.7 cells stimulated with lipopolysaccharide (LPS, 30ng/ml) 
or control (PBS, Con) were incubated with increasing concentrations of 
corticosterone (B), 5α-dihydrocorticosterone (5αDHB) or 5α-
tetrahydrocorticosterone (5αTHB) for 24 hours prior to quantification of TNFα (a) 
and IL-6 (b). Suppressive effects of the highest dose of each steroid are shown for 
TNFα (c) and IL-6 (d). Data are mean ± SEM for n=3 in duplicate per group. 
Comparisons (c, d) were by one-way ANOVA with Tukey post-hoc tests. 
###
P<0.001 
vs Con; *P<0.05, **P<0.01, ***P<0.001 vs V (vehicle); 
ψψ




P<0.001 vs 5αDHB.  
  













































































Figure 5.3 Effects of steroids in LPS-stimulated RAW264.7 macrophages are 
blocked by GR antagonism. RAW264.7 cells were incubated with or without the 
glucocorticoid receptor (GR) antagonist RU486 (1μM) (+RU486 and –RU486 
respectively) for 1 hour prior to treatment with corticosterone (B, 1μM), 5α-
dihydrocorticosterone (5αDHB, 1μM), 5α-tetrahydrocorticosterone (5αTHB, 1μM) 
or Vehicle (ethanol). 1 hour after steroid treatment, cells were stimulated with 
lipopolysaccharide (LPS, 30ng/ml) for 24 hours prior to quantification of cytokine 
levels by ELISA. B, 5αDHB and 5αTHB suppressed TNFα (a) and IL-6 (b) in the 
absence of the GR antagonist. Suppression of TNFα (a) or IL-6 (b) was not observed 
in the presence of the GR antagonist. Data are mean ± SEM for n=3-6 per group. 
Comparisons were by Two-way ANOVA with Bonferroni post-hoc tests. 
***P<0.001 vs respective vehicle (V).  








































5.3.4. Protein abundance and phosphorylation states in 
glucocorticoid-treated LPS-stimulated RAW26.7 
macrophages 
LPS stimulation resulted in an increase in the phosphorylation of both JNK (Figure 
5.4a) and p38 (Figure 5.4b) compared to control. Treatment with B resulted in a 
significant suppression of both JNK and p38 phosphorylation. Similar to B, both 
5αDHB and 5αTHB also suppressed JNK and p38 phosphorylation (Figure 5.4). 
LPS-stimulation reduced expression of IκBα (Figure 5.5a) and mitogen-activated 
protein kinase phosphatase 1 (MKP-1) (Figure 5.5b). All steroids increased the 
amount of MKP-1 compared to vehicle. Whilst both B and 5αDHB increased the 
amount of IκBα, 5αTHB had no significant effect.  
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 Figure 5.4 5α-Reduced metabolites suppress JNK and p38 phosphorylation. Total and phosphorylated protein levels of the c-Jun N-
terminal kinase (JNK) (a) and p38 kinase (b) were analysed in lipopolysaccharide (LPS) stimulated RAW264.7 macrophages. Steroids 
were administered 1 hour prior to LPS stimulation and cells harvested for protein 30 min later. Representative blot of single experiment 
shown above graphs. Both 5αDHB and 5αTHB suppressed phosphorylation of JNK and p38 to a similar extent to corticosterone (B), 
compared to Vehicle (V) treatment. Data are mean ± SEM for n=4 per group. Comparisons were by one-way ANOVA with Dunnett’s post-
hoc tests. 
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Figure 5.5 Both 5α-Reduced metabolites induce MKP-1 expression, but 5αDHB induces IκBα expression. Protein levels of IκBα (a) 
and MKP-1 (b) were analysed in lipopolysaccharide (LPS) stimulated RAW264.7 macrophages. Steroids were administered 1 hour prior to 
LPS stimulation and cells harvested for protein 30 min later. Representative blot of single experiment shown above graphs. Both 
corticosterone (B) and 5αDHB increased the amount of IκBα, whilst 5αTHB had no effect (a). All steroids increased amount of MKP-1 (b). 
Data are mean ± SEM for n=5 per group. Comparisons were by one-way ANOVA with Dunnett’s post-hoc tests. 
###
P<0.001 vs Con; 






























































5.3.5 Suppression of NFκB activation in TPA-stimulated 
HEK293 cells by glucocorticoids 
Phorbol ester (TPA) stimulation of HEK293 cells resulted in a significant increase in 
NFκB-mediated luciferase activity (Figure 5.6a) compared to control. In HEK293 
cells co-transfected with GR (Figure 5.6a), both B and 5αDHB significantly 
suppressed NFκB-mediated luciferase activity. However, 5αTHB increased NFκB-
mediated luciferase activity. In HEK293 cells not co-transfected with GR, the ability 
of B and 5αDHB to suppress NFκB-mediated luciferase activity was lost, however, 
5αTHB retained the ability to increase NFκB-mediated luciferase activity. 
 
5.3.6 Suppression of AP-1 activation in TPA-stimulated 
HEK293 cells by glucocorticoids 
Phorbol ester (TPA) stimulation of HEK293 cells resulted in a significant increase in 
AP-1-mediated luciferase activity (Figure 5.7a) compared to control. Both B and 
5αDHB suppressed AP-1-mediated luciferase activity in HEK293 cells co-
transfected with GR, whilst 5αTHB increased AP-1-mediated luciferase activity. The 
suppressive ability of B and 5αDHB on AP-1-mediated luciferase activity was lost in 
HEK293 cells not co-transfected with GR. However, 5αTHB retained the ability to 
increase AP-1-mediated luciferase activity (Figure 5.7b). 
 
5.3.7 Expression of A-ring reductases in RAW264.7 cells 
The presence of 5α-Reductase-1 (5αR1), 5α-Reductase-2 (5αR2), 5β-Reductase 
(5βR) and 3α-hydroxysteroid dehydrogenase (3αHSD) mRNA was assessed in 
RAW264.7 cells (Figure 5.8). Only 5αR1 was transcribed in RAW264.7 cells 
(Figure 5.8a), whilst none of the other genes were transcribed. Presence of a house-






Figure 5.6 Differential effects of steroids on NFκB-mediated luciferase activity 
in transfected HEK293 cells stimulated with TPA. HEK293 cells were co-
incubated with phorbol ester (TPA) or control (phosphate buffered saline, Con) and 
corticosterone (B, 1μM), 5α-dihydrocorticosterone (5αDHB, 1μM), 5α-tetrahydro-
corticosterone (5αTHB, 1μM) or Vehicle (ethanol) for 24 hours. HEK293 cells were 
studied with glucocorticoid receptor (GR) co-transfected (+GR) (a) and without GR 
co-transfection (-GR) (b). B and 5αDHB suppressed NFκB-mediated luciferase 
activity in cells with GR present, however, 5αTHB increased activity (a). In cells 
without GR, the suppressive effects of B and 5αDHB were not seen. However, 
5αTHB maintained the ability to increase NFκB-mediated luciferase activity (b). 
Data are mean ± SEM for n=3 in triplicate per group. Comparisons were by two-way 
ANOVA with Bonferroni post-hoc test. 
###
P<0.001 vs Con; *P<0.05, ***P<0.0001 
vs respective Vehicle. 



































































Figure 5.7 Differential effects of steroids on AP-1-mediated luciferase activity in 
transfected HEK293 cells stimulated with TPA. HEK293 cells were co-incubated 
with phorbol ester (TPA) or control (phosphate buffered saline, Con) and 
corticosterone (B, 1μM), 5α-dihydrocorticosterone (5αDHB, 1μM), 5α-tetrahydro-
corticosterone (5αTHB, 1μM) or Vehicle (ethanol) for 24 hours. HEK293 cells were 
studied with (+GR) (a) and without (-GR) (b) glucocorticoid receptor (GR) co-
transfected. In HEK293 cells with GR present (a), B and 5αDHB suppressed AP-1-
mediated luciferase activity in cells However, 5αTHB increased activity. In HEK293 
cells without GR (b), 5αTHB maintained the ability to increase AP-1-mediated 
luciferase activity, whilst B and 5αDHB lost their suppressive ability. Data are mean 
± SEM for n=3 in triplicate per group. Comparisons were by two-way ANOVA with 
Bonferroni post-hoc tests. 
###






































































Figure 5.8 Expression of A-ring reductases in RAW264.7 cells. The presence of 
mRNA for 5α-Reductase-1 (a), 5β-Reductase (b), 3α-hydroxysteroid dehydrogenase 
(c) and 5α-Reductase-2 (d) were assessed in RAW264.7 cells. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (e) was assessed as a positive control for 
successful PCR reaction. 5α-Reductase-1 was expressed in both unstimulated and 
lipopolysaccharide (LPS)-stimulated RAW264.7 cells (a, lanes 4 and 7 respectively). 
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In this chapter, in vitro inflammatory systems were used to investigate the cellular 
mechanisms underpinning the effects of 5α-reduced metabolites of corticosterone, 
with the effects summarised in Table 5.1. In LPS-stimulated RAW264.7 
macrophages, both 5αDHB and 5αTHB suppressed release of the pro-inflammatory 
cytokines TNFα and IL-6 in a dose-dependent manner. Pre-treatment with the GR 
antagonist RU486 ameliorated the suppressive effects of all steroids, indicating anti-
inflammatory actions through GR. The cellular mechanisms underpinning the anti-
inflammatory effects of 5α-reduced metabolites in macrophages were investigated by 
analysing inflammatory signalling pathways. LPS-mediated phosphorylation of both 
JNK and p38 was inhibited by 5αDHB and 5αTHB. Transactivation of MKP-1 was 
observed following 5αDHB and 5αTHB treatment. However, of the two 5α-reduced 
metabolites, only 5αDHB increased the amount of IκBα. To establish if these anti-
inflammatory effects were a result of inhibition of pro-inflammatory transcription 
factor activation, HEK293 cells were transiently transfected with luciferase reporter 
plasmids for NF-κB and AP-1. Following stimulation with TPA, 5αDHB suppressed 
NF-κB and AP-1-activation to a similar level to corticosterone. However, 5αTHB 
increased both NF-κB and AP-1 activation. The effects of 5αDHB in HEK293 cells 
was found to be GR-dependent, however, those of 5αTHB were GR-independent.  
 
Metabolism of steroids represents a mechanism by which tissues can regulate 
exposure to, and subsequent action of, a range of steroids. In particular, A-ring 
reduction of steroids provides an intriguing pathway by which endogenous steroids 
are metabolised. The presence of 5α-reductases and 3α-hydroxysteroid 
dehydrogenase means that steroids possessing a double bond at the ∆
4,5
 position may 
first be 5α-reduced and then 3α-hydroxylated. In terms of glucocorticoids, it was, 
until recently, believed that such metabolism was a pathway of inactivation. 
However, evidence from other steroids suggested this may not be the case. Indeed, 
the role of 5α-reduction was first discovered in androgen physiology, in which it was 
147 
 




inflammatory cytokine release 
Yes  Yes  Yes
Suppression of MAPK 
inflammatory signalling       
Induction of MKP-1       
Induction of IκBα       
        
Kidney 
(HEK293) 
Suppression of NFκB activation  Yes  Yes  No 
Suppression of AP-1 activation  Yes  Yes  No
 
Table 5.1 Summary of in vitro effects of corticosterone and its 5α-reduced metabolites. Highlighted are the effects of each 
corticosterone (B), 5α-dihydrocorticosterone (5α DHB) and 5α-tetrahydrocorticosterone (5αTHB) on various inflammatory mechanisms in 
RAW264.7 murine macrophages and the HEK293 human kidney cells. The column directly adjacent to each steroid depicts if the effect 




found that 5α-dihydro-testosterone (5αDHT), the 5α-reduced form of testosterone 
(T), binds to the androgen receptor with a greater affinity than T (Siiteri and Wilson 
1974). Further work identified that whilst T is the principal androgen, the active 
androgen in many tissues is 5αDHT (George 1997). 5α-Dihydro-progesterone 
(5αDHP), the 5α-reduced form of progesterone (P), is also capable of exerting effects 
via the progesterone receptor (Muller and Kerschbaum 2006). In microglial cells, 
5αDHP has been shown to suppress LPS-induced nitric oxide release, as has the 
tetrahydro form of P, 5αTHP. Such work stimulated interest in the study of 5α-
reduced glucocorticoids and their potential to exert similar actions to their parent 
steroid. Initial work revealed that both 5αDHB and 5αTHB bind to the GR, with 
5αTHB having a greater binding affinity (McInnes et al. 2004). This led to further 
investigation into 5αTHB as an activator of GR. In HEK293 cells, it was found that 
5αTHB translocated GR into the nucleus, although at a significantly slower rate than 
B (Yang 2009). Unlike B, 5αTHB failed to transactivate several glucocorticoid 
responsive genes in these cells, namely PEPCK and TAT, suggesting an inability to 
fully activate GR (Yang 2009), although this is in contrast to a previous report 
suggesting an ability to transactivate TAT and PEPCK (McInnes et al. 2004). 
Despite this, further work into this metabolite revealed that 5αTHB was in fact 
capable of suppressing pro-inflammatory cytokine release in LPS-stimulated bone-
marrow derived macrophages. 
 
In the data presented here, both 5α-reduced glucocorticoid metabolites suppressed 
LPS-induced pro-inflammatory cytokine production, yet their efficacy compared to 
B was reduced, indicating that they do not retain the full anti-inflammatory potential 
of the parent glucocorticoid. To investigate possible cellular mechanisms behind 
these effects, protein levels of genes involved in inflammatory signalling pathways 
(Figure 5.9) were investigated in LPS-stimulated macrophages. Inflammation is 
initiated through the action of pro-inflammatory signals, including LPS, cytokines, 
viral factors and phorbol esters. Binding of these molecules to their cognate receptors 

















Figure 5.9 Overview of inflammatory signalling pathways. Stimulation via an 
inflammatory stimulus, whether it be lipopolysaccharide (LPS), pro-inflammatory 
cytokines such as TNFα, or a phorbol ester (TPA), results in the activation of 
multiple intra-cellular signalling cascades. The IκBα complex that holds NF-κB in 
the cytoplasm is phosphorylated and targeted for degradation, freeing NF-κB to 
translocate to the nucleus. Members of the MAPK family, including ERK, p38 and 
JNK are phosphorylated and thus activated by upstream kinases. This activation 
leads primarily to the activation of AP-1, but also, in the case of ERK and p38, the 
phosphorylation of NF-κB. The activation of both NF-κB and AP-1 leads to 




activation of the pro-inflammatory transcription factors NF-κB and AP-1 (Nissen and 
Yamamoto 2000; Hayden and Ghosh 2008; O'Neill 2008). However, such pathways 
involve multiple intermediary factors. One of these factors is IκBα, a protein that, in 
the resting state, is responsible for sequestering NF-κB within the cytoplasm (De 
Bosscher et al. 2003). However, upon inflammatory stimulation, an upstream kinase 
complex, namely IKK, phosphorylates IκBα, targeting it for degradation. This results 
in the release of NF-κB, enabling its translocation to the nucleus and subsequent 
transcriptional activity.  
 
An important group of intermediary factors within inflammatory signalling pathways 
is the MAPK family of protein kinases, including JNK, p38 and ERK, all of which 
are activated through phosphorylation by upstream kinases. This family of MAPK 
proteins are particularly important in mediating AP-1 transcriptional activity, 
primarily through increasing expression of the AP-1 subunits c-Jun and c-Fos 
(Beyaert et al. 2002; Hazzalin and Mahadevan 2002; Johnson and Lapadat 2002). 
However, these kinases also have a role to play in the activation of NF-κB. In 
particular, both ERK and p38 act to phosphorylate the p65 subunit of NF-κB, 
ensuring the ability of the pro-inflammatory transcription factor to associate fully 
with transcriptional machinery and necessary coregulators (Goebeler et al. 2001). 
Naturally, inflammation is a highly regulated process and so the cell has several 
negative regulatory systems in place to ensure a balance in intracellular 
inflammation. With regard to the MAPK family, perhaps the most extensively 
studied negative regulator is MKP-1 (Camps et al. 2000; Salojin et al. 2006). This 
phosphatase is responsible for dephosphorylating the MAPK family of kinases, and 
thus inhibiting downstream activation of pro-inflammatory transcription factors. 
Given its role as a negative regulator, inflammatory stimuli induce protein expression 
of MKP-1, yet this is reported after approximately 60 minutes. However, both 
mRNA and protein expression immediately after stimulation (10 to 30 minutes), is 






Figure 5.10 Intra-cellular glucocorticoid targets in inflammation. 
Glucocorticoids (GCs) are capable of acting at several sites to exert their anti-
inflammatory effects. 1, glucocorticoid receptor (GR) homodimers induce expression 
of IκBα, which acts to sequester NF-κB in the cytoplasm, inhibiting downstream 
activation. 2+3, GR monomers tether to DNA-bound NF-κB and AP-1, preventing 
initiation of transcription. 4, GR monomer induces transcription of MKP-1, which 
serves to dephosphorylate the MAPK family of proteins, preventing activation and 



















In order to explore the cellular mechanisms behind the effects of 5α-reduced 
glucocorticoid metabolites, it is important to understand first how glucocorticoids 
exert changes in gene expression (Figure 5.10). Glucocorticoids mediate their effects 
through ligation with the GR, a nuclear receptor with three functional domains, 
namely the N-terminal transactivation domain, activation-function 1 (AF1), the 
central DNA-binding domain (DBD) and the C-terminal ligand-binding domain 
(LBD) which also contains a second transactivation domain, AF2. Upon ligand 
binding, the GR dissociates from the multi-protein chaperone complex that maintains 
the GR in the cytoplasm, unmasking the nuclear localisation signal (NLS) and 
allowing translocation of the active GR to the nucleus. Within the nucleus, the anti-
inflammatory effects of GR can be characterised primarily in two ways, 
transactivation of anti-inflammatory molecules and transrepression of pro-
inflammatory molecules. In terms of transactivation, a number of genes are 
upregulated by glucocorticoids that have an anti-inflammatory role, including IκBα, 
MKP-1, IL-10 and lipocortin-1 (Clark 2007; Newton and Holden 2007). 
Transactivation primarily occurs through binding of GR homodimers to simple 
glucocorticoid-response elements (GREs) within target genes (Saklatvala 2002; 
Schacke et al. 2002). However, GR monomers may also play an important role 
through tethering mechanisms with other transcription factors including C/EBPα. 
Indeed, this is believed to be the mechanism behind glucocorticoid-inducible MKP-1 
gene expression, with a study demonstrating that dexamethasone was still able to 
induce MKP-1 expression in macrophages with a mutated GR that prevented 
dimerisation (Abraham et al. 2006).  
 
In our study, both 5α-reduced metabolites, along with B, significantly increased the 
amount of MKP-1 following LPS-mediated suppression. However, it is debatable 
whether the actions of these steroids serve specifically to induce protein expression 
of MKP-1, or prevent LPS-mediated degradation. It has previously been 
demonstrated in unstimulated RAW264.7 cells that dexamethasone treatment for 1 
hour increases both mRNA and protein expression of MKP-1, an effect that was 
attenuated by co-incubation with the GR antagonist RU486 (Cho and Kim 2009). 
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This suggests that the increased amount of MKP-1 observed with 5α-reduced 
glucocorticoid metabolite treatment is a result of induction of protein expression 
rather than inhibited degradation. This upregulation also supports a role for MKP-1 
in dephosphorylating the MAPK family (Kassel et al. 2001), given that treatment 
with both 5α-reduced glucocorticoid metabolites and B also resulted in a suppression 
of JNK and p38 phosphorylation. A similar situation to MKP-1 exists with IκBα, in 
which B and 5αDHB appear to increase protein expression. Again, it remains unclear 
whether this is due specifically to increased protein expression, or reduced IκBα 
degradation. To address these issues, it would be valuable to assess mRNA levels of 
both MKP-1 and IκBα to see if they follow the pattern shown in protein expression. 
Furthermore, the role of de novo protein synthesis could be addressed through co-
incubation with protein synthesis inhibitors. This would not only provide evidence as 
to whether glucocorticoids actually induce protein expression, but in terms of MKP-
1, it would reveal whether the upregulation of MKP-1 was essential for the 
suppression of JNK and p38 phosphorylation mediated by the steroids. In terms of 
IκBα, it was interesting that of the two 5α-reduced metabolites, only 5αDHB altered 
protein expression. A possible explanation for the lack of IκBα induction with 
5αTHB may lie with an inability to induce dimerisation of GR. It has previously 
been shown that a dimerisation defective GR mutant is unable to enhance IκBα 
levels, indicating the importance of GR dimerisation in transactivation of IκBα (Heck 
et al. 1997). However, this mutant still retained the ability to repress NFκB activity, 
demonstrating that whilst IκBα plays a role in the anti-inflammatory effects of 
glucocorticoids, its overall importance remains debatable. Given that 5αTHB has 
been shown previously to have an inability to transactivate other glucocorticoid-
responsive genes (Yang 2009), it would be interesting to look more closely at the 
effect that both 5α-reduced glucocorticoid metabolites have on GR dimerisation. 
Several studies have utilised the dimerisation-deficient GR (GR
dim
) to assess whether 
the anti-inflammatory effects of GR ligands are dependent upon dimerisation 
(Reichardt et al. 1998; Tuckermann et al. 1999; Reichardt et al. 2001). Such a 
system would be extremely useful in determining whether 5αTHB loses any of its 





Despite the clear anti-inflammatory properties of proteins induced by 
glucocorticoids, their role in the overall anti-inflammatory response is controversial. 
The classical view is that the primary anti-inflammatory effects of glucocorticoids 
are mediated by transrepression of pro-inflammatory gene expression (De Bosscher 
and Haegeman 2009). Indeed, some studies have demonstrated that de novo protein 
synthesis plays little to no role in the ability of glucocorticoids to suppress expression 
of pro-inflammatory genes (De Bosscher et al. 1997; Wissink et al. 1998). 
Glucocorticoid-induced transrepression of pro-inflammatory gene expression is 
believed to mainly involve tethering of GR monomers with pro-inflammatory 
transcription factors such as NFκB and AP-1 (Beck et al. 2009). As such, direct 
DNA binding of GR is not required. However, the DBD still appears to be important 
in GR-mediated transrepression, as shown in a study using a GR with a mutation in 
the DBD (Bladh et al. 2005). This mutant GR was still able to repress AP-1 activity, 
but not NF-κB activity, indicating that not only is this region important even when 
DNA binding is not evident, but also that it is possible to discriminate between GR-
mediated NF-κB and AP-1 repression. To investigate the effects of 5α-reduced 
metabolites specifically on pro-inflammatory transcription factor inhibition, we 
decided to utilise luciferase reporter plasmids with NF-κB of AP-1-binding sites. 
Initially, transfection of these plasmids in RAW264.7 cells was attempted. Although 
previous reports demonstrated transfection of RAW264.7 cells with FuGENE HD 
(Yamauchi et al. 2007; Shi and Kehrl 2008; Renga et al. 2009), in our hands, we 
could not achieve successful transfection, despite numerous optimising routines. 
Future work utilising other transfection reagents, such as Lipofectamine, which has 
been reported to induce transfection in these cells (Jiang and Pisetsky 2008), may 
yield more successful results.  
 
In light of the inability to transfect RAW264.7 macrophages, an alternative cell line 
was used, namely HEK293 kidney cells, which had previously been utilised 
successfully with these plasmids (Bladh et al. 2005), and are a commonly transfected 
cell line. However, they lack the advantage of being an immune cell line. Whilst this 
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switch to a different cell line resulted in successful transfection, it also revealed some 
interesting results. Similar to B, 5αDHB suppressed TPA-stimulated transcriptional 
activity of both NF-κB and AP-1, indicating the ability of this metabolite to repress 
pro-inflammatory transcription factor activity. However, whilst 5αDHB retained the 
anti-inflammatory properties seen in macrophages, suppressing both NF-κB and AP-
1 activation, 5αTHB actually increased activation of both transcription factors. This 
indicates that, in HEK293 cells, 5αTHB actually augments TPA-mediated 
inflammation, in direct contrast to the anti-inflammatory effects observed in 
macrophages. To further understand the different effects of 5αTHB in both cell 
types, the role of the GR in mediating these effects was investigated. In RAW264.7 
cells, co-incubation with the GR antagonist inhibited the ability of both 5α-reduced 
metabolites to suppress LPS-induced pro-inflammatory cytokine release. This 
demonstrates that, in macrophages, anti-inflammatory effects of both 5αDHB and 
5αTHB are mediated by GR. In HEK293 cells, actions mediated by GR were 
assessed by not transfecting cells with a GR plasmid. In the absence of GR, the 
inhibitory effects of B and 5αDHB on TPA-mediated transcriptional activity of NF-
κB and AP-1 was ameliorated. Surprisingly, the absence of GR did not affect the 
ability of 5αTHB to augment NF-κB or AP-1-mediated transcription, indicating a 
GR-independent mechanism of action in HEK293 cells.   
 
It has previously been shown that HEK293 cells express little to no endogenous GR 
(Bladh et al. 2005). Whilst it is possible that that residual endogenous GR is 
mediating the effects of 5αTHB, this seems highly unlikely given the apparent lack 
of effects induced by other steroids in the absence of co-transfected GR. Several 
alternative possibilities exist as to how 5αTHB exerts these effects independent of 
GR. Firstly, 5αTHB may be acting through another nuclear receptor within these 
cells. Aldosterone, the cognate ligand for the mineralocorticoid receptor (MR), has 
been shown to induce inflammation in heart and kidney cells (Gilbert and Brown 
2010). As glucocorticoids are capable of binding and activating MR (Walker 2007), 
this provides a potential mechanism through which 5αTHB could further enhance 
inflammation. However, this again would appear unlikely given that characterisation 
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of HEK293 cells revealed an absence of endogenous MR (Ziera et al. 2009). 
Evidence also exists in neuronal cells that 5α-tetrahydro derivatives of both 
progesterone and cortisol are capable of acting via gamma-aminobutyric acid 
(GABA) receptors (Stromberg et al. 2005). These receptors are ligand-gated chloride 
ion channels that are found both in the central and peripheral nervous system, in both 
neuronal and non-neuronal cells. Whilst these receptors only appear to be present in 
cells involved with the nervous system, it highlights the potential of 5α-tetrahydro 
metabolites to bind to other receptors and modulate responses.  
 
What has become evident from investigating the effects of 5α-reduced metabolites in 
both macrophages and kidney cells is the differences that exist between the two 5-
reduced glucocorticoid metabolites. It appears that, in macrophages, 5αDHB retains 
more of the anti-inflammatory effects of the parent glucocorticoid than 5αTHB, 
whilst in kidney cells, the effects of the two metabolites on inflammation differ. This 
highlights the cell-specific nature of these effects, as well as alluding to the role of 
the GR ligand in determining GR action. To understand why this may be the case, 
one must consider the fact that the GR belongs to a superfamily of nuclear receptors, 
and so previous work on other such receptors can provide valuable clues as to the 
nature of GR function. As mentioned above, all nuclear receptors within this family 
consist of the three domains described above, namely AF-1, DBD and LBD, and 
share many structural and functional features (Bledsoe et al. 2002; van der Laan and 
Meijer 2008). In terms of ligand-mediated effects, the LBD is perhaps the most 
interesting domain and serves several essential functions. It contains a binding 
pocket specific for the binding of the cognate ligand, as well as the second activation 
function (AF-2) (Bledsoe et al. 2002; McMaster and Ray 2007). The AF2 has been 
extensively studied in the androgen receptor (AR), and its contribution to receptor 
activity appears dependent upon both ligand- and cell-specific factors. In particular, 
AF-2 in known to recruit cofactors, including the p160 family of coactivators, upon 
ligand binding, thus enhancing AR activity. The recently published crystal structure 
of AR with bound T or 5αDHT has allowed for much greater insight into specific 
binding patterns and has shed valuable light on the differences in potency of these 
157 
 
two androgens (Askew et al. 2007). Naturally occurring mutations in AR have been 
shown to increase AR activity through enhanced coactivator recruitment to AF-2 (He 
et al. 2006) and, as such, the ability of AF-2 to recruit coactivators is now believed to 
be crucial to both the binding affinity and the activity of the AR.  
 
T is a less potent androgen than 5αDHT, with a 10-fold higher concentration needed 
to achieve AR-mediated effects of 5αDHT, and dissociates 3x faster from AR than 
the latter (Askew et al. 2007). Structural data suggests that such differences can be 
attributed to differences within the H-bonding pattern between the ligand and the 
hydrophobic binding-pocket within the LBD of the receptor. Both T and 5αDHT 
have 19 carbons and differ only in that T has a ∆
4,5
 double bond in ring A. Unlike the 
saturated A-ring of 5αDHT, T has two fewer protons, ensuring a superior hydrophilic 
property relative to 5αDHT and, therefore, greater H-bonding potential. The crucial 
bond in this pattern appears to be between 3-keto O on the steroid and Arg752, a 
conserved helix 5 residue on the receptor. The ∆
4,5
 double bond in T has a more 
planar angle than 5αDHT, ensuring more favourable H-bonding (Askew et al. 2007). 
One might hypothesise that greater bonding would result in greater affinity. 
However, this does not appear to be the case here. Indeed, the ‘counterintuitive 
hypothesis’ states that greater H-bonding is detrimental to agonist activity. This is 
believed to be due to the introduction by T of an unfavourable hydrophilic character 
within the hydrophobic binding pocket (Askew et al. 2007). This is evidenced by the 
network of H-bonds through structural water HOH1 between the steroid and key 
residues within the AF2 domain. The planar structure of T would appear to allow T 
to accept a bridged H-bond with Met745. In contrast, the lack of a ∆
4,5
 double bond 
in 5αDHT appears to weaken or eliminate such a bridged H-bond. This Met745 
residue in the AF2 domain lies directly above the ∆4,5 double bond of the steroid, 
and projects towards Leu712, a proximal residue within AF2. This residue is crucial 
in mediating hydrophobic contacts with residues within cofactor molecules. A 
mutation in this residue has been shown to cause androgen insensitivity without 
altering androgen binding affinity, demonstrating that the recruitment of cofactors is 
paramount to the activity of this receptor (Ghali et al. 2003). 5αDHT has been 
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suggested to impart greater structural integrity to Leu712, permitting greater cofactor 
binding and thus greater AR activity (Askew et al. 2007).  
 
These findings with AR show that A-ring chemistry can have direct effects on 
cofactor recruitment. However, ligand-mediated activities only form part of the 
picture, as the presence of specific cofactors can also determine receptor activity, 
possibly explaining the cell-specific effects of steroids. Indeed, this has been shown 
when investigating the estrogen receptor (ER) antagonists tamoxifen and raloxifene 
(Shang and Brown 2002). Both of these antagonists were shown to recruit 
corepressors to target genes in mammary cells, thus repressing gene transcription. 
However, in endometrial cells, tamoxifen acts as an ER agonist, inducing gene 
transcription through recruitment of coactivators. This demonstrates the ability of a 
steroid receptor ligand to act as either an agonist or antagonist depending on the 
cellular environment. This may provide an explanation for the differential effects of 
5αTHB on inflammation between macrophages and kidney cells. The reasons behind 
the ability of different ligands to recruit either coactivators or corepressors to their 
cognate receptor appear to be related to the structural changes that occur upon ligand 
binding. This has been investigated for the binding of the GR agonist dexamethasone 
and the GR antagonist mifepristone (Schoch et al. 2010) (Figure 5.11). Binding of 
dexamethasone to GR places helix 11 in an ‘agonist’ conformation, favouring 
binding of the transcriptional intermediary factor-2 (TIF2) coactivator (TIF2 is the 
human homologue of murine GRIP1) (Figure 5.11a). The antagonist RU486, which 
binds to the GR-LBD in the same location and orientation as dexamethasone, induces 
a distinctly different conformation within the GR (Figure 5.11b). Helix 11 is 
displaced from its agonist position, creating a cofactor binding site that has a bigger 
volume than the site forTIF2. This results in the inability to form charge interactions 
between Glu755 from helix 11 and the N-terminus of the TIF2-interacting helix. 
However, the nuclear receptor corepressor (NCoR) is now able to bind, forming 
interactions via its C-terminus with Lys759 of the GR (Schoch et al. 2010). This 











Figure 5.11 Conformational changes induced in helix 11 of the GR by different 
ligands. In (a), dexamethasone (Dex) binding results in a conformational change in 
the position of helix 11 (H11) to the agonist position. This allows the recruitment of 
the transcriptional intermediary protein-2 (TIF2) coactivator. In (b), RU486 
(mifepristone, Mif) displaces helix 11 from the agonist position, enlarging the 
coregulator binding site and thus permitting the binding of the nuclear corepressor 
(NCoR). Figures were generated using the RCSB Protein Workshop software. 
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the ability to recruit coactivators or corepressors and similar mechanisms may 
underpin the difference in actions between 5αDHB and 5αTHB. 
 
The effects of 5α-reduced glucocorticoid metabolites most likely involve the 
recruitment of such cofactors, however, this has yet to be investigated. What remains 
perplexing is the ability of 5αTHB to suppress inflammation in one cell type, but 
induce it in another. Furthermore, it remains to be fully established whether the 
effects of 5αTHB in the kidney cells where it enhanced inflammation is mediated 
through GR. If 5αTHB does indeed act via GR in these cells, what appears a likely 
scenario is that it recruits a different set of cofactors to both B and 5αDHB, and 
whilst these cofactors are present in macrophages, permitting the suppression of 
inflammation, they are absent in kidney cells. As shown above, ligand binding 
determines the ability of the receptor to recruit such cofactors. Whilst this has been 
shown for GR binding with dexamethasone (Schoch et al. 2010), no studies exist on 
5α-reduced metabolite binding.  Of course, the cell-specific effects of 5αTHB, along 
with the difference in effects between the two metabolites highlight potential in vivo 
implications for the use of 5α-reduced metabolites of glucocorticoids. Given their 
ability to cause cell-specific effects, it raises the question as to whether they would 
provide desirable effects if administered as an anti-inflammatory agent. Furthermore, 
the fact that these steroids are metabolites leads to the issue of whether 5αDHB 
would be metabolised to 5αTHB in the body, thus negating any potential anti-
inflammatory benefits. To investigate this, the expression of A-ring enzymes were 
investigated in RAW264.7 macrophages. In these cells, it was found that only 5α-
reductase type 1, the enzyme responsible for reducing the parent glucocorticoid to its 
5α-dihydro metabolite, and not 3αHSD, was present. This indicates that the effects 
observed following administration of either 5αDHB or 5αTHB were due specifically 
to that steroid, and not as a result of it being further metabolised within the cell. 
However, within the body, distribution of these enzymes is tissue-specific and so it 
remains a distinct possibility that when administered in vivo, these steroids would be 
metabolised, particularly within the liver. 
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In summary, 5α-reduced glucocorticoid metabolites have anti-inflammatory effects 
in macrophages, but, at equilmolar concentrations, are less effective than the parent 
glucocorticoid. The ability to suppress pro-inflammatory cytokine production in 
macrophages is mediated through GR. At the molecular level, the anti-inflammatory 
effects appear to be mediated, in part, through inhibition of inflammatory kinase 
phosphorylation and activation. For the parent glucocorticoid, this inhibition 
correlates with an increase in the levels of MKP-1, a phosphatase responsible for 
dephosphorylating these inflammatory kinases. This may also be the case for the 5α-
reduced glucocorticoid metabolites, however, the evidence here suggests not. The 
effects of 5αTHB appear to be cell-specific, given the differential effects on 
inflammation in macrophages and kidney cells. More work is necessary in order to 
establish the mechanism behind such cell specific effects, possibly utilising 
chromatin immunoprecipitation (ChIP) to investigate the association of cofactors 
with 5αTHB-bound GR, as well as utilising cofactor-binding inhibitors to determine 
if the effects of 5αDHB are dependent upon cofactor associations. It would also be 
exciting to determine whether these metabolites are capable of inducing GR 
dimerisation or whether the effects are mediated by GR monomers. However, this 
work provides new mechanistic insights into the actions of 5α-reduced 
glucocorticoid metabolites in vitro. In terms of the dysregulation of A-ring 
metabolism observed in obesity (Andrew et al. 1998; Livingstone et al. 2005), it is 
interesting to hypothesise the consequence of increased hepatic 5αR1 expression. 
The parent glucocorticoid acts in the liver to increase gluconeogenesis, as well as 
affecting cycling of glycogen, such that the body is primed to be responsive 
(Sugiyama et al. 1998; van Schaftingen and Gerin 2002; Dostert and Heinzel 2004; 
Macfarlane et al. 2008). Whilst this is necessary in the setting of starvation, such 
action in the setting of obesity is detrimental. The increased expression of 5αR1 in 
the liver is believed to be an adaptation to obesity, protecting the liver from the 
harmful metabolic actions of glucocorticoids by inactivating them. Although an 
attractive hypothesis, this implies that the 5α-reduced glucocorticoid metabolites 
formed are inert, which, as demonstrated in previous studies and in this thesis, is 
untrue. Whilst the metabolic effects of 5αDHB are yet to be fully established, 
5αTHB has reduced metabolic actions compared to the parent glucocorticoid (Yang 
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2009). In terms of the immunomodulatory effects of glucocorticoids, both 5α-
reduced metabolites exert clear anti-inflammatory effects, although the effects appear 
to be cell-specific for the 5α-tetrahydro form. This has important consequences as 
hepatic inflammation is clearly evident in the setting of obesity.  Therefore, it 
suggests that the liver is not merely ‘disposing’ of local glucocorticoid in an attempt 
to prevent their metabolic action, but actively producing a form of the glucocorticoid 
that retains the anti-inflammatory action of the parent and may serve to suppress the 
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As outlined in Chapter 5, both 5α-reduced metabolites of corticosterone are capable 
of exerting anti-inflammatory effects in vitro. In murine macrophages, both 5αDHB 
and 5αTHB suppressed release of the pro-inflammatory cytokines TNFα and IL-6 
from LPS-stimulated macrophages. This suppression in macrophages appears to be 
mediated through inhibition of both NF-κB and AP-1 activation, as shown by 
changes in the both total protein and phosphorylation states of several molecules 
involved in these inflammatory pathways. However, in a distinctly different cell 
type, namely kidney cells (HEK293), only 5αDHB was capable of suppressing 
inflammatory signalling, with 5αTHB actually increasing the activation of pro-
inflammatory transcription factors. Such a discovery poses an intriguing question as 
to whether there are tissue specific effects of these steroids which may influence their 
spectrum of anti-inflammatory effects. There is a need for alternative glucocorticoid 
drugs due to the detrimental side effects of chronic conventional glucocorticoid 
treatment for inflammatory conditions, including osteoporosis and development of 
type 2 diabetes (Saklatvala 2002; Schacke et al. 2002; Wei et al. 2004). Previous 
work in mice has indicated that, in contrast to corticosterone, chronic exposure to 
5αTHB does not affect body weight, blood pressure or insulin sensitivity (Yang 
2009), although 5αDHB has yet to be tested. The potential anti-inflammatory effects 
of both 5αDHB and 5αTHB remain to be investigated in vivo. 
 
Hypothesis 
The hypothesis of this chapter is that 5α-reduced metabolites of corticosterone 








The aims of this chapter were to investigate: 
1) Whether 5α-reduced metabolites of corticosterone suppress inflammation 
associated with thioglycollate-induced peritonitis. 
2) Whether the effects of 5α-reduced corticosterone metabolites in the above model 





6.2 Materials and methods 
6.2.1 Experimental outline 
Steroid injections were administered 2 hours prior to the induction of peritonitis with 
thioglycollate, with tail-nick blood immediately prior to thioglycollate 
administration. Four hours after induction of peritonitis, animals were sacrificed by 
decapitation, trunk blood taken, and peritoneal lavages performed. 
 
6.2.2 Animal Maintenance 
Adult male C57Bl/6 mice (12 weeks) were maintained as described (2.3.1). 
 
6.2.3 Thioglycollate-induced peritonitis 
Thioglycollate-induced peritonitis was induced as described (2.4.3). 
 
6.2.4 Preparation of steroid solutions 
To assess dose response relationships, corticosterone (2.5, 7.5, 25, 75, 250 mg/ml) 
was prepared dissolved in vehicle of DMSO. For comparison of corticosterone with 
5α-reduced metabolites, solutions containing corticosterone, 5αDHB or 5αTHB (25, 
75 and 250 mg/ml) were prepared dissolved in a vehicle of hydro-propyl-β-
cyclodextrin in DMSO (5% w/v) immediately prior to use. 
 
6.2.5 Dose response to corticosterone to suppress 
inflammation 
Two hours prior to induction of peritonitis (09:00), corticosterone (2.5, 7.5, 25, 75 
and 250mg/ml) or vehicle was administered by subcutaneous injection (20μl). 
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6.2.6 Comparison of the efficacy of steroids to suppress 
inflammation 
Two hours prior to induction of peritonitis (09:00h), corticosterone, 5αDHB, 5αTHB 
(25, 75, 250mg/ml) or vehicle were administered by subcutaneous injection (20μl). 
 
6.2.7 Terminal procedures 
Animals were sacrificed as described (2.4.4) 
 
6.2.8 Peritoneal lavage 
Peritoneal lavages were performed as described (2.4.5). 
 
6.2.9 Quantification of total cell infiltration 
Cells within peritoneal lavage fluid were primarily quantified by NucleoCounter 
(6.2.9.1). However, in the absence of NucleoCassettes, cells were quantified by 
haemocytometer (6.2.9.2). 
 
6.2.9.1 Quantification of cell infiltration by NucleoCounter 
Peritoneal lavage samples were subjected to centrifugation (1000g, 5min, RT), with 
the cell pellet resuspended in BSA (Fraction V, 0.1% w/v, 0.5ml). The cell 
suspension was diluted (1 in 10 in 0.1% w/v BSA) and the total number of 
inflammatory cells was determined using a NucleoCassette and a NucleoCounter 
NC-100 (ChemoMetec, Denmark). The two reagents provided (Reagent A-100 and 
Reagent B) were each added (50µl) into the suspension and mixed. Reagent A-100 
(pH 1.25) is a lysis buffer that disaggregated cell clusters and disrupted cell 
membranes. Reagent B was a stabilizing buffer that raised the pH value and allowed 
more efficient staining of DNA in the NucleoCassette. The fluorescent dye 
propidium iodide is immobilized within the flow channels of the NucleoCassette. 
Upon addition of sample mixture (50μl), the propidium iodide is dissolved and the 
168 
 
DNA stained. The loaded NucleoCassette was then placed in the NucleoCounter and 
the total cell number was generated automatically by NucleoView Software 
(ChemoMetec, Denmark). 
 
6.2.9.2 Quantification of cell infiltration by haemocytometer 
A coverslip was firmly attached on top of the chamber of the haemocytometer, with 
lavage fluid (10μl) added to both sides of the chamber. Cells were counted in the four 
corner quadrants of each side of the chamber. For each side, the total number was 
divided by four, and the average of both sides equated to the number of cells per 
mm
2
. This value was multiplied by 10
4
 to give the number of cells per ml of the cell 
suspension.  
 
6.2.10 Quantification of inflammatory cells by fluorescence 
activated cell sorting (FACS) analysis 
 
6.2.10.1 Preparation of antibody mixes 
Alexa Fluor 647 conjugated monoclonal rat-anti-mouse 7/4 (IgG2a, AbD Serotec, 
Oxfordshire, UK), fluorescein isothiocyanate (FITC) conjugated monoclonal rat-anti-
mouse Ly-6G (IgG2a, BioLegend, CA, USA), phycoerythrin (PE) conjugated rat-
anti-mouse monoclonal F4/80 (IgG2a, Invitrogen, Paisley, UK) and tandem Peridinin 
Chlorophyll Protein Complex/Cy5.5 (PerCP/Cy5.5) conjugated monoclonal rat-anti-
mouse CD11b (Biolegend, CA, USA) were diluted (1/100) in mouse serum (10% v/v 
in PBS). Single stain controls consisting of each of the antibodies above separately 
were also prepared, as were isotype controls for each antibody (purchased from same 




6.2.10.2 Preparation of peritoneal cells 
Peritoneal lavage samples were mixed thoroughly and transferred to chilled FACS 
tubes (BD Falcon, Oxfordshire, UK) (300μl). Mouse serum (30μl) was added to 
block non-specific binding sites and incubated (10 min, 4°C). Appropriate antibody 
mixes were added to each sample (50μl), followed by mixing and incubation in the 
dark (30 min, 4°C). Peritoneal cells were washed with PBS (1ml) and subjected to 
centrifugation (300g, 5 min, 4°C) to form a pellet. The supernatant was removed and 
cells fixed with formalin (10% v/v in PBS, 100μl) until analysis. 
 
6.2.10.3 FACS analysis 
Analysis was performed using the LSRFortessa Cell Analyser (BD Biosciences, 
Oxfordshire, UK). Specific and non-specific fluorescence was determined by 
processing > 5000 cells per sample. Data analysis was performed using FlowJo 
software (Treestar, OR, USA). Myeloid cells were identified as CD11b positive cells 
and were further distinguished based upon staining for Ly6G, 7/4 and F4/80 as 
described (Henderson et al. 2003).  Ly6G is a marker for neutrophils that is not 
expressed on monocytes or macrophages (Cash et al. 2009), whilst 7/4 is a marker 
for recently generated inflammatory monocytes, as well as neutrophils (Cash et al. 
2009; Rosas et al. 2010). F4/80 serves as a marker for macrophage differentiation, 
allowing distinction between monocytes and macrophages (Cash et al. 2009; Rosas 
et al. 2010). A combination of these markers was used to identify distinct 
populations of neutrophils and inflammatory monocytes. Neutrophils were 
characterised by high expression of 7/4, and are distinguished from monocytes and 





 cells revealed low expression of the F4/80, indicating these cells were newly 




6.2.11 Quantification of cytokines within peritoneum by 
ELISA 
Cytokine levels within the peritoneal lavage fluid were quantified by ELISA as 
described for cell media (2.6.7).  
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Figure 6.1 Flow cytometric analysis of myeloid cells. Peritoneal myeloid were analysed by staining with 7/4 and Ly6G 4 hours after PBS 




 cells (R2) in thioglycollate treated lavage (b), which contains 
two distinct populations of cells, of which the F4/80
lo




 population (R1) consists 
primarily of F4/80
lo
 cells, which are inflammatory monocytes. The location of these cells within the scatter of Ly6G and 7/4 is shown in 
















6.2.12 Quantification of plasma corticosterone by RIA 
Plasma corticosterone levels were quantified by RIA as described (2.6.5). 
 
6.2.13 Statistics 
Data are presented as mean ± SEM and were analysed by One-way Analysis of 







6.3.1 Dose response to corticosterone to suppress 
inflammation 
Plasma corticosterone concentrations increased following administration of the 
steroid in a dose responsive manner (Figure 6.2). Peak physiological levels are 
highlighted, demonstrating that the concentrations reached following corticosterone 
administration are pharmacological. Compared to control injection of PBS, 
thioglycollate injection increased the number of cells infiltrating the peritoneum. The 
two highest doses of B (75 and 250 mg/ml) significantly suppressed peritoneal cell 














Figure 6.2 Plasma corticosterone increased in response to corticosterone 
injection. Corticosterone (B) levels in plasma 2 hours post-corticosterone 
administration were quantified by RIA. Circulating levels elevated in accordance 
with increasing dose of corticosterone. Data are mean ± SEM for n=3-4 per group. 
Con = Control (PBS). Comparisons were by one-way ANOVA with Dunnett’s post-
hoc tests. *P<0.05 vs Vehicle (V, DMSO). 
Figure 6.3 Peritoneal infiltration in response to corticosterone. Peritoneal cell 
infiltration following thioglycollate challenge quantified by NucleoCounter, with 
effect of corticosterone (B) pre-treatment expressed as percentage of response to 
Vehicle (V). Cell infiltration was suppressed with increasing concentration of B. 
Data are mean ± SEM for n=3-4 per group. Comparisons were by one-way ANOVA 
with Dunnett’s post-hoc tests. ###P<0.001 vs Con (Control, PBS, hatched bar); 
*P<0.05 vs V (Vehicle, DMSO, black bar). 























































6.3.2 Suppression of thioglycollate-induced peritonitis by 5α-
reduced glucocorticoid metabolites 
 
6.3.2.1 Suppression of cell infiltration into peritoneum 
The parent glucocorticoid B suppressed cell infiltration into the peritoneum in a 
dose-dependent manner. Both 5αDHB and 5αTHB also suppressed the influx of cells 
into the peritoneum (Figure 6.4). At the highest dose tested, there were no significant 
differences in terms of efficacy between the steroids. 
 
6.3.2.2 Identification of cell populations within peritoneal infiltrate 
 In order to establish whether  this reduction in the number of cells in the peritoneum 
was universal for all types of inflammatory cells, or if a specific subset of cells were 
affected, peritoneal cells from these mice was analysed by FACS.  In mice given a 
control injection of PBS, 1.1 ± 0.2% of the cells were neutrophils and 0.2 ± 0.05% 
were inflammatory monocytes. Thioglycollate injection induced significant 
infiltration of both neutrophils and monocytes. The predominant population was 
neutrophils, which made up 59.7 ± 1.5% of cells present within the peritoneal lavage 
following thioglycollate injection, whilst inflammatory monocytes comprised 3.7 ± 
0.5% of infiltrating cells. Neutrophil numbers were reduced to a similar extent by all 
doses of B (Figure 6.5a), whilst inflammatory monocyte infiltration was suppressed 
in a dose-dependent manner by B (Figure 6.5b).  Both 5αDHB and 5αTHB 
suppressed neutrophil infiltration to a similar extent to B (Figure 6.5a). Inflammatory 
monocyte infiltration was suppressed by 5αDHB and 5α THB, both of which were 















Figure 6.4 5α-Reduced metabolites reduce cell infiltration in peritoneum. Total 
cell influx into the peritoneal cavity 4 hours after induction of peritoneal 
inflammation by thioglycollate injection was quantified using a haemocytometer. 
Mice were pre-treated with increasing doses of corticosterone (B), 5α-
dihydrocorticosterone (5αDHB) or 5α-tetrahydrocorticosterone (5αTHB) for 2 hours 
prior to induction of inflammation. Both 5α-reduced metabolites suppressed 
infiltration of cells into the peritoneum along with the parent glucocorticoid B. V = 
steroid vehicle (5% β-cyclodextrin in DMSO). Data are mean ± SEM for n=6 per 
group. Comparisons were by one-way ANOVA with Dunnett’s post-hoc tests. 
###P<0.001 vs Con (Control, PBS, hatched bar); *P<0.05, **P<0.01, ***P<0.001 vs 









































Figure 6.5 Suppression of peritoneal neutrophil and inflammatory monocyte infiltration. The population of cells entering the 
peritoneum 4 hours after thioglycollate injection was assessed by flow cytometry. Both 5α-dihydrocorticosterone (5αDHB) and 5α-
tetrahydrocorticosterone (5αTHB) suppressed the influx of neutrophils into the peritoneum, as did the parent glucocorticoid B (a). B 
suppressed the increased influx of inflammatory monocytes into the peritoneum in a dose-dependent manner. Whilst 5αDHB and 5αTHB 
also reduced the number of inflammatory monocytes, they were less efficacious than the parent glucocorticoid (b). Data are mean ± SEM 
for n=6 per group. Comparisons were by one-way ANOVA with Dunnett’s post-hoc tests. ###P<0.001 vs Con (Control, PBS, hatched bar); 
*P<0.05, **P<0.01, ***P<0.001 vs V (Vehicle, 5% β-cyclodextrin in DMSO, black bar). 
(a) (b) 
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6.3.2.3 Peritoneal cytokine and chemokine levels 
IL-6 levels within the peritoneum were increased following thioglycollate 
stimulation, whilst treatment with B suppressed this rise (Figure 6.6a). 5αDHB also 
reduced IL-6 levels, but was less efficacious than B, only achieving suppression at 
the highest dose tested. Interestingly, 5αTHB suppressed IL-6 levels at the lowest 
dose tested, but failed to suppress at higher doses (Figure 6.6a). The results for MCP-
1 are similar, with B reducing peritoneal levels. Again, 5αDHB suppressed levels, 





 Figure 6.6 Peritoneal cytokine and chemokine levels. IL-6 (a) and  MCP-1 (b) levels were quantified in peritoneal lavage fluid 4 hours 
after thioglycollate injection by ELISA.  Corticosterone (B) suppressed release of IL-6 to a greater extent than the both 5α-
dihydrocorticosterone (5αDHB) and 5α-tetrahydrocorticosterone (5αTHB) (a). Similar to IL-6, MCP-1 levels were suppressed by several 
doses of B, yet only the highest dose of 5αDHB had a suppressive effect.  Data are mean ± SEM for n=6 per group. Comparisons were by 
one-way ANOVA with Dunnett’s post-hoc tests. ###P<0.001 vs Con (Control, PBS, hatched bar); *P<0.05, **P<0.01, ***P<0.001 vs V 
(Vehicle, 5% β-cyclodextrin in DMSO, black bar). 
(a) (b) 










































In this chapter, thioglycollate-induced peritonitis was used as an inflammatory model 
in which to assess the potential anti-inflammatory effects of 5α-reduced 
glucocorticoid metabolites. The total number of cells infiltrating the peritoneum 
following thioglycollate challenge was significantly reduced with both 5αDHB and 
5αTHB pre-treatment, similar to that seen with the parent glucocorticoid B. Analysis 
of these cells revealed that neutrophil numbers were reduced to a similar extent 
following pre-treatment with all doses of steroids. Infiltration of inflammatory 
monocytes was also altered by steroid pre-treatment, with B having the most 
significant suppressive effect. Although less efficacious than B, both 5αDHB and 
5αTHB also reduced inflammatory monocyte numbers. B suppressed the levels of 
both IL-6 and MCP-1 within the peritoneum, but the effects of 5α-reduced 
glucocorticoid metabolites were less pronounced, with only the highest dose of 
5αDHB suppressing IL-6 and MCP-1 levels. Interestingly, the lowest dose of 5αTHB 
suppressed IL-6 levels, whilst the higher doses had no significant effect. 5αTHB did 
not alter MCP-1 levels. 
 
Inflammation is the response of tissues to injury and infection. Acute inflammation is 
normally resolved within a matter of days. However, some inflammatory responses, 
classified as chronic inflammation, persist over an extended period of weeks and 
even years, leading to irreversible tissue remodelling and damage (Nathan 2002; 
Medzhitov 2008). In terms of acute inflammation, neutrophils are rapidly recruited to 
the site of infection or injury and form the basis of infiltrating leukocytes. The 
classical view has been that later in the inflammatory response, leukocytes of the 
monocyte and macrophage lineage are recruited, thus becoming the dominant 
leukocyte population at the site of infection. This switch in profile is thought to play 
a critical role in the inflammatory response, as macrophages phagocytose leukocytes 
that are undergoing apoptosis, preventing the release of intracellular pro-
inflammatory molecules and enabling the resolution of inflammation (Medzhitov 
2008). Glucocorticoids are well established anti-inflammatory steroids, and 
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pharmacological doses have multiple anti-inflammatory effects on numerous cell 
types (Saklatvala 2002). In terms of neutrophils, glucocorticoids act to inhibit their 
chemotactic activity, preventing their migration to the site of infection (Pitzalis et al. 
2002). The release of pro-inflammatory cytokines and chemokines from 
macrophages is also suppressed by glucocorticoids, as demonstrated in Chapter 5, as 
well as in several other reports (Reichardt et al. 2001; Tuckermann et al. 2007). 
Furthermore, glucocorticoids have been shown to promote macrophage phagocytosis 
of apoptotic neutrophils, potentially promoting the resolution of inflammation 
(Heasman et al. 2003).  
 
Injection of pathogens into the peritoneal cavity is widely used as a murine model to 
study acute inflammation. These models have allowed insights into the specific 
mechanism of inflammatory responses, including the cell types involved and the time 
course over which the inflammatory response occurs. Administration of 
thioglycollate into the mouse peritoneum leads to an acute inflammatory response 
that peaks within hours (4-8h) and resolves within days (3-4 days) (Melnicoff et al. 
1989; Henderson et al. 2003; Chen et al. 2008). The peak response is characterised 
as the time-point at which the greatest number of neutrophils have been recruited to 
the peritoneal cavity, and so for this study, we chose to assess cell infiltration into the 
peritoneum 4h after thioglycollate challenge.  Of further importance was the 
selection of a model which was glucocorticoid-responsive. A previous study has 
shown that treatment with the synthetic glucocorticoid dexamethasone suppresses 
cell infiltration following intra-peritoneal injection of thioglycollate in C57Bl/6 mice 
(Montesinos et al. 2006), demonstrating that this is an appropriate choice of model to 
study the potential anti-inflammatory effects of 5α-reduced glucocorticoid 
metabolites. 
 
Whilst dexamethasone has been shown to suppress inflammation in thioglycollate-
induced peritonitis, previous data does not exist on the anti-inflammatory ability of 
corticosterone. Therefore, to establish a comparable working model of 
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glucocorticoid-induced suppression of inflammation, the effect of B was explored in 
a 4 hour, acute model of thioglycollate-induced peritonitis. The dose of 
dexamethasone previously described to suppress cell infiltration equates to 
approximately 2.3 mg/ml. Given that dexamethasone is approximately 30x more 
potent than endogenous glucocorticoids, a corticosterone dose in the region of 69 
mg/ml would be expected to have a similar effect.  Total peritoneal cell infiltrate was 
suppressed with increasing concentration of B, (IC50 = 73.9 mg/ml) demonstrating 
the anti-inflammatory effects of corticosterone are in accordance with that seen with 
dexamethasone. An increase in the circulating levels of B was observed in line with 
the increasing doses administered. Physiological levels of circulating B in mice 
peaks at approximately 260 nmoles/L, however this rises to approximately 400 
nmoles/L under conditions of stress, such as acute restraint (Carter et al. 2009). 
Given that only the top two doses suppressed cell infiltration, it is evident that 
pharmacological doses of corticosterone are necessary to achieve anti-inflammatory 
effects.  
 
Having demonstrated in Chapter 5 that the 5α-reduced glucocorticoid metabolites 
retain similar anti-inflammatory properties to B in vitro, it was important to establish 
whether or not these properties were displayed in vivo. The three highest doses used 
for the corticosterone (B) dose response were chosen to test the effects of the 5α-
reduced metabolites. Following thioglycollate injection, B reduced cell infiltration 
into the peritoneum in a dose-dependent manner. Both 5αDHB and 5αTHB also 
suppressed cell infiltration in a dose-dependent manner, and at the highest dose 
tested, were equally as efficacious as B, indicating that these metabolites retain the 
anti-inflammatory properties displayed in vitro when examined in an in vivo model 
of inflammation. However, it should be noted that full suppression of cell infiltration 
was not achieved with any of the steroids. Indeed, the highest dose of B achieved a 
maximal suppression of 45.4 ± 5.0%, indicating that non-glucocorticoid-responsive 
elements exist within the response to thioglycollate. Previous work with 
dexamethasone documented <50% suppression of peritoneal cell infiltration with the 
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single dose used. To our knowledge, there is no work demonstrating that higher 
doses of dexamethasone achieve greater suppression of cell infiltration. 
 
Given the various cell populations involved in the stages of the inflammatory 
response, it is important to understand the cell types affected by these steroids. 
Neutrophils are known to be rapidly recruited to sites of infection, and at the 4h time-
point, comprise the largest population of infiltrating cells (Melnicoff et al. 1989; 
Reichardt et al. 2001). B suppressed neutrophil infiltration to a similar extent at all 
doses, suggesting that the maximal suppressive effect of B on neutrophil chemotaxis 
is achieved at a lower dose than that for suppression of total cells. Both 5αDHB and 
5α THB suppressed neutrophil infiltration in a similar manner to B, although here, 
the most efficacious response was achieved with the highest dose, potentially 
indicating that the 5α-reduced metabolites are less potent than B. In contrast to the 
effects on neutrophil infiltration, inflammatory monocyte infiltration, which is 
elevated 4h-post thioglycollate challenge, was much more responsive to increasing 
doses of B, which suppressed this cell population in a dose-dependent manner. At the 
highest dose, B suppressed inflammatory monocytes by 96.4 ± 0.9%, indicating 
significant effects on this population of cells. Whilst both 5α-reduced metabolites 
also suppressed the infiltration of inflammatory monocytes, they were significantly 
less efficacious than B, with 5αDHB achieving 57.3 ± 13.9% suppression and 
5αTHB achieving 69.5 ± 12.8% suppression 
 
According to the classical model of acute inflammation, neutrophils are the first 
population of leukocytes recruited to the site of infection, and release of 
inflammatory mediators from these infiltrated cells is necessary to initiate the 
recruitment of monocytes (Melnicoff et al. 1989). However, it was recently 
demonstrated that the recruitment of inflammatory monocytes is an early event in the 
inflammatory response, and occurs independent of neutrophil migration. 
Lymphocyte function-associated antigen-1 (LFA-1)-deficient mice, which have 
significantly inhibited peritoneal neutrophil infiltration, had unaltered recruitment of 
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inflammatory monocytes compared to wild type mice (Henderson et al. 2003). Data 
in this thesis supports the presence of these inflammatory monocytes early in the 
inflammatory response, and highlights the ability of both the parent glucocorticoid B 
and the 5α-reduced glucocorticoid metabolites to suppress the recruitment of this 
population of leukocytes. 
 
The recruitment of cells into the peritoneum is driven by the release of inflammatory 
mediators, specifically chemokines, which attract cells to the site of inflammation 
(Zlotnik and Yoshie 2000). The crucial role of chemokines in models of 
inflammation is well established. In mouse, neutrophils are recruited in response to 
the chemokines macrophage inflammatory protein-2 (MIP-2) and keratinocyte 
chemoattractant (KC) (Zhang et al. 2001), whilst monocytes are recruited in response 
to MCP-1 (Takahashi et al. 2009). Previous reports have indicated the critical 
importance of MCP-1 in monocyte recruitment. Indeed, in MCP-1-deficient mice, 
numbers of recruited monocytes were significantly reduced compared to wild-type 
mice following induction of peritonitis (Lu et al. 1998). Initially it was believed that 
recruited neutrophils released MCP-1, driving the recruitment of monocytes. 
However, the discovery that inflammatory monocyte infiltration occurs independent 
of neutrophil migration indicated that another cell type was perhaps responsible for 
MCP-1 release. Indeed, it was demonstrated that resident cells within the 
peritoneum, specifically resident macrophages and to a lesser extent mesothelial 
cells, produce the MCP-1 crucial to the recruitment of inflammatory monocytes 
(Henderson et al. 2003). Given the anti-inflammatory effects of 5α-reduced 
glucocorticoid metabolites on macrophages in vitro, it raised the possibility that the 
anti-inflammatory effects seen in vivo were a result of actions upon resident 
macrophages to suppress MCP-1 release. Analysis of peritoneal lavage revealed that 
treatment with B significantly reduced MCP-1 levels in a dose-dependent manner, 
with a similar pattern of suppression to that seen with inflammatory monocyte 
infiltration, supporting the positive correlation between MCP-1 levels and monocyte 
recruitment. 5αDHB also suppressed MCP-1 levels, although it was significantly less 
efficacious than B, again showing a similar pattern to that seen with inflammatory 
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monocyte recruitment. In contrast to both B and 5αDHB, MCP-1 levels following 
5αTHB treatment did not match the pattern of inflammatory monocyte infiltration. 
Interestingly, 5αTHB had no significant effect on MCP-1 levels, despite reducing 
inflammatory monocyte recruitment, potentially indicating that 5αTHB affects an 
alternative chemokine involved in the recruitment of such cells. 
 
MCP-1 also affects neutrophil recruitment. In MCP-1-deficient models of 
inflammation, neutrophil infiltration into the peritoneum was increased in MCP-1-
deficient mice compared to wild-type mice (Takahashi et al. 2009). This may 
potentially explain the lack of dose-dependent changes in neutrophil numbers in our 
study, despite overall changes in total cell number. It should be noted that the 
inflammatory monocyte cell population at this time-point is relatively small, 
comprising less than 5% of all cells. As such, the changes in the number of 
inflammatory monocytes are likely to contribute only a small amount to the overall 
changes in the total number of cells. Whilst neutrophils are the predominant 
population, the lack of dose-dependent change seen in this population with steroid 
treatment suggests that other cell populations are also affected by glucocorticoids and 
their 5α-reduced metabolites. Previous work has demonstrated that resident 
lymphocytes, both T- and B-cells, alter the recruitment of leukocytes to the 
peritoneum following thioglycollate-injection (Kipari et al. 2009). Furthermore, 
recruitment of lymphocytes into the peritoneum has also been reported (Pitzalis et al. 
1997). It may be that glucocorticoids alter inflammatory mechanisms within these or 
other cells to prevent recruitment of lymphocytes, as well as that of leukocytes. 
Indeed, it has been reported that glucocorticoids inhibit the ability of endothelial cells 
to bind lymphocytes, thus preventing migration of these cells (Pitzalis et al. 1997). 
To investigate this further, mice deficient in T-cells (NUDE mice) or B-cell (μMT 
KO mice) could be utilised to establish if these cells play a role in the anti-
inflammatory effects of 5α-reduced glucocorticoid metabolites in thioglycollate-




Both resident and newly recruited cells have been implicated in the release of pro-
inflammatory cytokines following thioglycollate challenge (Henderson et al. 2003; 
Cailhier et al. 2005). Having shown that 5α-reduced glucocorticoid metabolites 
suppress pro-inflammatory cytokine release from macrophages in vitro, the ability to 
do the same in vivo was expected. Treatment with B reduced peritoneal levels of IL-6 
in a dose-dependent manner. Similar to the suppression of MCP-1, 5αDHB 
suppressed IL-6 only at the highest dose. 5αTHB also suppressed IL-6, yet this was 
achieved with only the lowest dose tested. Indeed it appears that increasing the dose 
of 5αTHB may actually be increasing the levels of IL-6 within the peritoneum, 
although the effect is not significant. Whilst this is unexpected and is at odds with the 
reduction in infiltration of inflammatory cells following 5αTHB administration, it 
does provide support for a potential cell-specific, pro-inflammatory role for 5αTHB 
that was demonstrated in Chapter 5.  
 
Having seen the anti-inflammatory properties of 5α-reduced glucocorticoid 
metabolites in suppressing inflammatory signalling in macrophages in vitro, and the 
suppressive effects on the recruitment of inflammatory monocytes in vivo, it is clear 
these metabolites affect cells of the monocyte/macrophage lineage. However, these 
inflammatory cells are only beginning to appear at the 4h time-point analysed here. It 
would be of real interest to investigate the effects of these steroids in the later stages 
of the inflammatory response, namely the resolution phase. In this phase of 
inflammation, neutrophils undergo apoptosis, preventing excessive local damage 
from their presence (Heasman et al. 2003). Phagocytosis of these apoptotic cells by 
macrophages ensures their clearance from the inflamed site and prevents the release 
of their intracellular toxic contents, enabling resolution of the inflammatory 
response. This process is crucial, with mutant mice showing defects in the clearance 
of apoptotic cells displaying persistent tissue inflammation (Duffield 2003). Previous 
work looking at the effects of glucocorticoids on macrophage function demonstrated 
that glucocorticoids enhance macrophage phagocytosis of apoptotic cells (Liu et al. 
1999). Further work showed that glucocorticoid treatment of peripheral blood 
monocytes induced a highly phagocytic monocyte-derived macrophage phenotype 
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(Giles et al. 2001). Such a cell-type may accelerate the resolution phase of the 
inflammatory response, and demonstrates further anti-inflammatory capacity of 
glucocorticoids.  
 
Investigation into the effects that 5α-reduced glucocorticoid metabolites have on 
macrophage phagocytosis, as well as the resolution of inflammation would allow for 
a much more detailed view of the anti-inflammatory properties of these metabolites. 
This could be achieved using both an in vitro and an in vivo approach. Firstly, the 
ability of 5αDHB and 5αTHB to induce a phagocytic phenotype could be assessed in 
vitro through a phagocytosis assay. Secondly, the effects that 5αDHB and 5αTHB 
have on the resolution of inflammation could be assessed in vivo using the 
thioglycollate-induced peritonitis model established here. However, in this instance, 
it would be necessary to analyse the peritoneal exudates at several time points over 
the course of the peritonitis. Whilst inflammatory monocytes are recruited rapidly 
within 4 hours of thioglycollate challenge, this is by no means the peak influx of 
monocytes and macrophages. Indeed, macrophage infiltration rises relatively slowly 
within the first 12 to 24 hours post-thioglycollate challenge (Henderson et al. 2003). 
Instead, infiltration increases dramatically between 24 and 72 hours post-
thioglycollate challenge. It is during this period when macrophages are believed to 
develop a phagocytic phenotype, removing apoptotic neutrophils from the site of 
inflammation, thus aiding resolution. As such, it would be extremely interesting to 
repeat the current experiment, but analyse peritoneal cells at time points beyond the 4 
hours tested, specifically 16, 48 and 72 hours post-thioglycollate challenge. In 
particular, measurement of the levels of apoptosis in the peritoneum throughout such 
a time course would offer more mechanistic insights into the action of these steroids. 
 
In conclusion, these results demonstrate for the first time the anti-inflammatory 
properties of 5α-reduced glucocorticoid metabolites in vivo. Treatment of mice with 
5αDHB and 5αTHB resulted in inhibition of thioglycollate-induced cell infiltration 
into the peritoneum, a similar result to that achieved with the parent glucocorticoid 
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B. The effects of these steroids on cell infiltration suggest that they may be acting 
through resident peritoneal cells to inhibit recruitment of neutrophils and 
inflammatory monocytes. Further use of this model will allow for a clearer 
understanding of the anti-inflammatory mechanism of these 5α-reduced 
glucocorticoid metabolites. Furthermore, both 5α-reduced glucocorticoid metabolites 
suppressed the levels of IL-6 in the peritoneum of thioglycollate-treated mice, 
although to a lesser extent than B. However, these findings provide exciting evidence 
that the anti-inflammatory effects of 5α-reduced glucocorticoid metabolites 
demonstrated in vitro are retained in vivo, and so these metabolites may potentially 






























The central theme of this thesis is that glucocorticoid metabolism alters the 
inflammatory state evident in obesity, and vice versa. The aims were to investigate 
the effects of anti-inflammatory salicylate treatment on glucocorticoid metabolism in 
obesity and the anti-inflammatory properties of 5α-reduced glucocorticoid 
metabolites. The work described in this thesis demonstrates that the insulin 
sensitising effects of salicylate are dependent upon 11βHSD1 and suggests that this 
enzyme plays a role in regulating the inflammatory state of obese adipose tissue. 
Furthermore, this thesis demonstrates that both in vitro and in vivo, 5α-reduced 
glucocorticoid metabolites have similar anti-inflammatory properties to the parent 
glucocorticoid, indicating that increased hepatic A-ring metabolism in obesity is not 
a pathway of simple inactivation.  
 
Obesity rates are increasing in almost all countries, with 1.5 billion adults worldwide 
predicted to be overweight or obese by 2015 by the WHO. With this rise comes 
increased incidence of insulin resistance, type 2 diabetes and cardiovascular disease, 
factors which together have been termed the ‘metabolic syndrome.’ Given the 
increased mortality rates amongst obese individuals, as well as the economic burden 
due to healthcare, much emphasis has been placed on achieving a greater 
understanding of the mechanisms underlying the development and progression of the 
metabolic syndrome, as well as novel therapeutic strategies. 
 
Under normal conditions, feeding results in the release of insulin from pancreatic β-
cells, which acts to promote the uptake and non-oxidative metabolism of glucose in 
adipose, liver and muscle, as well as inhibiting hepatic gluconeogenesis and 
glycogenolysis (White 2002). Glucocorticoids act in catabolic manner, such that in 
times of starvation, the body is primed to respond. In doing so, glucocorticoids act to 
counter-regulate the actions of insulin, whose actions are inhibited through disruption 
of insulin signalling pathways (Macfarlane et al. 2008). The role that glucocorticoids 
play in energy homeostasis is most dramatically exemplified in conditions of 
glucocorticoid deficiency or excess, namely Addison’s disease and Cushing’s 
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syndrome respectively (Boscaro et al. 2001; Kyriazopoulou 2007). Patients with 
Cushing’s syndrome display strikingly similar symptoms to patients with metabolic 
syndrome, with visceral obesity, hypertension, dyslipidemia and insulin resistance. 
Those with Cushing’s have pronounced hypersecretion of glucocorticoids primarily 
due to the presence of pituitary adenomas, thus raising circulating levels (Boscaro et 
al. 2001). In contrast, metabolic syndrome does not present with elevated circulating 
levels of glucocorticoids (Walker 2007). However, there are distinct, tissue-specific 
changes in pre-receptor metabolism of glucocorticoids in obesity and the associated 
metabolic syndrome. Adipose levels of the glucocorticoid-regenerating enzyme 
11βHSD1 are elevated in obesity (Wake et al. 2003; Livingstone et al. 2005), 
elevating local levels of glucocorticoids, whilst hepatic levels of 5αR1, an enzyme 
which reduces glucocorticoids to their 5α-metabolites, are increased (Livingstone et 
al. 2005). Whilst these alterations have been characterised, much remains to be 
elucidated about both the regulation of these enzymes, as well as the consequences of 
their altered expression. 
 
The role that inflammation plays in obesity-related disorders has been an area of 
intensive research since the discovery that the expression of pro-inflammatory 
cytokines was increased in obese adipose tissue (Hotamisligil et al. 1995). In terms 
of adipose tissue, the general hypothesis involves the development of adipocyte 
hypertrophy in response to chronic over-nutrition. This provokes the infiltration of 
macrophages, which subsequently become activated and release pro-inflammatory 
cytokines, thus initiating a cycle of inflammation. Recently it was demonstrated, in 
vitro, that pro-inflammatory cytokines induce expression of 11βHSD1 in both 
adipocytes and macrophages (Ishii et al. 2007; Ishii-Yonemoto et al. 2010), 
potentially explaining the elevated levels of this enzyme in obese adipose tissue. In 
this thesis, we have demonstrated an in vivo link between adipose inflammation and 
glucocorticoid metabolism in obesity. Treatment of DIO mice with the anti-
inflammatory drug sodium salicylate improved insulin sensitivity and reduced 
markers of adipose inflammation in visceral adipose. These changes were 
accompanied by a downregulation of 11βHSD1 in the same visceral adipose depots, 
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demonstrating an association between inflammation and 11βHSD1 specifically 
within visceral adipose. The utilisation of 11βHSD1-deficient mice allowed us to 
determine if 11βHSD1 downregulation was crucial to the insulin sensitising effects 
of salicylate. In these 11βHSD1-deficient mice, salicylate treatment did not 
recapitulate the insulin sensitising effects observed in wild type mice, revealing that 
the downregulation of visceral adipose 11βHSD1 is a central factor in the ability of 
anti-inflammatory agents to improve insulin sensitivity.  
 
Whilst this work has clearly demonstrated a link between obese adipose 
inflammation and glucocorticoid metabolism dysregulation, several intriguing 
aspects remain to be fully addressed. Firstly, one must consider the tissue-specific 
nature of the effects, given that the majority of alterations, in terms of inflammatory 
mediators and 11βHSD1, as well as lipid metabolism, occurred in visceral adipose. 
Accumulating evidence indicates that visceral adipose is more metabolically active 
than peripheral adipose depots, and clear differences exist between adipose depots in 
terms of both inflammatory state and glucocorticoid action (Wajchenberg 2000). The 
ability of salicylates to reduce expression of 11βHSD1 is likely a consequence of 
their suppressive actions of the inflammation within these adipose depots, and so by 
reducing the levels of pro-inflammatory cytokines, the induction of 11βHSD1 is 
reduced. However, this leads onto a further question that remains to be elucidated, 
that of 11βHSD1 regulation. Given that pro-inflammatory cytokines upregulate 
11βHSD1, the above hypothesis that salicylates reduce 11βHSD1 indirectly through 
suppression of inflammation is an attractive one, yet one that has yet to be fully 
investigated. Indeed, it is possible that salicylates act directly to alter transcriptional 
regulation of 11βHSD1 and this is an area that needs to be addressed. To date, the 
only reported direct regulators of 11βHSD1 gene transcription are members of the 
CCAAT/enhancer-binding protein (C/EBP) transcription factor family (Sai et al. 
2008). Recent unpublished data in a human fibroblast cell line has shown that pro-
inflammatory cytokines upregulate mRNA levels of C/EBPβ in accordance with 
increases in 11βHSD1 mRNA levels, whilst knockdown of C/EBPβ inhibited the 
increase in 11βHSD1 expression (Róg-Zielinska 2009). Therefore, it would be 
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interesting to assess the impact that salicylate has directly on the mRNA expression 
of not only 11βHSD1, but also transcription factors of the C/EBP family. 
Furthermore, the use of chromatin immunoprecipitation (ChIP) analysis, which 
enables assessment of the interactions between proteins and DNA, would provide 
crucial information as to whether C/EBPβ binds to the promoter region of 11βHSD1 
following salicylate treatment, as well as other transcription factors potentially 
involved in the regulation of 11βHSD1. Such data could provide new mechanistic 
insights into links between inflammation and glucocorticoid metabolism.  
 
A further issue involves the apparent paradoxical situation within obese adipose 
tissue, whereby there is an increase in the levels of an enzyme that generates steroids 
known for their anti-inflammatory properties, yet there is also an increase in 
inflammation. Whilst this appears counter-intuitive, one must consider that the well 
characterised anti-inflammatory properties of glucocorticoids are seen primarily at 
pharmacological levels. Much less is known about the effects of physiological levels 
of endogenous glucocorticoids, although there are indications of a pro-inflammatory 
role for glucocorticoids. A recent study showed TNFα induced an increase in 
11βHSD1 in pre-adipocytes, augmenting the release of pro-inflammatory mediators 
(Ishii-Yonemoto et al. 2010). Furthermore, treatment with 11βHSD1 inhibitors 
reduced TNFα-induced release of pro-inflammatory mediators. Such data presents an 
intriguing situation whereby increasing local glucocorticoid levels through increased 
11βHSD1 actually intensifies inflammation. An especially interesting point from this 
study was that overexpression of 11βHSD1 using a targeted vector did not enhance 
inflammation (Ishii-Yonemoto et al. 2010). This suggests that the ability of 
11βHSD1-mediated glucocorticoid to induce inflammation is dependent upon a pre-
existing inflammatory state. Furthermore, one must take into account the differences 
in the chronic, low-grade, inflammatory state seen in obesity with that seen in acute 
inflammatory conditions, such as thioglycollate-induced peritonitis. In acute 
inflammation, an immune response is mounted against a foreign body, whether it be 
pathogen or allergen, until it is eliminated, at which point the immune response is 
downgraded. However, in chronic inflammation, whilst the body mounts an initial 
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response to an insult, the continuous stimulation of inflammatory pathways prevents 
the resolution of the response, resulting in persistent inflammation.  
 
The accumulation of this evidence clearly establishes that the pathways involved in 
the development of insulin resistance from inflammation and glucocorticoid excess 
are highly complex and by no means linear in nature. It may be the case that an 
initial inflammatory insult in adipose, possibly provided by hypertrophied 
adipocytes, begins a cycle in which 11βHSD1 expression is increased in adipocytes 
and stromovascular cells, including macrophages and pre-adipocytes. This local 
amplification of glucocorticoids serves to enhance the local inflammatory response, 
as well as inducing metabolic effects, both of which serve to induce an insulin 
resistant state. Certainly, future investigations are necessary to unravel the 
intracellular mechanisms at work within obese adipose tissue.  
 
The demonstration that hepatic levels of 5αR1 are elevated in obesity ignited interest 
in the consequences of changes in this route of glucocorticoid metabolism 
(Livingstone et al. 2000). Initially viewed as a pathway of inactivation, this 
hypothesis was challenged when it was revealed that 5α-reduced metabolites of the 
rodent glucocorticoid corticosterone, namely 5αDHB and 5αTHB, are capable of 
binding the glucocorticoid receptor (GR) (McInnes et al. 2004). Further work has 
since shown that 5αTHB does not potently induce transactivation of glucocorticoid-
responsive metabolic genes such as PEPCK and TAT, but is capable of suppressing 
pro-inflammatory cytokine release, demonstrating a transrepressive ability (Yang 
2009). This evidence suggested that 5αTHB was a potential ‘dissociated’ steroid that 
retained the anti-inflammatory effects of the parent steroid, but lacks to the metabolic 
effects. The development of ‘dissociated’ steroids has become a principal aim within 
glucocorticoid research, given that the pharmacological doses required to control 
inflammation in patients are often coupled with the development of detrimental side 




In this thesis, the aim was to investigate the molecular mechanisms behind the 
potential anti-inflammatory properties of both 5αDHB and 5αTHB, and how they 
compared to those of the parent glucocorticoid. Whilst both 5αDHB and 5αTHB 
suppress pro-inflammatory cytokine release in macrophages, the mechanisms 
underlying this suppression, whilst similar, display distinct differences. In particular, 
the ability to induce transactivation of anti-inflammatory proteins was different 
between the two metabolites. 5αDHB induced expression of MKP-1 and IκBα, whilst 
5αTHB only increased expression of MKP-1. This is intriguing as the mechanisms of 
transactivation differ between MKP-1 and IκBα differ, with MKP-1 shown to be 
induced by GR monomer binding (Abraham et al. 2006), whilst IκBα requires GR 
dimerisation (Heck et al. 1997). This suggests that 5αTHB is unable to induce GR 
dimerisation, and so is unable to induce transactivation of genes that require GR 
dimerisation, including IκBα, PEPCK and TAT. This is an area that certainly 
warrants further investigation and one that would yield invaluable knowledge into 
the actions of these 5α-reduced glucocorticoid metabolites. One approach could be to 
utilise in vitro techniques with reporter plasmids that are activated through either GR 
monomers or GR dimers. Specifically, one could use the glucocorticoid-responsive 
PNMT reporter, which has been shown to be activated in GR dimerisation-deficient 
mice (Adams et al. 2003), and a more conventional glucocorticoid-responsive 
reporter that requires dimerisation, such as the MMTV reporter (Michailidou et al. 
2008), and compare the effects of each 5α-reduced glucocorticoid metabolite. 
 
Whilst both 5α-reduced glucocorticoid metabolites exerted similar effects in 
macrophages, the same was not observed in a different cell line. In kidney cells, 
5αDHB suppressed activation of pro-inflammatory transcription factors in a similar 
manner to corticosterone, again demonstrating potent anti-inflammatory effect. 
However, 5αTHB augmented pro-inflammatory transcription factor activation. This 
presents the intriguing issue of cell-specific effects of these metabolites, in particular 





Given the anti-inflammatory effects of these 5α-reduced metabolites witnessed in 
macrophages in vitro, it was important to establish if a similar story unfolded when 
they were tested in an in vivo model of inflammation. Here we demonstrated that 
both 5αDHB and 5αTHB suppress the influx of cells to the site of inflammation, in 
particular neutrophils and inflammatory monocytes, as well as reducing the local 
levels of IL-6. This data reveals for the first time in vivo that 5α-reduced 
glucocorticoid metabolites retain the anti-inflammatory properties of the parent 
glucocorticoid, and appear similarly efficacious in terms of suppression of total cell 
infiltration. This is particularly pertinent when one considers the cell-specific effects 
seen in vitro of 5αTHB. Given those results, it may have been expected that 5αTHB 
may not exhibit such an anti-inflammatory effect in an in vivo setting. Furthermore, 
the indication that 5αTHB is unable to induce GR dimerisation may also have been 
expected to dampen potential suppressive effects on inflammation. Yet in terms of 
ability to suppress cell infiltration, 5αTHB was similarly efficacious to 
corticosterone. This is perhaps an indication that induction of anti-inflammatory 
molecules through GR dimerisation-dependent mechanisms has little overall anti-
inflammatory effect. Indeed, previous work has been shown that glucocorticoids are 
capable of suppressing an inflammatory response in GR dimerisation-deficient mice 
just as effectively as in wild type mice (Reichardt et al. 1998; Reichardt et al. 2001).  
 
However, there were still distinct differences evident between the parent 
glucocorticoid and the metabolites. This was particularly apparent for the infiltration 
of inflammatory monocytes, as well as the release of IL-6 and MCP-1, in which in all 
cases, corticosterone was markedly more efficacious than both 5αDHB and 5αTHB. 
The effects on inflammatory monocytes are intriguing and are an area that would 
benefit from further investigation as these cells are only beginning to enter the 
inflammatory site at the time point tested (Henderson et al. 2003). Analysis at later 
time points may reveal further effects on the differentiation of these monocytes into 
macrophages, which would have implications for the resolution of the inflammatory 
response, as well as highlighting differences between the parent glucocorticoid and 
the 5α-reduced metabolites. However, this data provides an initial first-step into the 
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potential application of 5α-reduced glucocorticoid metabolites as an alternative anti-
inflammatory treatment to conventional glucocorticoids. 
 
In terms of the role these metabolites play in obesity, very little is currently known. 
The increase in hepatic 5αR1 seen in obesity was initially viewed as increased 
clearance of local glucocorticoids, thus protecting the liver from their adverse 
metabolic effects. Whilst this appears to be accurate, it fails to deal with the prospect 
of increased levels of 5α-reduced glucocorticoid metabolites. In terms of 
immunomodulatory effects, data in this thesis indicates that 5αDHB retains the anti-
inflammatory properties of corticosterone, and given that this was evident in two 
distinct cell types, as well as in vivo, it lends to the theory that 5αDHB would also act 
in an anti-inflammatory manner in the liver. The cell-specific effects of 5αTHB 
demonstrated in vitro make it difficult to establish the potential effects of this 
metabolite on inflammation within the liver. Yet the in vivo data suggests that within 
a whole body, 5αTHB exerts anti-inflammatory effects. Investigation utilising a liver 
cell line would provide important insights into the hepatic effects of these 
metabolites. Use of such an in vitro system would also allow for a greater 
understanding of the possible metabolic effects, or lack thereof, of these metabolites. 
Certainly in terms of 5αTHB, previous work has indicated a reduced effect on 
metabolic gene induction compared to the parent glucocorticoid (Yang 2009). No 
data currently exists on the metabolic effects of 5αDHB, and this is clearly an issue 
that needs to be addressed. A further issue is that of metabolism of these steroids. For 
example, whether the results from treatment with 5αDHB are truly 5αDHB-
dependent or whether they are a result of its metabolism to 5αTHB and subsequent 
action.  We addressed this issue in vitro by characterising the cell types used for the 
presence of A-ring enzymes, demonstrating that HEK293 cells lack A-ring 
metabolising enzymes, whilst RAW264.7 cells only express 5αR1. Therefore, it 
appears that the effects are specific for the steroid administered. This could be further 
addressed by measuring the levels of these metabolites within cells, potentially via 
gas chromatography-mass spectroscopy, thus ensuring conversion to another form is 
not responsible for effects.   
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Nonetheless, data presented in this thesis indicates that aside from simply ‘clearing’ 
local glucocorticoids, 5α-reduction actively generates glucocorticoid metabolites that 
exert distinct and cell-specific effects, perhaps revealing an endogenous pathway of 
dissociation. Whilst this thesis has dealt with possible consequences of A-ring 
metabolism, the issue of 5αR1 regulation remains an area yet to be fully explored. 
The presence of hepatic inflammation in obesity is likely to play a role in 5αR1 
expression, yet this has yet to be tested. However, given the ability of pro-
inflammatory cytokines to induce 11βHSD1 expression, it suggests that increased 
pro-inflammatory mediators in the liver may act to induce 5αR1.  
 
Figure 7.1 provides a simplified overview of possible pathways at work within the 
body in response to obesity, although several of the interactions remain to be 
investigated. Data in this thesis suggests that the inflammation associated with 
obesity has a key role to play in the regulation of glucocorticoid metabolism. The 
upregulation in 11βHSD1 will enhance local levels of glucocorticoid which will act 
upon metabolic pathways, and in the case of adipose tissue, may also act to enhance 
inflammation, resulting in the development of insulin resistance. Whilst 
inflammatory mediators have not been directly shown to regulate 5αR1, the elevated 
presence of both these in obesity indicates a possible link exists. By metabolising 
local glucocorticoids, hepatic 5αR1 increases the levels of 5α-reduced glucocorticoid 
metabolites, which have the anti-inflammatory properties of the parent 
glucocorticoid, but not the adverse metabolic effects, potentially resulting in a 










Figure 7.1 Proposed interactions between inflammation and glucocorticoid metabolism in obesity. Left panel; inflammation seen in 
the obese state results in the upregulation of adipose 11βHSD1, increasing local glucocorticoid (GC) levels, which act through the GC 
receptor (GR) to activate metabolic pathways, resulting in the development of insulin resistance. Whilst classically seen as anti-
inflammatory, it is debatable whether the regenerated GCs in adipose are acting to dampen or exacerbate the inflammatory response. 
Right panel; obesity-induced inflammation may potentially upregulate hepatic levels of 5αR1, generating greater levels of 5α-reduced 
GC metabolites. Whilst these 5α-reduced metabolites retain anti-inflammatory properties, they lack the adverse metabolic effects of the 
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